20 11

Scientific Program

Powerful. Potent. Professional.
Introducing

A NEW comprehensive antiaging system of potent, multi-action products developed to address photoaging at all skin layers.
The most powerful ingredients working synergistically to address the multiple mechanisms of skin aging. Reverse the appearance of deep lines and wrinkles, sagging skin and discoloration. Physician dispensed.

new

©2011 NeoStrata Company

Elite Science. Professional Results.
Contact your NeoStrata representative or call 1-800-628-9904

CONTINUING MEDICAL EDUCATION INFORMATION
MISSION The American Academy of Dermatology (AAD) is the premier provider of dermatology CME activities. The purpose of its CME Program is to advance quality dermatologic care and improve competence and performance. DEFINITION OF CONTINUING MEDICAL EDUCATION Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public.
Source: www.accme.org

LEARNER BILL OF RIGHTS AAD recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge or skill; and to attain or enhance a desired competency. As part of AAD’s duty to you as a learner, you have the right to expect that your continuing medical education experience with AAD includes the following. Content that: • Promotes improvements or quality in healthcare • Is current, valid, reliable, accurate and evidence-based • Addresses the stated objectives or purpose • Is driven and based on independent survey and analysis of learner needs, not commercial interests • Has been reviewed for bias and scientific rigor • Offers balanced presentations that are free of commercial bias • Is vetted through a process that resolves any conflicts of interest of planners and faculty • Is evaluated for its effectiveness in meeting the identified educational need A learning environment that: • Is based on adult learning principles that support the use of various modalities • Supports learners’ abilities to meet their individual needs • Respects and attends to any special needs of the learners • Respects the diversity of groups of learners • Is free of promotional, commercial and/or sales activities Disclosure of: • Relevant financial relationships that planners, teachers and authors have with commercial interests related to the content of the activity • Commercial support (funding or in-kind resources) of this activity
American Academy of Dermatology 930 East Woodfield Road, Schaumburg, Illinois 60173 Phone: 847.330.0230, Fax: 847.330.1090, Website: www.aad.org © 2011 American Academy of Dermatology, Schaumburg, Illinois No part of this publication may be reproduced without the prior written permission of the American Academy of Dermatology.

COMMERCIAL BIAS A personal judgment in favor of a specific proprietary business interest of a commercial interest.
Source: www.accme.org

SCIENTIFIC ASSEMBLy COMMITTEE
Henry W. Lim, M.D., FAAD; Chair Janet A. Fairley, M.D., FAAD Ilona J. Frieden, M.D., FAAD Joan Guitart, M.D., FAAD Ronald L. Moy, M.D., FAAD; President Daniel M. Siegel M.D., FAAD; President-Elect Robert D. Greenberg, M.D., FAAD; Secretary-Treasurer Suzanne Olbricht, M.D., FAAD; Assistant Secretary-Treasurer Robert S. Kirsner, M.D., Ph.D., FAAD; Chair, Council On Education Edward W. Cowen, M.D., FAAD; Chair,
Annual Meeting Evaluation Task Force M. Christine Lee, M.D., FAAD; Chair, Needs Assessment Task Force

REGISTER FOR THE MEETING AND MAkE HOTEL RESERvATIONS ONLINE AT

www.AAD.ORG

and tools you’ll need to move forward into the next century.. FAAD President. a world-wide group of specialists. as it will be for the Summer Academy Meeting 2011. American Academy of Dermatology 2 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 . I want to welcome the world to engage in Summer Academy Meeting 2011. and may loosely describe everyone from the dermatologists who diagnose and treat patients to the patients themselves. however. often unveiled for the first time. but it’s the words on the statue that express the true sentiment: all are welcome. And although the Statue of Liberty will invariably be a symbol of New York City. your poor. As you look through the program book.President’s Message DERMATOLOGy: THE NEw COLOSSUS It was more than a century ago when the iconic Statue of Liberty was engraved with Emma Lazarus’s sonnet “The New Colossus. presenters. diversified. including many new courses. I think it’s good to remember the “world-wide welcome” Lady Liberty was offering. I think the American Academy of Dermatology’s Summer Academy Meeting 2011 aspires to similar ideals. but the sonnet also includes these words: “From her beacon-hand glows world-wide welcome. your huddled masses. “Give me your tired. a gathering place. come from across the United States and abroad. M. New York City is a hub. lecturers. Sincerely. you’ll find the summation of a century of dermatology advances made relevant for today’s practitioner. The Summer Academy Meeting 2011 serves as a “port of entry” to the newest advances in dermatology. The actual components of the meeting.” Most are familiar with its immortal line.” The grand statue has become synonymous with New York. grown. and marvel at the colossus of modern medicine dermatology has become. Ronald Moy.D. to appreciate the diversity of our specialty. and prospered. In modern terms. and some one-of-a-kind sessions and events that only happen at the summer meeting. and attendees. the “huddled masses” have endured.

.

. FAAD Chair. Stratman. M. Margolis. In addition. M... as well as to anticipate future changes in the specialty. Author and lecturer Don Tapscott is an internationally renowned authority on the strategic impact of information technology on innovation.D.D. and Traps. will talk about the basics of comparative effectiveness in dermatology and how it will impact the provisions of health care. is presenting the Everett C. marketing and talent. Attendees will be taken on an epidemiologic journey of contact dermatitis. Henry W. we have planned the Summer Academy Meeting 2011 with the need of our Academy members in mind. Another hot dermatology topic is comparative effectiveness research. M. M. M.D.” will not only assess the current education system but offer a glimpse at its future. Sam T. The plenary also includes a presentation by Roy G. M. Scientific Assembly Committee 4 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 . A major reason is the high demand for quality dermatology education. M. who will provide the latest development in nonablative and ablative fractional resurfacing. will provide “An Update in CTCL: A Tale of Two Kinds of T-Cells” to explain the clinical manifestations of Sézary syndrome and mycosis fungoides. which makes use of existing therapeutic options to determine which therapy provides the greatest benefits for patients. and will address the controversy of sentinel node biopsies in dermatology. David J. Central Park.D.. facets that are applicable to dermatologists facing a new era of technology. the AAD’s Summer Academy Meetings offer many new sessions. I do hope that you will find the program informative and educational.D. Hwang. Ph..Chair’s Message There are several reasons that the American Academy of Dermatology offers two scientific meetings each year. New York City is a great city to visit in the summer. and some that are not available at the Annual Meeting. His talk on “Overhauling CME and Dermatology Education: Laps. As reflected by the Plenary session topics. I encourage you to start reviewing the program book today. Another reason the Academy presents two scientific meetings a year is that it addresses the rapid advances in dermatology over a relatively short period of time. and many tourist sites. In addition to all the Summer Academy Meeting 2011 offers. Memorial Lectureship.. This summer’s guest speaker at the Sunday Plenary Session is emblematic of the sort of change and shift we are all undergoing as the world moves a little faster each year. who will also talk about the relevence of patch testing. Maps. M. Johnson.D. I’m particularly excited about the plenary session this summer. health care. We have an array of well recognized experts who will provide the latest advances in dermatology science and research. Sincerely. through an informative presentation by David Eric Cohen.D. The meeting venue is within walking distance to theatres. Timothy M. practice management... Geronemus.D. museum. has been passionately involved in dermatology education over the years. In addition to the core curriculum. treatments.. and plan to attend the sessions that will inform and affect your practice in the future. the Summer Academy Meeting 2011 provides the ideal venue to do so. For today’s dermatologist to keep up with the changes in science. Fox. Gaps.D. Lim. Erik J.

Inc. and alpha-hydroxy acid to exfoliate and hydrate dry skin and dry skin associated with Keratosis Pilaris (KP) ● AmLactin Moisturizing Body Lotion & Cream ® Everyday hydration— 12% lactic acid provides powerful therapy leaving skin noticeably soft and smooth ● AmLactin XL® Moisturizing Lotion Visit us online at www.com for samples.. dry skin. TM 1-800-654-2299 www. MN 55369 103985. coupons & more information! Targets severely dry skin— features ULTRAPLEX. please refer to individual product labels.02 . Maple Grove. Omnibus Study.upsher-smith. Reference: 1.® an extra-strength blend of three alpha-hydroxy compounds.amlactin. dry skin1 AmLactin® Rejuvenating Moisturizers Nourishing formulas— combine emollients. clinically proven to improve smoothness and hydration Serious care for softer skin For complete directions and cautions.When dry skin calls for a serious solution… Recommend AmLactin ® recommended by dermatologists for rough. Dermatology Times.com ©2010 Upsher-Smith Laboratories. humectants. May 2009. Most recommended moisturizing product for rough.

........................................................... 103 Continuing Medical Education Information Mission ........................................................ 30 Child Care Services ........... 37-51 Friday........................ 30 Tours ................................................................................. 26 Committee Meetings..................................................................................................................................................... 17-18 Registration Information Member Instruction .................................................................................................. 25 Identification ........................ 75-78 What’s New This Year .............................. 22 Registration Categories.................................................. 19 President’s Message ............................................... 87-100 Alphabetical Directory ........................ 27 Air Travel .... 1 Learner Bill of rights ................................................................................... 18 Attendance Verification ............................................................................................................................................................................... 28 Speaker Ready Room .................. 27 Car Rental ... August 6 .................................... 30 Disclosure ...................................................................... 12-13 Disclaimer ......... 21 On-Site Services and Exhibits Academy Offices/Exhibits ...................................................................................................................................................................... 32 Scientific Sessions ............................................. 27 Indices Subject ................................................................................................... 24 table of contents SEPARATE ENCLOSURE REGISTRATION AND HOUSING BROCHURE Registration and Housing Form / Office Staff / Registered Nurses Registration Form / Hotel Reservation Information 6 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 ... 26 Chair’s Message ................ 25 Payment Information ................... 28............................................................. 1 Statement of Need ................................ 98-100 Independence in CME ... 29 Exhibits AAD Resource Center ......................................... 1 Commercial Bias ................... 12 Disclosure Information ................................................................................................................................................................ 31 Official Language . 30 Content Validation....................................................................................... 26 Payment Information .................................................... 24 Cancellations ............. 2 Program Overview ............................... 28 Attendance Verification .............................................................................. 31 Cell Phones .................... 30 Personal Program Schedule ............... Access and Fees ............ 1 Definition of ......................................................................................... August 4................. 28 Registration ................................................................................................................................................................................................ 21-22 Non-member Instructions ..................................................................................... 30 Meeting Location ............................................. 1 Scientific Sessions Thursday.............................table of contents General Information Accreditation ............................................................................................................................ 112 Letters of Invitation .......................................... 31 Smoking ................................................................................................28-29........................................................................ 31 Outcomes Measurement ................. 29.................................................................................................................................................................................................... 32 Hotel and Travel Information Hotel Accommodations and Reservations ................... 83-85 Technical ....... 21-22 Spouse/Guest Instructions ............................ 31 Camera/Video Recording ...... 31 Alcoholic Beverages ......................................... 13 CME Credit Information .............................................................................................. August 5 ..................... 26 Certificate of Attendance................. 28 Exhibits ............................................. 14 Evaluation and CME Verification ....... 108-110 Advertising .................................... 28............................................... 12 Target Audience . 26 Hotel Cancellation ...... 25................................................................ 31 Age Limits.................. Access and Fees .......... 29 Cyber Center ................................................. 21-22 Confirmations and Changes ................................................................................... 12 Global Learning Objectives ................................ 26 Scientific Assembly Committee ................................................................................................................................................................................................. August 7 .... 104-107 Faculty .......................................................................................................................................... 4 Charitable Contribution ................................................................................................... 52-62 Saturday.............. 29 Press Information ........................ 26 Meeting Handouts ...................................................... 83-100 Business Center ..... 33-34 Electronic Posters .................................................................................... 28 Badge Information Mailing of .......... 23 Session Categories.................... 87-97 Product Category Directory............................... 63-74 Sunday.............................................................................................................

photosensitivity has been reported. • This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. including light-headedness. This formulation of minocycline has not been evaluated in the treatment of infections. Medicis Pharmaceutical Corporation. can cause fetal harm when administered to a pregnant woman. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs. SOLODYN is a registered trademark of Medicis Pharmaceutical Corporation. National Prescription Audit (NPA). Important Safety Information for SOLODYN Tablets • The most commonly reported side effects were headache. SOL 10 . and pruritus.038R 01/31/12 . • Safety beyond 12 weeks of use has not been established. like other tetracyclines. dizziness. fatigue. See following pages for Brief Summary of Full Prescribing Information. Data on file. • Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range from mild to life-threatening. • Central nervous system side effects. therefore. • In rare cases. Data through December 2010. • Tetracycline drugs should not be used during tooth development (last half of pregnancy and up to 8 years of age) as they may cause permanent discoloration of teeth. SOLODYN should be used only as indicated. SOLODYN did not demonstrate any effect on noninflammatory lesions. concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. dizziness. have been reported with minocycline therapy. • Should not be used during pregnancy nor by individuals of either gender who are attempting to conceive a child. it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Safety of SOLODYN has not been established beyond 12 weeks of use. IMS Health. and vertigo. Reference: 1. • Minocycline.SOLODYN is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

anaphylaxis. Limitations of Use SOLODYN did not demonstrate any effect on non-inflammatory acne lesions. Under such conditions. bone. IF ANY TETRACYCLINE IS USED DURING PREGNANCY OR IF THE PATIENT BECOMES PREGNANT WHILE TAKING THESE DRUGS. INFANCY. pancreatitis. Use of all tetracycline-class drugs should be discontinued immediately. This has been reported Malaise 26 (4) 9 (3) rarely with minocycline. transient lupus-like syndrome. rash. Evidence of loss that may be permanent or severe embryotoxicity has been noted in animals exists. Mild cases of pseudomembranous colitis usually respond to discontinuation of To reduce the development of drugthe drug alone. Appropriate tests for autoimmune syndromes should be performed as indicated. Bacterial resistance to the tetracyclines has also been reported. eosinophilia. oral cavity (teeth. including hematopoietic. Renal: reversible acute renal failure. a systemic retinoid. arthralgia. ADVERSE REACTIONS Clinical Trial Experience Because clinical trials are conducted under prescribed conditions. mucosa. dizziness or vertigo have been reported with minocycline whereas other tissue pigmentation has UP TO THE AGE OF 8 YEARS) MAY been reported to occur upon prolonged therapy. Myalgia 7 (1) 4 (1) Postmarketing Experience Serious Skin/Hypersensitivity Reaction Adverse reactions that have been reported Post-marketing cases of anaphylaxis with minocycline hydrochloride use in a and serious skin reactions such as variety of indications include: Stevens-Johnson syndrome and erythema Skin and hypersensitivity reactions: multiforme have been reported with fixed drug eruptions. If renal impairment exists. alveolar bone). Autoimmune Syndromes Tetracyclines have been associated with the development of autoimmune syndromes. The long-term use of minocycline in the treatment of acne has been associated with drug-induced lupus-like syndrome. hyperphosphatemia. associated with infection should be hypertension) in adults and adolescents C. Clinical mg/kg every 6 hours. LIKE OTHER TETRACYCLINE-CLASS ANTIBIOTICS. SOLODYN should not be used during pregnancy or by individuals of either gender who are attempting to conceive a child (see Nonclinical Toxicology & Use in Specific Populations). While this is not a problem in those with normal renal function. liver failure. dysphagia. SOLODYN should be used only as indicated protein supplementation. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of “antibiotic-associated colitis”. hypersensitivity reactions. skin. sclerae and B. bulging fontanels in infants. THE USE OF DRUGS OF THE heart valves. This formulation of minocycline has not been evaluated in the treatment of infections. symptoms should be cautioned about diffuse pigmentation as well as over sites driving vehicles or using hazardous This adverse reaction is more common of scars or injury. during long-term use of the drug but These symptoms may disappear during Development of Drug Resistant has been observed following repeated therapy and usually rapidly disappear Bacteria short-term courses. Central nervous system: pseudotumor cerebri. tooth discoloration. Hepatotoxicity Post-marketing cases of serious liver injury. consideration should be given to effectiveness of other antibacterial drugs. and can cause discontinuation of treatment. therapeutic measures should be initiated. Oncology: papillary thyroid cancer. with an antibacterial drug clinically effective against Clostridium difficile colitis. MINOCYCLINE. associated with the use of tetracyclines of SOLODYN may result in overgrowth of Results of animal studies indicate that in infants. pulmonary infiltrates with eosinophilia. management with fluids and electrolytes. the antibiotic found in fetal tissues. including nails. All tetracyclines form a stable calcium considered in selecting antimicrobial has been associated with the use complex in any bone-forming tissue. In symptomatic patients. DRUG INTERACTIONS Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity. Preliminary studies suggest that use of minocycline may have deleterious effects on human spermatogenesis (see Nonclinical Toxicology).BRIEF SUMMARY (see package insert for full prescribing information) SOLODYN® (minocycline HCl. THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS. USP) Extended Release Tablets Rx Only KEEP OUT OF REACH OF CHILDREN INDICATIONS AND USAGE Indication SOLODYN is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. Patients should minimize or avoid exposure to natural or Mood alteration 17 (3) 9 (3) artificial sunlight (tanning beds or UVA/B Somnolence 13 (2) 3 (1) treatment) while using minocycline. renal and hepatic studies should be performed. Tetracycline therapy may induce hyperpigmentation in many organs. and if therapy is prolonged. higher serum levels of tetracycline-class antibiotics may lead to azotemia. they should wear loose-fitting Arthralgia 9 (1) 2 (0) clothes that protect skin from sun exposure Vertigo 8 (1) 3 (1) and discuss other sun protection measures Dry mouth 7 (1) 5 (1) with their physician. Symptoms may be manifested by fever. hepatitis. Although signs and symptoms nonsusceptible organisms.379 (56) 197 (54) emergent event Photosensitivity Headache 152 (23) 83 (23) Photosensitivity manifested by an Fatigue 62 (9) 24 (7) exaggerated sunburn reaction has been Dizziness 59 (9) 17 (5) observed in some individuals taking Pruritus 31 (5) 16 (4) tetracyclines. Safety of SOLODYN has not been established beyond 12 weeks of use. Sporadic cases of serum sickness have presented shortly after minocycline use. THEREFORE. treated early in pregnancy (see Use in Specific Populations). Gastrointestinal: enterocolitis. erythema minocycline use in treatment of acne. Skin pigmentation includes OF THE TEETH (YELLOW-GRAY-BROWN). decreased hearing. Patients should be questioned for Autoimmune conditions: polyarthralgia. serum level determinations of the drug may be advisable. Stevens-Johnson syndrome. multiforme. visceral tissue. the possibility should be discontinued and appropriate retardation of skeletal development for permanent sequelae such as visual therapy instituted. AND CHILDHOOD including light-headedness. Tissue Hyperpigmentation Tetracycline-class antibiotics are known to cause hyperpigmentation. abnormal thyroid function. CBC. Selected Treatment-Emergent Adverse Reactions in at least 1% of Clinical Trial Subjects Adverse Reactions SOLODYN PLACEBO (1 mg/kg) N=364 N=674 (%) (%) At least one treatment. visual disturbances prior to initiation of treatment with tetracyclines and should be routinely checked for papilledema while on treatment. anaphylactoid purpura. angioneurotic edema. Skin and oral pigmentation Central Nervous System Effects TETRACYCLINE-CLASS DURING has been reported to occur independently TOOTH DEVELOPMENT (LAST HALF OF Central nervous system side effects of time or amount of drug administration. Endocrine: thyroid discoloration. are of pseudotumor cerebri resolve after If superinfection occurs. SHOULD NOT BE therefore. PREGNANCY. thyroid. of which is papilledema. thrombocytopenia. In moderate to severe resistant bacteria as well as to maintain the cases. Patients who experience these CAUSE PERMANENT DISCOLORATION administration. Concomitant use of isotretinoin and minocycline should be avoided because isotretinoin. pigmentation of skin and mucous membranes. Minocycline has decrease in fibula growth rate has been been reported to cause or precipitate drug-resistant bacteria to develop during observed in premature human infants the use of SOLODYN. patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Benign Intracranial Hypertension DRUGS. including fungi. CONTRAINDICATIONS This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. in patients with significantly impaired function. TETRACYCLINE may develop in patients using SOLODYN. photosensitivity. and malaise. Oral: glossitis. Metabolic Effects The anti-anabolic action of the tetracyclines may cause an increase in BUN. it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. the hallmark given oral tetracycline in doses of 25 as indicated. the susceptibility of bacteria Pseudotumor cerebri (benign intracranial USED DURING TOOTH DEVELOPMENT. on the developing fetus. WARNINGS AND PRECAUTIONS Teratogenic Effects A. This reaction was manifestations include headache and Superinfection shown to be reversible when the drug blurred vision. use was discontinued. ANA. exacerbation of systemic lupus. tetracyclines cross the placenta. autoimmune hepatitis and vasculitis. eyes. After the diagnosis of pseudomembranous colitis has been established. is also known to cause pseudotumor cerebri. . pericarditis. liver function tests. including irreversible drug-induced hepatitis and fulminant hepatic failure (sometimes fatal) have been reported with minocycline use in the treatment of acne. and acidosis. Hematology: hemolytic anemia. it should be used only pseudotumor cerebri. and treatment (see Warnings and Precautions). Therefore. machinery while on minocycline therapy. Bulging fontanels have been As with other antibiotic preparations. The following table summarizes selected adverse reactions reported in clinical trials at a rate of ≥1% for SOLODYN. lower than usual total doses are indicated. Enamel hypoplasia when the drug is discontinued. A therapy. CAN CAUSE FETAL HARM WHEN ADMINISTERED TO A PREGNANT WOMAN. Pseudomembranous Colitis Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range from mild to life-threatening. adverse reaction rates observed in the clinical trial may not reflect the rates observed in practice. If Urticaria 10 (2) 1 (0) patients need to be outdoors while using Tinnitus 10 (2) 5 (1) minocycline. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. balanitis. and other appropriate tests should be performed to evaluate the patients. even usual oral or parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity. Because of the potential for of tetracyclines. Laboratory Monitoring Periodic laboratory evaluations of organ systems.

NDC 99207-467-30 Bottle of 30 development in nursing infants from the an apparent reduction in the percentage tetracycline-class antibiotics. Reduced mean fetal body weight was observed in studies in which minocycline was administered to pregnant rats at a dose of 10 mg/kg/day (which resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use SOLODYN). Each tablet account the importance of the drug to the Morphological abnormalities observed in contains minocycline hydrochloride mother (see Warnings and Precautions). Drug/Laboratory Test Interactions False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test. like other tetracycline-class drugs. Low Dose Oral Contraceptives In a multi-center study to evaluate the effect of SOLODYN on low dose oral contraceptives. unscored. a decision The 115 mg extended release tablets are of sperm that were motile. supplied as follows: Use of tetracycline-class antibiotics below HOW SUPPLIED/STORAGE AND HANDLING NDC 99207-462-30 Bottle of 30 the age of 8 is not recommended due to How Supplied NDC 99207-462-10 Bottle of 100 the potential for tooth discoloration (see SOLODYN (minocycline HCl. supplied as follows: NDC 99207-463-30 Bottle of 30 The 80 mg extended release tablets are gray. or *90 mg is also covered by U. Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum. oral administration of NDC 99207-461-10 Bottle of 100 100 or 300 mg/kg/day of minocycline to The 105 mg extended release tablets are male rats (resulting in approximately 15 to 40 times the level of systemic exposure to purple.S. equivalent to 45 mg minocycline. renal. NDC 99207-460-10 Bottle of 100 Manufactured for: OVERDOSAGE The 55 mg extended release tablets are Medicis.5 times the systemic exposure to minocycline observed in patients as a result of use of SOLODYN). and debossed with “DYN-080” on one side. USP) Extended Warnings and Precautions). 80 mg. and (at 100 should be made whether to discontinue green. reflecting the greater as follows: U. AZ 85256 medication. and there was no effect on gross appearance of F2 pups (offspring of F1 animals). supplied 17110163 hemodialysis or peritoneal dialysis. female patients are advised to use a second form of contraceptive during treatment with minocycline. taking into of morphologically abnormal sperm cells. coated. it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. gray. coated. In this study. and concomitant disease NDC 99207-460-30 Bottle of 30 7. 105 mg. learning ability. light-resistant container be cautious. 10. Minocycline contains minocycline hydrochloride August 2010 is not removed in significant quantities by equivalent to 55 mg minocycline. or of contraceptive failure. The Dermatology Company In case of overdosage. coated. treat symptomatically and with “DYN-055” on one side. moisture. The 65 mg extended release tablets are Impairment of Fertility blue. However. Minocycline was assessed for effects on peri. and identified differences in responses between The 45 mg extended release tablets are excessive heat. No effects were observed on the physical development.and post-natal development of rats in a study that involved oral administration to pregnant rats from day 6 of gestation through the period of lactation (postpartum day 20). Rare spontaneous reports of congenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post-marketing experience. at dosages of 5. in patients 12 years and older. include sufficient numbers of subjects aged 65 mg. Mutagenesis—Minocycline was not mutagenic in vitro in a bacterial reverse mutation assay (Ames test) or CHO/HGPRT mammalian cell assay in the presence or absence of metabolic activation. Each tablet contains minocycline hydrochloride Nursing Mothers of use of SOLODYN) adversely affected Tetracycline-class antibiotics are excreted spermatogenesis. Minocycline. pink (orange-brown). Mutagenesis. can not be ruled out. Based on the results of this trial. and abnormal flagella. and debossed Carcinogenesis—Long-term animal with “DYN-065” on one side. and debossed dose selection for an elderly patient should with “DYN-045” on one side. FSH and LH plasma levels. supplied of the dosing range.541. Each tablet rats was unaffected by oral doses of contains minocycline hydrochloride minocycline of up to 300 mg/kg/day (which equivalent to 90 mg minocycline. 115 mg 65 and over to determine whether they or 135 mg minocycline. Each tablet contains minocycline patients below the age of 12 has not conceive a child. respectively. coated. with “DYN-115” on one side. calcium or magnesium and iron-containing preparations. are supplied Handling respond differently from younger subjects. discontinue pink. Patents cardiac function. supplied as follows: NDC 99207-466-30 Bottle of 30 The 90 mg extended release tablets are Impairment of Fertility—Male and yellow. contains minocycline hydrochloride equivalent to 65 mg minocycline. There are no adequate and well-controlled studies on the use of minocycline in pregnant women. A structurally related compound.838* and Patents Pending frequency of decreased hepatic. supplied as follows: misshapen heads. coated. Storage Release Tablets are supplied as aqueous Geriatric Use film coated tablets containing minocycline Store at 25ºC (77ºF). Each tablet contains minocycline hydrochloride equivalent to 80 mg minocycline.Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin. 90 mg. usually starting at the low end contains minocycline hydrochloride with child-resistant closure. unscored. oxytetracycline. the patient should be apprised of the potential hazard to the fetus and stop treatment immediately. Patent 5. unscored. No effects of treatment on the duration of the gestation period or the number of live pups born per litter were observed. coated. In general. (resulting in approximately 3 times and 2 times. no conclusion on causal association can be established. and debossed and 300 mg/kg/day) increased numbers nursing or discontinue the drug. crosses the placenta and may cause fetal harm when administered to a pregnant woman. of breakthrough bleeding. Each tablet Dispense in tight. the elderly and younger patients. the systemic exposure to minocycline observed in patients as a result of use of SOLODYN). Because of the potential for mg/kg/day included a reduced number serious adverse effects on bone and tooth of sperm cells per gram of epididymis. Each tablet studies have not been performed to . or reproduction of F1 pups. therefore. hormone levels over one menstrual cycle with and without SOLODYN 1 mg/kg once-daily were measured. Only limited information is available regarding these reports. as follows. and debossed female reproductive performance in with “DYN-090” on one side. sperm samples included absent heads. improperly rotated forelimbs. was found to produce adrenal and pituitary tumors in rats. coated. unscored. Gross external anomalies observed in F1 pups (offspring of animals that received minocycline) included reduced body size. Keep out of reach of children Other reported clinical experience has not Protect from light. equivalent to 115 mg minocycline. Minocycline induced skeletal malformations (bent limb bones) in fetuses when administered to pregnant rats and rabbits in doses of 30 mg/kg/day and 100 mg/kg/day. and debossed minocycline observed in patients as a result with “DYN-105” on one side. as follows: NONCLINICAL TOXICOLOGY NDC 99207-465-30 Bottle of 30 Carcinogenesis. excursions are Clinical studies of SOLODYN did not hydrochloride equivalent to 45 mg. Each tablet institute supportive measures. progestinic hormone. If the patient becomes pregnant while taking this drug. minocycline. evaluate the carcinogenic potential of minocycline. coated.373 or other drug therapy. Effects observed at 300 equivalent to 105 mg minocycline. hydrochloride equivalent to 135 mg been established. USE IN SPECIFIC POPULATIONS Pregnancy Teratogenic Effects: Pregnancy category D (see Warnings and Precautions) SOLODYN should not be used during pregnancy. supplied resulted in up to approximately 40 times the as follows: level of systemic exposure to minocycline observed in patients as a result of use of NDC 99207-461-30 Bottle of 30 SOLODYN). unscored. unscored. behavior. supplied as follows: in human milk. 55 mg. unscored. Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. minocycline-related changes in estradiol. To avoid contraceptive failure. unscored. Minocycline was not clastogenic in vitro using human peripheral blood lymphocytes or in vivo in a mouse micronucleus test.S. permitted to 15º-30ºC (59º-86ºF) [See USP Controlled Room Temperature].347 and 7. or 50 mg/kg/day.908. body weight gain was significantly reduced in pregnant females that received 50 mg/kg/day (resulting in approximately 2. and reduced size of extremities. SOLODYN should not be used by individuals and debossed with “DYN-135” on one Safety and effectiveness in pediatric of either gender who are attempting to side.544. Pediatric Use SOLODYN is indicated to treat only NDC 99207-464-30 Bottle of 30 Limited human studies suggest that inflammatory lesions of non-nodular minocycline may have a deleterious effect The 135 mg extended release tablets are moderate to severe acne vulgaris on spermatogenesis. and debossed Scottsdale. respectively.

.

.

D.cme information SUMMER ACADEMy MEETING 2011 DIRECTLy SPONSORED By The American Academy Of Dermatology STATEMENT OF NEED The American Academy of Dermatology’s Summer Academy Meeting 2011 is planned to comprehensively address the nine content areas within the Dermatologic Core Curriculum and provide dermatologists and other dermatology health care professionals with high quality educational opportunities for the optimization of dermatologic knowledge. Novartis Pharmaceuticals. Centocor Ortho Biotech. Stratman.P.D. Yaupon American College of Physicians. nails. • Suzanne Olbricht. Galderma Laboratories.D. M. Stiefel Pierre Fabre Dermatology Bristol-Myers Squibb. Johnson & Johnson. competence and performance.D. Robert S. Tissue Repair Company Molynecke. Ilona J. M. Joan Guitart. PharmaDerm/Veregen Abbott Laboratories. • Robert David Greenberg. Genzyme Astellas Eisai.D. Orfagen Lumenis. The following planning committee members reported they do have relationship(s) with commercial interest(s) to be disclosed to learners: Planner Robert T. 12 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 . GlaxoSmithKline. National Healing Board. • Janet A. Eichenfield. Lim. WebMD Elsevier Advanced Biohealing. Johnson & Johnson. Ortho Dermatologics Elsevier.. Elsevier. Galderma. Dermik/BenzaClin. Amgen. dermatologic surgery. Kirsner. Healthpoint. pediatric dermatology. TARGET AUDIENCE The primary target audience of the American Academy of Dermatology’s Summer Academy Meeting is its members. Genentech Dow Pharmaceuticals Sciences. Organogenesis GlaxoSmithKline Mosaic Clinuvel. M. NOTE: Each session has its own specific learning objectives which are included with the session description in the scientific sessions portion of the Program Book. Medicis Inamed Suneva CLRS Technology cme information Lawrence F. M.D. L.D.D. James. M. Honoraria – Investigator Honoraria – Consultant Honoraria – Speaker Honoraria – Consultant Royalty Investigator – No Compensation Received Honoraria – Consultant Honoraria – Consultant Honoraria – Advisory Board Grants – Investigator Honoraria – Other Royalty Grants – Investigator Honoraria – Advisory Board Honoraria – Other Advisory Board – No Compensation Received Honoraria – Consultant Honoraria – Speaker Investigator – No Compensation Received Grants – Investigator Stockholder – Investigator The Academy staff involved with this CME activity and all content validation/peer reviewers of this CME activity have reported no relevant financial relationships with commercial interest(s).D. Frieden. management and treatment of diseases of the skin. • Self assess current practice management skills and develop strategies for improving these skills. Henry W. Allergan. Ming. Brodell. Astellas. Role Honoraria – Speaker Commercial Interest 3 M/Graceway Pharmaceuticals. M. and mucous membranes. Novartis. M. M.D.D. • Develop new skills to improve their everyday practice of dermatology. GLOBAL LEARNING OBJECTIvES This comprehensive meeting provides learners with opportunities to: • Review and apply basic knowledge and skills in medical dermatology. • Assess the relationship of evidence-based diagnostic approaches and therapies with new dermatologic treatment developments. M.D. Wiley-Blackwell Allerderm. hair. M. DISCLOSURES PLANNER DISCLOSURE OF RELEvANT FINANCIAL RELATIONSHIP(S) The following planning committee members reported they have no relationship(s) with commercial interest(s) to disclose relevant to the content of this CME activity: • Michael E. Moy. M. M. Ronald L. Medicis. Secondary audiences for the Summer Academy Meeting 2011 include dermatology residents and other dermatology health care professionals. • Erik J. Promius Coria Galderma. Fairley.D. La Roche-Posay. M. William D. SanofiAventis. • Update their knowledge about recent advances in the diagnosis. and dermatopathology.

the American Academy of Dermatology has implemented mechanisms. Statements or opinions expressed in this program reflect the views of the faculty and do not reflect the official policy of the American Academy of Dermatology. prior to the planning and implementation of this CME activity. such relationships would be with companies that sell health care products or services that are consumed by or used in the treatment of patients.aad. interim analyses. Food and Drug Administration approved labeling. contact the medical affairs department of the manufacturer for the most recent approval information.org | 13 .S. but rather to provide learners with information on which they can make their own determination whether or not said relationship(s) influenced the content of the educational activity. The American Academy of Dermatology is not responsible for statements made by faculty. Faculty at this meeting will be discussing information about pharmaceutical agents that is outside of U. or child). sibling. unlabeled (not approved for any indications). Session director and faculty disclosure information is located within the Program-at-a-Glance book after the scientific schedule. Typically. for the lAteSt ProgrAm Book informAtion PleASe refer to www. ACCREDITATION The American Academy of Dermatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. It is the policy of AAD that all faculty participating in a CME-certified activity are required to disclose to AAD and to learners relevant financial relationships with any commercial interest(s) that they or their first-degree relative (spouse. The intent of this disclosure is not to prevent participation in CMEcertified educational activities by individuals with a relevant financial relationship with commercial interest(s). and any limitations on the information that is presented. management and treatment options of a specific patient’s medical condition. such as data that are preliminary or that represent ongoing research. COMMERCIAL SUPPORT DISCLOSURE Merz Aesthetics Injectables for Live Patient Demonstration The following commercial interests provided in-kind support for the Summer Academy Meeting 2011: cme information DISCLAIMER RESOLUTION OF CONFLICTS OF INTEREST In accordance with the ACCME Standards for Commercial Support of CME. Faculty have been asked to also make a verbal disclosure at the start of their presentations supplemented by a disclosure slide in order to verify the accuracy of the disclosure information printed in the Program-at-a-Glance and ensure their disclosure information is shared with the learners PRIOR to the presentation taking place. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to the diagnostic. to identify and mitigate conflicts of interest for all individuals in a position to control the content of this CME activity. This information is intended solely for continuing medical education and is not intended to promote off-label use of these products/procedures. and/or unsupported opinion. and/or investigational (not FDA approved). If you have questions. “Relevant financial relationships” include financial relationships in any amount occurring within the past 12 months that create a conflict of interest. experimental. parent.cme information FACULTy DISCLOSURE OF RELEvANT FINANCIAL RELATIONSHIP(S) UNAPPROvED USE DISCLOSURE The American Academy of Dermatology requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label (not approved for the indications being discussed).

please submit a copy of the CME Claim Form and check “yes” where asked if you would like to receive the CME Credit Certificate. CME credits can also be claimed online at www. 14 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 . Learners should complete the session evaluation forms and drop them into the boxes labeled “CME Evaluations” throughout the duration of the meeting. learners should complete the CME credit claim form and drop it into the “CME Evaluations” boxes for processing. Physicians should claim the credit commensurate only with the extent of their participation in the activity. Prior to departure. are approved for direct-sponsored AAD Category 1 CME Credit. If you are a physician and would like to receive a CME Credit Certificate. wHAT yOU NEED TO DO TO RECEIvE CME CREDIT cme information CME Credit is awarded based on actual participation in the learning activities. Non-member physicians who attend the meeting can receive a CME Credit Certificate which includes documentation of the total CME credits claimed. Credit is calculated on a 1/4-hour basis and will be reflected on member transcripts within four to six weeks after the meeting.cme information AMA PRA CATEGORY 1 CREDIT TM DESIGNATION NON-MEMBER PHySICIAN CME CREDIT CERTIFICATE The American Academy of Dermatology designates this live activity for a maximum of 30 AMA PRA Category 1 CreditsTM. The online claim system is available for 2 weeks post meeting.aad. unless otherwise specified. An overall evaluation form and CME credit claim form will be provided in the registration bag distributed on-site at registration.org/cme/claim. AAD RECOGNIZED CREDIT The American Academy of Dermatology’s Summer Academy Meeting 2011 is recognized by the American Academy of Dermatology for 30 AAD Recognized Category 1 CME Credits and may be used toward the American Academy of Dermatology’s Continuing Medical Education Award. All Summer Academy Meeting 2011 activities.

3% on one half of the face and tretinoin gel microsphere.com . and sunburn (1. 12-week.1%1* HIGH PATIENT SATISFACTION 86% of patients on adapalene gel.04%2† *A phase 3b. investigator-blinded. neither product was found to be inferior. lesion reduction (total. occurred early in treatment.differin. Subjects received Differin® Gel. and decreased thereafter. may increase the potential for irritation. multicenter. pruritus (1.8%). desquamation (1. www.0%).1%1* Local tolerability scores comparable to tretinoin gel microsphere. scaling. Use of sunscreen and protective clothing over treated areas are recommended when exposure cannot be avoided. Pregnancy Category C. 160 patients participated in the satisfaction survey. 0. 0. the majority of cases were mild to moderate in severity. † A single-center. and inflammatory) was similar to tazarotene gel. 0. 0.2%). Please see brief summary of Prescribing Information on adjacent page.3% Primarily comedonal acne: EXAMPLE A EXAMPLE B POWERFUL EFFICACY From baseline to week 12. 0.9%). Important Safety Information Of the patients who experienced cutaneous irritation (erythema. Concomitant use of potentially irritating products or overexposure to sunlight or sunlamps. investigator/evaluator-blinded.6%). bilateral (split-face) comparison of healthy subjects ≥18 years of age (N=30). noninflammatory. randomized. and/or stinging/burning) during the clinical trial. 0.When comedonal acne is your primary concern… PRESCRIBE DIFFERIN® GEL. controlled clinical study of patients 12 to 35 years of age with acne vulgaris (N=172). Adverse events that occurred in greater than 1% of the subjects included dry skin (14.04% on the other half for 22 days. dryness.3% were satisfied or very satisfied vs 69% on tazarotene gel. At the end of 12 weeks. skin discomfort (5. 0. noninferiority. extreme wind or cold.

San Antonio.1%) 110 (43. No effects of adapalene were found on the reproductive performance or fertility of the F0 males or females. two patients delivered healthy babies by normal delivery. 0.0. 0.15 to 5.3. 0.8%). 0.5. 1 Human Data In clinical trials involving DIFFERIN® Gel. 2 0.3% only . use of th ar. Data on file. and/or burning/stinging). oral doses of 0. h ive pr g ducts s and used e e ve b t c g rol m ac d dur n apy How be avoided. 0.P. Efficacy and tolerability of adapalene 0. 2. Reproductive function and fertility studies were conducted in rats administered oral doses of adapalene in amounts up to 20 mg/kg/day (up to 26 times the MRHD based on mg/m² comparisons). Although the significance of these studies to human use is not clear. USAGE DIFFERIN® G l. Safety and effectiveness in geriatric patients age 65 and above have not been established. Pediatric Use: Safety and effectiveness in pediatric patients below the age of 12 have not been established.3% gel at topical doses of 6. er and ug mg/kg/day. 0 3%. 0. Patients who normally Ad p len gh no e h sun xpo n and th se with ects in v nsi Am s est.3% is administered to a nursing woman. or ge otoxic e nherent s tro iv ty to sun should be mst r ov xercise a mouse mphoma TK products and protec ve m onucl treated tion Us of suns reen assay) and in vivo (mou lothcng over us test). Chronic t t e t of l lt t d d b b d. two p ye to el medi o babi sresult n ea t nsy stwo s swelling.2%).3% DIFFERIN® Ge . A 3-week. For topical use only roa for ophthalmic.54:242 lead to the same side effects as those associated with excessive oral intake of vitamin A.6%) Vehicle Gel N 134 6 (4. caution should be exercised when DIFFERIN® Gel.0%) 0 (0. ssumed to be 2. 0.0%) 36 (14. t or n d e o 0 potential sk kg o d 8 o te ep lat o should s wereperfo med oa str ated k doses to the 15 to 5. eczematous. the exposure in acne patients treated with adapalene 0. 0 3%. Galderma Laboratories. or to icity and appro n ma incr aution Particular caution in d be ex rc and sing prepa icat on in abb ts lime) should be only m ched with ases n super umerary r b houboth sp ci ed n e ayed oss at ons conta n ng Syst sorc nol. R N® el 0. scaling or skin discomfort may occur. skin discoloration. Findings included cleft palate.5 gr sry FFER scaling.7 times. 14501 N. and in rats at Bec use man drugs ar exc e ed ducted n Moth at topical doses ofwhe 1.0o mg n e d yo s Wax atogen ef ec not be seen in 6 im s e maximu re ommended human exacerbation b acne may m c pari may A due n ha 9. is for xternal usein pre . a th e rm rr ta io nimal Dat 7. Adapalene has been shown to be teratogenic in rats and rabbits when administered orally (see Animal Data below).4. 2. investigator/evaluator-blinded. 0 3% o thesemg/kg d ions h ve be n used. no f P p l f more rapid or better results will be obtained and marked redness.3%. Chinese h arn d to y cel s exp ri nce hdid levels of bit utag ur . chest and back (2 grams applied to 1000 cm2 of acne involved skin). Animal Data • No teratogenic effects were seen in rats at oral doses of 0. Texas 78215 USA GALDERMA is a registered trademark. The safety and efficacy of DIFFERIN® Gel. The incidence of local cutaneous irritation with DIFFERIN® Gel. This ons. Systemic exposure (AUC0 24h) to adapalene 0. ed at the maximum S ety andnd d h man dose (MRHD).3% in the treatment of acne vulgaris. DIFFERIN® Gel. L.3% in pregnancy has not been established. Fort Worth. and products at doses of 0. pruritus (1. Texas 76177 USA Manufactured by: DPT Laboratories. L. Dermatol the drug may 50 Marketed by: GALDERMA LABORATORIES. 0. 0. rash. d du m dicat on is y on y if the potential benefit the physician. ehicle mg/kg/day.5 grams DIFFERIN®been estab n the oral ® Geria ric Use inc cal s s of DIFFERIN Gel 3% did not inc oma in the 65 yea s of ge nd o l ts wa study. The product should e e be applied Avoid con act with the eyes. 0 3% ndi FFER N Ge . Revised: June 2007 325089-0607 DI7-1 TRIM 7 BL ED: N SAFETY References: 1. pat have wn an creased rto eo sk use a mo s ld be structed sk ther n n oplasm w er. ©2010 Galderma Laboratories.3% once daily included: dry skin (14.5%) 2 (1. t l d h II t A ingestion of 2006. re G l. concom om exophthalmos a tan id y other po nt ally ima ng top calrab ducts (medicated or abrasive soaps and cleansers. houldand ve thewhen ng nform tion nd instr m Dat tions s This in pregn n o be used on y as directed by justi ies the 1. the pattern of adverse events was similar to the 12 week controlled study. occurred early in treatment and decreased thereafter. ncreasedCl n d nceudif benign and malignan0 pheochromocy ude ub ectsadrenal med llas of m d r o dete m erv d ob ne wh and above have not be studies were No photocarcinogenicity n estab ished conducted.P. 6 women treated with DIFFERIN® Gel. No cation D ogen city stud es ev ty duct d. abrasions. r mic expos salicyl c 0ac h) in combin t on 0. retinoids) when exposed to UV irradiation in the laboratory or to sunlight. In th a da s udy.Humancon ct with the eyes. Pregnancy: Teratogenic effects. con prem tur nd deye 6 pregn of the ien s th ed h h may by n m d e ch t nts de iv ed unct s. be apa to the eeno own o m di at ogen p n ats a d abb leswh aad n s er not b c t do red a 5 mg/ to d scont n n act of the b ra n on ev ously un een s on d ho ld d ora nsid es eas n g epresen e 2 and therapy. Adapalene has been shown to be teratogenic in rats and rabbits when administered orally at doses 25 mg/kg representing 32 and 65 times. espectively® Gel. 0. In a one year.9%). angles lit the nose. 0. 0. erythema.0%) * Selected adverse events defined by investigator as Possibly.D ug Interactions: As D FFER Ge 0.7%) 72 (28. he Expos ecy. or sunburned skin. Ltd.3% ese of ac t vulgar s been used IND CATIONS AND or salic ic acid in comb nation i th D ated for the topic l tr a mentprepa e ons hav in patients it years s age and older. Mutagenesis Gel. Geriatric Use: Clinical studies of DIFFERIN® Gel. 3%.5%) 113 (44. 0 3%. dryness.3% from Controlled Clinical Study (N 253*) Maximum Severity Scores Higher Than Baseline Erythema Scaling Dryness Burning/Stinging Mild 66 (26. L. angles of the nose. and usually lessen with continued use of the st erved.. An ffe ud es ents m d photoc rc pending upon he wer rco of th se sid al ts. including sunlamps. . randomized. Nursing Mothers: It is not known whether this drug is excreted in human milk. n n ated urize nt on be used v nec d a n g w ver. 0. and 6.0 mg/kg/day adapalene representing up to 6 times the maximum recommended human dose (MRHD) based on mg/m² comparisons. controlled clinical trial. two patients delivered prematurely and the babies remained in intensive care until reaching a healthy state and one patient was lost to follow up. oDuring thet early weeks of therapy. it isrepre ab e not 7 and 28 7 times. n Cle set aff cted ar a w t FFER orGel. 0. The following selected adverse events occurred in less than 1% of patients: acne flare. If the medication is applied excessively. Th PRECAUTIONS: at the m x rta n taneou huma dose (MRHD a treatment such a D ema. spices.. Animal studies have shown an increased risk of skin neoplasms with the use of pharmacologically similar drugs (e. pruritus.5 in human T ese doses re up to 3 erc s (mic DIFFE IN (rats) in terms of stered ursing wom n.P. ® Gel 0 d yness. exophthalmos and kidney and skeletal abnormalities in the rabbit.6%).0 apal ny of op omponents 0 . fa e.3% gel compared to tazarotene 0. until a effects of eated t ad p e subsided applied to the M tagenesis.3% N 258 Related* Adverse Events Dry Skin Skin Discomfort Desquamation 57 (22.3% from the controlled clinical study is provided in the following table: Table 2: Physician assessed local cutaneous irritation with DIFFERIN® Gel Incidence of Local Cutaneous Irritation with DIFFERIN® Gel. Table 3: Patient reported local cutaneous adverse events with DIFFERIN® Gel DIFFERIN® (adapalene) Gel. Freeway Fort Worth. Nu sing mice rs It is not known 0. 2008. Arsonnaud S. dev ions.2%) 2 (0.areas is recommended when exposure cannot R product function tremes. OVERDOSAGE: DIFFERIN® Gel. 0.7 and 28. 0. conjunctivitis.3% is intended for topical use only. 2. back (2 g t f Fert lity 1000 cm2 of acne in s with dapalene have been con Carcinogenesis.1%) 36 (14%) 15 (5.1% gel in the treatment of acne vulgaris. desquamation (1.P. Because many drugs are excreted in human milk. abra lopm nt and sub e u t reproduct func ion of t to owth.15. Thiboutot D.0 mg/kg/day in rats and rabbits represented 5. and eczema.8%) 4 (1. encephalocele and skeletal abnormalities in the rat and umbilical hernia. Galderma Laboratories. microphthalmia. soaps and cos u of nd skelet l abno r t es n the pr t. 12 is adv of b e not to star Carcinogenesis. and 1.ds) when di cont nue UV If o rea ght s ggesting sens ti vity ce of thes al u tation occ ns. Ad ts e e ntsbeen shown o be Gel. or e AUC 2 d to adapal e with gel at topica doses If 6. 0. exposure inth ne pat en ut h pr pwra ons h ene 0. Adapalene did not exhibit mutagenic or genotoxic effects in vitro (Ames test. caution hould be e tim s d wh )nand 2 imes Gel 0 3% s admi mg/m² dtoyathe pot nt al e posure Pediatric Use: r omm ef ecti eness in pediatric p ients be ow the age of 12 have not Gel.7 (6)(suppl):S3-S10. 0. should be minimized during use of adapalene. eyelid edema.his d 4. d o ats be i ered a doses o adap re in amounts be avo ded eWeath r e nd fe til y stud e wind c duct al n mayadm rr tat ng oto pati nts under enetment with up to 20 adapalene on the reproductive performanc or fe t of of he F and mucous membranes. lips. Exposure to sunlight. pat e on shouldbe advi ed to a o a un tion A hough the s g ica or chemi s r es to um use i n c med cat ts hould be d s on nu d or minim ze exposu to either sunlight o artif cial UV irradiation sources.3% o exposed to use tur h the u ceothe freq n o of ppli it ar drugs e.0 s excreted n human m k. respectively. Avo d Da 3. patients should be advised to avoid or minimize exposure to either sunlight or artificial UV irradiation sources. contact dermatitis.3% did not include subjects 65 years of age and older to deter mine whether they respond differently than younger subjects.5%) Moderate 33 (13.6%) 43 (17. lips. Galderma is a registered trademark.6%) * Total number of subjects with local cutaneous data for at least one post Baseline evaluation. the majority of cases were mild to moderate in severity. lin l ia invol ng a mi ® soapless in the befo applying thi med is. L. Pregnancy Category C.4%) 3 (1.2%) Severe 1 (0. • Cutaneous teratology studies in rats and rabbits at doses of 0. Chinese hamster ovary cell assay.6. an apparent ose (MRHD of sed on m occur. are mostly mild to moderate in intensity. One patient elected o terminate the pregnancy.3% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. chest an Impairme a s applied t Carc nogenicity stud olved s n). oral or cular ca t onuse li e) should be ap Not hed wi h caution Part intravaginal sh g ADVERSE REACTIONS: In the multi center.0%) 47 (18.8%) 9 (3.0 mg/kg/day exhibited no feto toxicity and only minimal increases in supernumerary ribs in both species and delayed ossification in rabbits. Probably or Definitely Related Related adverse events from the controlled clinical trial that occurred in greater than 1% of patients who used DIFFERIN® Gel. and of 0 mg/kg/da ingents. J Drugs Dermatol. respectively.g. 0. the MRHD based on mg/m² comparisons.3% once daily for 12 weeks. development and subsequent reproductive function of the F1 offspring. These are most medulto occur during the fiob four weeks of treatment. red e pharm o y ic y s on of DIFFERIN® ino 0.3% became pregnant. Soto P. and mucous membranes. males or females There were also no etec ab not fects on the offspr g. mg/kg/day m k.5%) 0 (0.3% g advi ented 5 to start therapy with DIFFERIN the 0 3%. open label safety study of 551 patients with acne who received DIFFERIN® Gel. such s were o old.3%cleansertreat en of acne ulga catiwo 4. ast exhib d no to metics that have a olog g drying effect. • Cut neous te stro tudies in ra and rabbits with high concentrations 6 alco ol. scaling. Gene al: C mum ommen digns a d symp oms of sumed to e 2.6.3% et s abnorm nti el to nduce o al irr t b n ln erni pat en s. Of the patients who experienced cutaneous irritation (erythema. There are no adequate and well controlled studies in pregnant women. mouse lymphoma TK assay) and in vivo (mouse micronucleus test). and sunburn (1. However. Th s med c tion should not be applied to cuts. single-center.differin. czemato s or s nbur ed skinveAs wi h other r tFnoids u e of “waxing” as a depilatory method Pregnancy: eratogenic t fects th nancy C should be avo ded on sk n e eated wPre dapalene ® pregnant for Pat e pa P ti as using DIFFERIN eratogenic ats rec bbits follo mi stere oral (see An c Info matiowomen. TX 76177 DIFF-088 03/10 www.0%). g uts. when administered to pregnant women.com . There were also no detectable effects on the growth.3% h DIFFERIN® (adapalene)NGel.g. increased inc be experienced and use of DIFFERIN® omocytom s in he adrena likely as of male rats wa stinging/burning may dence of benign with mal gnant pheoch Gel. skin discomfort (5.3% gel applied to the face. p ancy c nta ning alp a ydro y or n ycoli asu sshould 5 Mo s reat may y ter h f g h sary. signs and symptoms of local cutaneous irritation were monitored in 258 acne patients who used DIFFERIN® Gel.3% of Fertility: rc no tered s nd v a s adap l e have been con CONTRAINDICATIONS: DIFFERIN®Impa rment should not beC dmin enicityto udie dwi h who r hyp rsens t ve to a uctedn om ce at the al doses of in he gel nd 4. bilateral (split-face) comparison.3% tan u SUMMARY BRIEF e o other pot e patien Rx only su ur resorcinol. women of chi d bearing potential initiated treatment only after having had a negative pregnancy test and used effective birth control measures during therapy. clinical study of adults 18 years of age and older with healthy skin (N=30).3. Retinoids may cause fetal harm.0 prepa a y n ts and abbit sulfur. ® m crophthalmia cephalocele nd ske h l the po li in the r nd u ti c Drug Interactions Ae DIFFERIN G l.

55 11:00 a. . . . .42 Negotiating Your Way to Great Leadership . .51 W004 Friday. to 1:45 p. . . . . . . Memorial Lectureship: Sentinel Node Biopsy: Just the Facts. . . to 12:00 p.m. . . Update in CTCL: A Tale of Two Kinds of T-Cells / Sam T. 54 10:30 a. . . .41 E.m. . President’s Address / Ronald L. . . . . . . . . . . . . . .38 Forums — 9:00 a. . . .46 Course — 2:00 p. . . . . M. . . . . . . . Non-Ablative and Ablative Fractional Resurfacing: Cosmetic and Medical Indications / Roy G. . Overhauling CME and Dermatology Education: Laps. you Decide! / Timothy M. . . . . . 54 9:20 a. . . . . . .m. . . . . . . . . . . . . .49 U011 From the Dermatology-Rheumatology Clinic: Practical Tips and Advances in Management . . . . Eczema and Inflammatory Dermatosis . . . . . .40 workshop — 9:00 a.R. . .44 workshop — 12:00 p. . .m. . . . . .39 F002 F003 Case-Based Challenges in Consultative Dermatology . . . . . . . . . . . .47 S005 Medication Monitoring and Complications .39 Photoprotection .51 Dermoscopy . .53 Plenary Session — 9:00 a.Program overview Restricted Session open to dermatologist and adjunct (researcher.m. . . . . . . . . . Margolis. .m. . . . .43 F007 Case-Based Controversies: Procedural . Moy. . .42 Focus Sessions — 2:30 p. . . . . . . .. . EADV/AAD Joint Symposium .m. . . . . . . . .H.m.m. . . . . . . . .m. to 5:00 p. . . . . . . . . . . . . . . . . . . . . . . . . . A ticket is required for admittance M O C This activity has been approved by the ABD to satisfy component 2 of MOC-D Leadership Institute — addresses leadership competencies specific to dermatologists Practice Management Session open to eligible office staff/registered nurses Patient Safety Session Audience Response System Session Health Information Technology Sessions Thursday.43 What’s Boiling Over: Atopic Dermatitis and Other F006 Eczematous Conditions . . . . Ph. . . . . . . . . . . . . . . .50 Program overview workshops — 3:00 p. . . . . Geronemus. . . . . . . . 55 10:45 a. . . to 2:00 p.m. . . .m. . . . . . . .m. . .D.D. . . .m. Johnson. U001 Your True Colors: Know Yourself and Understand Others . . . to 4:00 p. . . . W003 MOC Self-Assessment: Acne. . . . . . . . . F001 Nails . . . . . . . . . . . . Guest Speaker / Don Tapscott . . . . W001 MOC Self-Assessment: Skin Cancer . . . . . . . . . . . M. . . . . . . .m. . . to 5:00 p. . . .m. . . . . . . . Everett C. . . . . . . . to 5:00 p. . .49 Forums — 3:00 p. . . F005 Infectious Disease and Infestation Update . . Psoriasis. . . . . . . . . . . . . to 8:45 a. . Chair’s Welcome / Henry W. . . . . .m.48 U009 Smoking and the Skin . to 5:00 p. M. . 9:00 a. . . . . . . . . . . Maps.46 U007 Neonatal Dermatology . .m. . . . . . . . . . 56 for the lAteSt ProgrAm Book informAtion PleASe refer to www.45 U006 Bringing out the Best in Others . W002 MOC Self-Assessment: Office-Based Safety . . . . . . . . . . .m. August 5 Forums — 12:00 p. . . . .48 Focus Sessions — 7:15 a. . . . . . .m. . . . . . . . . . to 11:00 a. .org | 17 . . . . U012 Patients Satisfaction: Measurement and Improvement . . . .D. . M. . . . . . .m. . . . . .40 F004 Face to Face: Management of Facial Dermatoses . . . . . .D. . .m. . . . . . . . . . . . . . . . .D. . . . . . . . 54 9:05 a. . . . 55 11:15 a. .m. .m. . . .m.53 U013 What’s New in Non-Melanoma Skin Cancer . . . . . . . . . . . . to 12:00 p. . . to 11:00 a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . U008 Quality and Customer Service for a Better Practice. . . . . . . S004 Leading High Performance Teams . . M. Stratman. . . . Gaps. .44 F008 Case-Based Controversies: Medical . . . . . . . . . .. . . . . . . U005 Pitfalls in Dermatopathology . . . . . . . . . . . . . . . . . . . . . . .m. . . . . . . .38 U003 U004 Medical Management of Actinic Keratoses . . . . . . . . . . . . . . . . . . . . . . . . .D. .aad. to 8:45 a. . . . . . . . . . .47 Symposia — 2:00 p.m. . . . . . . . August 4 Focus Sessions — 7:15 a.53 U015 Laser Update . . . . Fox. . . Comparative Effectiveness / David J. . . M. . .m. 55 11:30 a. . . . . . . . . . corporate) members. . . Hwang. . . . .41 Symposia S001 S002 S003 — 9:00 a. . . . . .m. .D. Physician Demonstration . . .38 U002 Asian American Skin . . M. . . . . . .m. . . . .D. . . .38 Hidradenitis Suppurativa: An Update. . . . F009 Review and Update of Regional Reconstruction . . . . . . to 2:00 p. . . . . . . . . . . .m. . . . . . . . .45 Focus Sessions — 12:15 p. . . . . . . .m. . . . 54 9:50 a. .m.50 F010 Legal Dilemmas in Dermatology . . . . . .D. . . . . . . . Lim. . . .48 U010 Skin of Color . . M. . . . . . . . Contact Dermatitis / David Eric Cohen. .m. . . . . . . . . . .53 U014 Mastering Moles in Pediatric Patients .m. . . . . C001 Live Patient Demonstration: Botulinum Toxin and Fillers . . . and Traps / Erik J. . . . . .m. . . . .m. . . . . . . . . . . .D. . . . . . . . . . . . M. . . .

. . . . . .m. . . . . . . . . . . . . . . . . . . U029 Leprosy . . F021 New Technologies in Minimally Invasive Skin Rejuvenation . . . . . to 5:00 p. . . . .68 Course — 9:00 a. . . . . . S008 What’s Hot in Women’s Dermatology . . . to 5:00 p. . . . . . . . . . F018 Hypercoagulability.72 Focus Sessions — 2:30 p. . . . . .Program overview Course — 2:00 p.m. . . . . . . . .59 F012 Case-Based Challenges for PA/NP’s . to 12:00 a. .70 workshop — 12:00 p. . .m. . W005 MOC Self-Assessment: Pediatric Dermatology . . . . . . . . .m. . . . . . . . . .78 18 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 .65 Use of Light for Diagnosis and U023 Treatment in Dermatology . . . C002 Live Patient Demoonstration . . . . . .m.m. . . . . . . . .m. . U024 When Clinical and Histological Findings Converge: Great Cases From a Dermatopathologist’s Perspective . F011 Using Technology to Improve Dermatology Access .76 U032 Spitz’s Genodermatoses . . . . . . . . . .67 S009 Dermatology Grand Rounds: A Discussion of CaseBased Dilemmas . . .73 workshop — 3:00 p. .76 U031 The Interface of Skin and Psyche . . . . . .64 Controversies in “Dysplastic” Nevi . . . .60 F013 F014 Finessing Surgical Technique . . . . . . . . . .59 Cellulitis: A Common (Mis)Diagnosis? .76 U033 Infectious Disease Update: What I Wouldn’t Have Known Without Evidence-Based Medicine . .m. . . . . . . to 11:00 a. . .m. .m. . . . .m. . . . . . . . . . . . . . . . . . . . . .57 Symposia — 2:00 p. . . . . . . . . . . . . to 5:00 p. . . . . . . . . . . . Purpura and the Skin . . . . . . . . . .70 Focus Session — 12:15 p. . . . . . . . . . . . . . .m. . to 5:00 p. .m. . . . . . . . . . W007 Coding and Documentation . . . . . . . . . . . . . to 5:00 p. . . . to 8:45 a. . . . . . . . . C003 Derm Exam Prep Course: Refresher . . . . . . . .m. . . . . . to 12:00 p. . . . . . . . . .m. . . . . . .m. . . . . . . . . . . . . . . . .m. . . . .68 Sunday. . . . . . . . . . . . . . . .m. . . . . . . to 1:45 p. . F015 Alopecia and Hair Loss. . . . . .m.66 Consultative Dermatology . . . .m. . . . . . . . . . .m. . .m. . . . S006 What’s Hot in Dermatopathology . . . . . . . .m. .77 Forum — 9:00 a.58 Focus Sessions — 2:30 p. . . . . . . . . . . . . S011 What’s Hot in Pediatric Dermatology. . . . . .m. . to 5:00 p. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .66 Symposia — 9:00 a.73 Psoriasis Guidelines: Implementing F022 them in Your Practice . . .78 S012 What’s Breaking Out: Acne and Rosacea . . . . . . . . .72 U028 Morphea: Not Just for Adults Anymore . . . . . . . . . . . . . . .m.66 F016 F017 Case-Based Controversies: Dermatopathology . . . August 6 Focus Sessions — 7:15 a. . . . . . . . . . . . . . . . . . .m. . .61 Forums — 12:00 p. . . . .76 Optimizing Management of Melanoma: U030 Recognizing and Responding to Common Dilemmas in Patient Care .Neurotoxins and Soft Tissue Augmentation . . . . . . . .m. . . . . . . . . . . . . . . . . . . .m. . . . to 2:00 p. . . . .74 Program overview workshop — 3:00 p. . .69 F020 Tumor Board . . . . . . . . . . .m. . .m. to 5:00 p. . . . U016 From Bench to Bedside: Important Clinical Advances .60 Melanoma . . . . . . . . .58 U017 Photodynamic Therapy. to 5:00 p. . . . . . . . . . . . . . . . August 7 Focus Sessions — 7:15 a. . . .m. . . . . . . . . . to 11:00 a. . . .71 U025 Impact of Nanotechnology and Dermatology. .64 U021 U022 Patch Test Allergens 101: A Detective’s Toolkit . . to 4:00 p. . . . . . . . . .m. . . . . .65 Forums — 9:00 a. . . . . . F023 Pathology and Procedures of the Aging Hand . .57 S007 Effective Communications: Delivering Key Messages . . . . . . . W006 Practical Approaches to Patient Problems . .71 U026 Pediatric Dermatology Jeopardy . . . . . . .77 Symposia — 9:00 a. . . . . . . . . . . . . . . . . . . . . . . . . . .69 F019 Oral Disease . . . . . . . . . . . . . . . . . . . . . . to 8:45 a. . . . . . . U020 Exploring Evidence Based Cosmeceuticals . . . . . . . .m. . . .58 U018 Dermoscopy for the Non-Dermoscopist . to 4:00 p. . . . . . . . . . U027 Practical Dermoscopy . . .m. .59 U019 Forums — 3:00 p. . . . . . S010 Cutting Edge Surgery and Oncology . . .71 Symposium — 2:00 p. . . .m. . . .m. . . . . . . .m. . . . . . . . . . . . . .72 Forums — 3:00 p. . to 2:00 p. . . . . . . . . . . . . . . . . .62 Saturday. . . . . . . . . . . . . .m. . .

2:30 p.Personal Program Schedule THURSDAy.m.m. to 11:00 a. to 5:00 p. to 2:00 p.m.m. AUGUST 6 7:15 a.m. 9:00 a. AUGUST 4 7:15 a. to 4:00 p. 9:00 a.m. 9:00 a.m. to 5:00 p. 12:15 p.m. to 8:45 a. Personal Program Schedule NOTES for the lAteSt ProgrAm Book informAtion PleASe refer to www. to 5:00 p. to 12:00 p.m.m. 12:00 p.m. FRIDAy. to 1:45 p. 9:00 a.aad.m. to 1:45 p. 2:00 p.m.m. 2:30 p.m.m.m.m. to 8:45 a. SUNDAy. to 8:45 a. 3:00 p. 9:00 a.m.m.m.m. to 12:00 p. 12:00 p. to 12:00 p.m.m. 9:00 a. to 5:00 p. to 5:00 p. SATURDAy.m.m. to 8:45 a. 2:00 p. to 5:00 p. to 12:00 p.m.m.m.m. to 11:00 a.m.m.m.m. 9:00 a.m.m.m. AUGUST 7 7:15 a.m. 2:00 p. 12:15 p.m.m. 3:00 p. to 4:00 p. to 5:00 p. 3:00 p. to 4:00 p.m.m.m.m.m. to 11:00 a.org | 19 . to 2:00 p. 9:00 a.m. 2:30 p.m.m. AUGUST 5 7:15 a.m.m.

.

com Non-members must submit an online request form for registration approval and access ID number. program books will no longer be mailed out to non-member registrants. On-site registration will begin at 12 p.... The deadline for submission and approval is Friday.m. or a child 16 years or older... Allow 3-5 business days for the processing of faxed forms... 2011.. and medical students ..... On-site offices. May 25 Early registration for members and approved non-members closes at 12:00 p.. Spouse/Guest registration is available for one person per physician registrant.general information MEETING LOCATION NON-MEMBER REGISTRATION Summer Academy Meeting 2011 will take place August 3-7 in New York... N........org/meetings-and-events/summer-meeting.. Please allow 10-12 days for approval... A “guest” is defined as a significant other. (CT) – August 3 at 12 p. (CT).. life.. general information SPOUSE / GUEST REGISTRATION Spouse/Guest registration includes spouses.hilton. and non-members . See the chart on page 23 for a list of non-member registration categories.Wednesday... and all educational sessions will be located at: Hilton New York 1335 Avenue of the Americas New York... office staff.... A co-worker or an associate within the industry does not qualify for the guest registration category.. non-member requests and required documentation will only be accepted via the online submission page located in the attendee registration area at www. physician assistants and nurse practitioners. 2011 at 12 p. and honorary members . This category will not be issued an ExpoCard or a Certificate of Attendance. Between July 27 at 12 p. Registrants in this category may attend non-restricted symposia.. July 15. May 11. 2011. birth certificate) will be required. NY 10019 www. according to the schedule below. electronic posters and technical exhibits.. July 6. May 11 Graduate members. (CT) on Wednesday.. and guests accompanying registrants.....m. (CT)..... (CT) on Wednesday. 2011.. New this year. (CT) all registration systems will be closed.Y. mail and an access ID number will be sent to the e-mail address supplied online.Wednesday... After this date and time late registration will apply. processing. registered nurses..org (866) 503-SKIN (7546) Toll-free phone: REGISTRATION INFORMATION Early registration Early registration and housing for Summer Academy Meeting 2011 begins at 12:00 p. for the lAteSt ProgrAm Book informAtion PleASe refer to www... Questions: E-mail: mrc@aad. including access ID number. plenary sessions.org | 21 .S. Photo ID and proof of age (driver’s license. Wednesday. Registration and housing forms faxed in prior to the opening of early registration will be held and processed based on the date and time received and the schedule listed below. the registration and housing brochure will be sent via U.org or registration@aad.........aad.m. friend.... exhibits... student ID. residents... May 18 Adjunct members.m..Wednesday. services. The complete program book can be accessed online.. research fellows.. August 3.m. family members (children 16 years or older). Once approved.. Note: In an effort to make the meeting more environmentally friendly. and receipt of materials.. Physician.m.aad. Program books will be available on-site for reference.......

Credit card Five to seven business days from receipt general information (Visa. If no e-mail address is provided. confirmation of fax receipt will not be provided. go to: www. All forms are non-transferable. Enrollment in multiple sessions during the same time slot is not permitted. or American Express) PROCESSING TIME Instant (Visa.org/meetings-and-events/summer-meeting click on Attendee Registration and Housing and follow the instructions.S. TICkETED EvENTS Registrants should identify sessions for which they are requesting tickets when they complete general registration (see chart page 24 for information on session categories.e. Visit www. Once you have received a confirmation letter. Mastercard. An updated confirmation will be sent after changes are processed. you may review and print registration information online.S. MAIL Send payment.aad.general information Registration instructions Registration and housing for the Summer Academy Meeting 2011 may be completed online. including ticket requirements and tuition fees). 22 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 . If neither an e-mail address or fax number is supplied. or American Express) (847) 996-5401 (International) Registration and housing forms faxed in prior to the opening of early registration will be held and processed based on the date and time received and the schedule on the previous page. Registration.org/meetings-and-events/summer-meeting 2. U. first-served basis. is on a first-come. Click on Already Registered 4. REGISTRATION TyPE ONLINE REGISTRATION REGISTRATION INSTRUCTIONS To register and book housing online for Summer Academy Meeting 2011. and Canada) Credit card Three to five business days from receipt PAyMENT METHOD Credit card only (Visa. Enrollment in ticketed sessions is on a first-come. To do so. ADA / SPECIAL ASSISTANCE Academy staff will be available to help individuals with any special needs (i. Click on Attendee Registration and Housing 3. Enter registration confirmation number and last name. You will need to input the ID number that is preprinted above your name on the back of the registration and housing brochure. take the following steps: 1. mail.. Registration forms are enclosed with this book. including enrollment in specific sessions. or American Express) or check payable to: AAD Housing and Registration CUSTOMER SERvICE For additional assistance in completing your registration call the AAD Registration Office at (847) 996-5876 or (800) 974-3084 or call the AAD Meetings and Conventions Department at (847) 330-0230. If an e-mail address is provided. complete all registration and housing forms and fax to: (800) 521-6017 (U. or by mail. registration. pay a balance due. confirmation will be sent via U. IL 60061-1731 Registrants should retain a copy of both sides of the form for their records before mailing. first-served basis. Alternate choices should be identified. the confirmation will be sent via fax. FAX REGISTRATION To register by fax. by fax. Mastercard. confirmation will be sent via e-mail.S. and housing forms to: AAD Housing and Registration 568 Atrium Drive Vernon Hills. Mastercard. physical). Due to fax volume.aad. you may print a copy of your receipt. Only materials delivered to the above address will be accepted. or make changes to your registration and housing. CONFIRMATIONS AND CHANGES Confirmation letters will be sent to all registrants who register prior to the start of on-site registation. Please complete the appropriate section on the registration form and a staff member will contact you. then click Find Me Once in your personal record.

285 $305 $135 $205 no fee $160 $1.m. (CT) RESTRICTED Y Y N Y Y Y – dermatologist N – non-dermatologist $305 $305 $305 $205 no fee $135 $325 $325 $325 $240 no fee $160 Y Y Y Non-member categories REGISTRATION CATEGORy Medical student* ** Non-dermatology resident** (See page 21 for information on obtaining a non-member request form for registration approval) general information REGISTRATION FEES 5/11/11 – 7/6/11 at 12:00 p. (CT) 7/27/11 at 12:00 p. corporate)** Adjunct other** Life member Honorary member Graduate member/Resident/Research Fellow** 5/11/11 – 7/6/11 at 12:00 p.410 Y $65 $85 Y N N * This category is not eligible to register a spouse/guest along with registation.org. For further information on membership eligibility.m. and Canadian program) Office staff/registered nurse* (working in a dermatologist’s office) Non-member.m. Member categories REGISTRATION FEES REGISTRATION CATEGORy Physician member Adjunct (researcher. (CT) SESSION ACCESS OPEN Y Y Y Y Y Y TICkETED Y Y Y Y Y RESTRICTED N N Y – dermatologist N – non-dermatologist N Y – dermatologist N – non-dermatologist EARLy LATE 7/6/11 at 12:01 p.aad. (CT) no fee $135 $1. ACCESS. + Only dermatologists in this category may register office staff/RN along with registration. please refer to www.410 $325 $160 $240 Non-member physician + (treating patients in an office-like setting) Physician assistant/nurse practitioner* ** (working in an AAD member dermatologist’s office) Resident/Research Fellow** (outside U. ** This category is not eligible to register office staff/RN along with registration.general information REGISTRATION CATEGORIES. for the lAteSt ProgrAm Book informAtion PleASe refer to www. AND FEES The chart below details fees and sessions access for all categories eligible to register for Summer Academy Meeting 2011.m. ++ This category of registration will not be issued an ExpoCard with registration.aad.m.org | 23 . (CT) SESSION ACCESS OPEN Y Y Y Y Y Y TICkETED Y Y Y EARLy LATE 7/6/11 at 12:01 p.285 $1.m. non-physician (Non-member corporate individuals and industry representatives or scientists working in field of the dermatology)* **++ Spouse/guest ++ Practice N management sessions only Y N $1.org/member-tools-and-benefits/become-a-member or e-mail mrc@aad. (CT) 7/27/11 at 12:00 p.S.

...... after which seats will be T available on a first-come first-served basis for eligible categories............. or at the AAD Resource Center located in Booth 906 in the Technical Exhibit Hall...... Meeting attendees should register for specific sessions requiring tickets when completing general registration.m..m.... without conflicts to their educational session schedule..... to 6 p...m. but this course is not designed as a Prep for initial board certification. the Academy is offering two hours of unopposed exhibit hours on: Friday.m............ open to dermatologists and adjunct (research.. ACCESS AND FEES The chart below details session types at Summer Academy Meeting 2011 as well as session fees where applicable... Saturday ....... physicians may visit the technical exhibits. 24 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 . August 5 .. and technical skills Sessions exploring a single subject Sessions with an emphasis on discussion and participant interaction Y $100 $400 $60 TICkET REQUIRED Y Members and PAs/NPs $300 Non-Members and Office Staff/RNs N/A Medical Students and Residents $150 Restricted symposia* Y No fee No fee No fee Non-restricted symposia* N No fee No fee No fee general information workshops** Forums* Focus sessions* Y Y Y $35 No fee No fee $95 No fee No fee $25 No fee No fee * ickets for sessions with no fee will hold a seat for 15 minutes after the official start time.. TUITION FEE SESSION TyPE Derm Exam Prep Course: Refresher** SESSION DESCRIPTION This couse is targeted at the Board Certified Dermatologist preparing for the American Board of Dermatology (ABD) Maintenance of Certification in Dermatology (MOC-D) exam. ** Attendees attending sessions with a fee must have a ticket for admittance.m...m....m...... Live patient demonstration** Interactive session presenting live demonstrations of botulinum toxin and soft tissue filler injections........ Residents preparing for their Board exam may also benefit........... 10 a.........general information SESSION CATEGORIES.. 12 p.... What’s new this year! CHARITABLE CONTRIBUTIONS Donate to the AAD Shade Structure Program and/or the AAD Camp Discovery Endowment! You can make a taxdeductible contribution when you register for the Summer Academy Meeting 2011...... During this time. to 2 p.............. open to dermatologists and adjunct (research............... to 2 p.... corporate) members only Sessions comprised of individual presentations focused on a specific subject..m..12 p.... 12 p.... UNOPPOSED EXHIBIT HOURS In addition to the regularly scheduled exhibit hours: Thursday ... Friday ......... See page 26 for details.... to 6 p... See page 25 for details on distribution of tickets and other meeting materials........... corporate) members only Sessions comprised of individual presentations focused on a specific subject Sessions emphasizing media training..... clinical care....

Ticketed event changes/cancellations for U. No-shows: No-shows are considered to have missed the Wednesday. and vouchers on site at the On-site Registration Counters. mail to U. No refunds will be issued for on-site registration. $25 (fee will be deducted for all spouse/guest cancellations) Cancellations received by 12 p. After this date and time.M. vouchers U. tickets. Refunds will not be issued for late arrival or for non-attendance. Registration is non-transferable. which will also be listed on your ExpoCard. If you cannot attend the meeting. and via special courier service to Canadian registrants between July 11 and July 15. please review materials for accuracy. 2011 AT 12:00 P. MEETING BAGS. www. 2011. In the event that you do not receive your materials prior to the meeting. / CANADIAN EARLy REGISTRANTS [By JULy 6. July 6. will have their badges. tickets.m. OTHER MATERIALS Session tickets must be returned prior to the start time of the session in order to obtain a refund. Corrected tickets must be picked up at the On-site Registration Counter (see page 28 for locations and times).m. registrants.m. To return session tickets prior to the meeting.S. ATTENDANCE vERIFICATION.org by 12 p.aad. INTERNATIONAL REGISTRANTS AND INDIvIDUALS wHO REGISTER AFTER wEDNESDAy.M. will need to pick up badges. CORRECTIONS For hotel reservation cancellation. and Canadian registrants who register after 12 p.S.S. See page 28 for counter times and location. you may not change the name on your registration.org | 25 for the lAteSt ProgrAm Book informAtion PleASe refer to . Wednesday. and Canadian registrants who will be receiving their materials by mail will only be accepted until Wednesday. The attendance verification/meeting bag voucher must be presented so that attendance can be verified and CME credit claimed. (CT). (CT) on July 6. July 27. Session ticket cancellations Upon receipt. ticket cancellations and changes will need to be made on site at the meeting. (CT).m. Tickets cannot be returned or exchanged after the start of the session. you must submit a cancellation. If a discrepancy or error is found. a new set can be picked up at the on-site registration counters. and attendance verification/meeting bag voucher sent by U. July 27.general information CANCELLATIONS General registration MEETING MATERIALS Registrants who wish to cancel all of their general registration should send a letter of cancellation via one of the following methods: E-mail: Fax: Deadline: aad@experient-inc.com (847) 996-5401 or (800) 521-6017 12 p. $75 (fee will be deducted from refund amount). July 6. 2011. 2011. refer to the Meeting Materials section. 2011 will be processed and refunds issued prior to the meeting. Session tickets may be returned on site at the On-site Registration Counter. 2011 deadline and are not eligible for a refund.m. Materials will be mailed to the address listed on your registration record. Wednesday. July 27. Corrections received after the deadline must be made On-site at the Registration Counter. Wednesday. tickets.m. (CT) Fee: Processing: Tickets returned on-site will be processed and refunds issued four to six weeks after the meeting. (CT). No exceptions will be made. 2011 AT 12 P. general information Onsite: Name change: All international registrants and U. send an e-mail to registration@aad. Badges. refer to the hotel and travel information section of the program book page 27. For housing changes/cancellations.S. 2011 at 12 p. on Wednesday.S. 2011. (CT). JULy 6. no refund will be given for cancellations received after this date. (CT). and Canadian registrants who complete registration by 12 p. See page 28 for locations. 2011 with the following information: • Full name • Registration confirmation number • Error or discrepancy found The AAD will make every attempt to make corrections received by the deadline prior to the start of the meeting. July 27. please see hotel and travel information section on page 26.S. Those who registered during the early registration phase and received their meeting packet may redeem their attendance verification/meeting bag voucher on site at the Attendance Verification/Meeting Bag Counter. (CT)] The following policies apply to cancellations: U.

org once you have completed your registration. a summer camp where they can meet others with similar conditions. please submit a written request via e-mail to registration@aad. August 5. Thank you for Furthering Excellence in Dermatology…Today and Tomorrow BLUE Medical personnel Physician members. physician assistants/nurse practitioners. office staff/registered nurses.general information BADGE IDENTIFICATION Registration categories will be indicated by badge color as described below. life members. graduate members. Reservations may be made online. (CT) deadline. letters will only be issued to registrants who have completed their registration by the Wednesday. non-dermatology residents. or American Express) or by check. Certificate of Attendance stations will be available beginning Friday. residents. take your ExpoCard to the registration area located on the 2nd Floor Promenade of the Hilton New York. and adjunct members may print a Certificate of Attendance on site. Letters will be sent once registration verification is complete. Individuals who book reservations directly with the hotel are not guaranteed the AAD discount.m. Please refer to the listing above. HOTEL AND TRAvEL INFORMATION Hotel accommodations and reservations Certificate of Attendance International registrants. and The London. honorary members. research fellows.000 people from harmful UV rays each day. or by mail through the AAD Housing Office in conjunction with registration for the meeting and according to the registration schedule on page 23. 2011 at 12 p. by fax.m. Please utilize the appropriate designated counters based on your registration type. sheltering more than 158. 26 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 . Be prepared to finalize your travel plans immediately as hotel rooms go quickly. More than 200 protective shade structures have been built through this program. (CT). PAyMENT INFORMATION Registration and housing fees may be paid by credit card (Visa. at AAD discounted meeting rates for those booking through the AAD Housing Office. Mastercard. AAD Shade Structure Program You can be a part of the Academy’s efforts to reduce skin cancer occurrences. payable to AAD Registration and Housing. Additional hotels may be added if needed. See the registration and housing brochure for information on hotel reservations. medical students. Letters of Invitation If you require a Letter of Invitation. Specific categories will appear in bold at the bottom of each badge. Sheraton New York. AAD Camp Discovery Endowment Children with chronic skin conditions enjoy AAD Camp Discovery. Due to security concerns. Guest rooms are being held for Summer Academy Meeting 2011 registrants at the Hilton New York. and non-member non-physicians Spouses/guests (note: no badge will be issued to children under 16 years) Exhibitors Press AAD staff yELLOw Allied health personnel GREEN RED BEIGE ORANGE general information Separate registration counters will be set up for medical personnel and allied health personnel. BADGE TyPE CHARITABLE CONTRIBUTIONS You can make a tax-deductible contribution when you register for the Summer Academy Meeting 2011. 2011. July 27. Your help is needed to expand this important component of our skin cancer prevention efforts. 12 p. non-member physicians Adjunct members. You can help support this unique summer camp opportunity! Six week-long sessions serve more than 300 children each year. medical students. physician assistants/nurse practitioners. Availability cannot be guaranteed for reservation requests received after the housing deadline of July 12. 2011. To do so. or at the AAD Resource Center located in Booth 906 in the Technical Exhibit Hall. Certificates will not be issued for the spouse/guest & non-member nonphysician categories. office staff/registered nurses. These rates are lower than available hotel rack rates. Hotel reservations for those not registered for the meeting cannot be accommodated.

m. Additional services are available through Association Travel Concepts when booking online. July 12. Tuesday. on United Airlines and American Airlines: • Up to 5 percent off applicable classes of service for United Airlines tickets purchased more than 30 days prior to the meeting. 2011 regardless of method of cancellation.S. Website: Phone: www. Avis Contact Avis directly and provide the Avis World Wide discount number A723900 when making your reservation. (CT).Y.S.m.com/aad reservations@atcmeetings. low fares search options.hertz. and Canada should contact their local Avis office. Association Travel Concepts Online: E-mail: Phone: Hours: Booking fees: www. Restrictions apply. The above discounts apply for flights between July 31. 2011 regardless of method of cancellation. July 12.) for the lAteSt ProgrAm Book informAtion PleASe refer to www. 2011 at 12 p. and Canada should contact their local Hertz office. No late check-in Failure to check in on the scheduled date of arrival will result in the loss of deposit and cancellation of the room. (CT) Online: $7 e-mail: $35 phone: $35 (Fees apply to ticketed reservations) New Users click “Create a New Account” to get started. and hotels will be processing reservations into their systems. • Low fare options. hold trips.m.general information HOTEL RESERvATION CANCELLATION Deadline Tuesday. Refunds of deposits will NOT be issued for cancellations received after 12 p. Tuesday. July 12.) (800) 879-2847 (Canada) Travel information AIR TRAvEL The following discounts and services have been negotiated for registrants traveling to the Summer Academy Meeting 2011 in New York.com (800) 831-8000 (U. • 5 percent off applicable classes of service for American Airlines tickets purchased prior to the meeting. July 12. 24/7 online access. 2011 to or from John F. Reservations may be made on the Web or by phone. by phone or e-mail with the AAD’s official travel agency.) (800) 263-0600 (Canada) (Those outside U. powerful search options. including airport parking. 2011 at 12 p. July 15. Refunds of deposits will NOT be issued for cancellations received after 12 p.atcmeetings. July 12. 2011 and Friday. (CT) Requests for changes or cancellations will NOT be processed by the AAD Housing Office after 12 p. 2011 The Academy will be transferring reservation information to hotels. (CT) Send a letter of cancellation to: • E-mail: aad@experient-inc. 2011 Contact the hotel directly to cancel or change a reservation. (Those outside U. (CT). Reservations may be made on the Web or by phone. United and American You may also book through your own agency or contact the airlines directly. Website: Phone: www. 2011 regardless of method of cancellation Between Tuesday. mobile device alerts. Starting July 16. through the Academy’s official travel agency. • Advanced seat assignment and special meal requests. (CT).m. Refund of deposits will NOT be issued for cancellations received after 12 p.avis.August 10.m. Association Travel Concepts Registrants may book online. 7:30 a. Kennedy or LaGuardia Airports. • Personalized services.S. personal profile.com or • Fax to AAD Housing Office: (847) 996-5401 or (800) 521-6017 A full refund of your deposit will be issued. United Airlines: 800) 521-4041 ID: 510CK American Airlines: (800) 433-1790 ID: 2971BC CAR RENTAL general information Discounts on vehicle rentals with Avis and Hertz are available to meeting registrants. event tickets. Tuesday.S. July 12.) Hertz Contact Hertz directly and provide the discount code 0010533 when making your reservation or submit a coupon or promotional coupon number. dining reservations. (CT).com (800) 654-2210 (U.aad.com (800) 458-9383 Monday – Friday.org | 27 . • Frequent flyer program updates. After Tuesday. N. July 12. to 6 p.m. Association Travel Concepts (ATC). Refer to the ID numbers indicated below to receive applicable discounts.m.m. 2011.

.......... Staff will be available during regular exhibit hours to answer questions.... 7 a......... – 6 p........................................ August 6 .............................................. with the exception of the spouse/guest badge................... Murray Hill Suite A Technical Exhibits .....m............m..... A photo ID must be presented...........2nd floor Promenade Speaker Ready Room .....m........m............................... August 6 ... This policy was created for the safety of the children of Academy members and guests.................................. Gramercy Suite AB Development Office ...................Harlem Suite Business Center ..............m............ ATTENDANCE vERIFICATION/MEETING BAG PICkUP COUNTER: 2ND FLOOR PROMENADE The Technical Exhibit Hall will be open during the following hours: Thursday......................... The On-site Registration Counter will be open during the following hours: Wednesday........... – 6 p..........2nd floor Promenade Poster Exhibits ..... 10 a.......................... August 3 at 12 p..... August 4...........m...............m......................................................... Rhinelander Gallery & Americas Halls I and II general information Registration services ON-SITE REGISTRATION COUNTER: 2ND FLOOR PROMENADE Exhibits TECHNICAL EXHIBITS: RHINELANDER GALLERy & AMERICAS HALLS I AND II On-site Registration will open on Wednesday................ – 5 p.............................................. and services on site at Summer Academy Meeting 2011 follows... Thursday....m..................m............m................ tickets for available sessions may be selected here................................................ – 6 p......... Additional information......... August 5 .................. 7 a............................................Booth 906 Board of Directors’ Office ........ Saturday..........m.............. August 7 ....................... August 5 ......................................................... 7 a....................................12 p........ Reception ........ 7 a... Unopposed Exhibit Hours .......................... AAD Resource Center ....... Your compliance is appreciated........12 p.........................m...................................................................... including hours of operation........ – 2 p.............. 5 p..................................m........ Each individual can pick up ONLY his or her own materials... AAD RESOURCE CENTER: BOOTH #906 All registrants should redeem their attendance verification/ meeting bag voucher at the Attendance Verification/Meeting Bag Counter during the on-site registration hours listed above..................2nd floor Promenade Press Registration ............................................................................. – 12 p.....m... Friday................................. The AAD Resource Center contains information on Academy membership as well as applications.............. 28 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 ..m.......................... exhibits....... August 3 .................................. – 2 p....................................m..................................m........................................................m....................................... – 6 p............. 2nd floor Convention Office .............. August 4............... and information on Academy services and products........... for these and other offices.....................m................................. For those who have not registered prior to this date............................. Infants and children under age 16 will not be admitted to the Technical Exhibit Hall....... Saturday.. This voucher must be redeemed in order to claim CME credit......12 p....m........................ 12 p..............................................................general information ON-SITE SERvICES AND EXHIBITS ACADEMy OFFICES/EXHIBITS All locations are in the Hilton New York unless otherwise indicated............................. – 6 p.................... – 6 p............. 3rd floor Promenade Registration ......... Friday..........................................................m....................................... Hudson Suite Cyber Center .............................................. Sunday..

m.. and FedEx and U.m.. – 5:30 p. Available services include photocopying.......m... August 6 ...m. The Business Service Center is available to all meeting registrants....12 p. Thursday... transparencies....m. 7 a........... – 5 p.............m...m........... 8 a......S..... CyBER CENTER: 2ND FLOOR PROMENADE Other Services EvALUATION AND CME vERIFICATION The Cyber Center will be open during the following hours: Wednesday..... 8 a.....aad..........m. The overall evaluation form and CME credit reporting form will be provided in the registration bag distributed on site.. Thursday......m... Sunday......m.m..........12 p. SPEAkER READy ROOM: MURRAy HILL SUITE A general information The Speaker Ready Room will be open during the following hours: Wednesday.12 p.m.......... – 6 p..... – 6 p.. August 5 .......m..... Saturday.... – 6 p.org in June................m... 7 a..... Payment is required at time of service.. August 3 . Friday..... August 5 ........... 6:30 a. 7 a...... – 5 p....... – 6 p.......m.......m.. 8 a. – 12 p..............m.. August 7 .... – 12 p... Saturday........ – 5:30 p....... fax transmissions and receipts............ Thursday. August 5 ......m.m......m...aad. – 5 p.. 6:30 a.. August 7 ..m........... major credit cards are accepted.....m...m... 7 a.. 6:30 a... Poster authors will conduct brief presentations of their electronic posters at the Poster Presentation Centers in the 3rd floor Promenade during the meeting. – 6 p.... 7 a... Sunday.. Only those who have submitted their Attendance Verification/Meeting Bag voucher are eligible to claim CME credit.... August 3 .. mail drop-off. – 12 p.... August 5 ................general information ELECTRONIC POSTER EXHIBITS/POSTER PRESENTATIONS: 3RD FLOOR PROMENADE BUSINESS SERvICE CENTER: 2ND FLOOR Electronic Poster Exhibits viewing stations will be open during the following hours: Thursday............. Saturday.. Friday... Friday. for the lAteSt ProgrAm Book informAtion PleASe refer to www......org | 29 ................. Sunday.............. Saturday.. August 4.......m....m.. – 6 p. 7 a............ August 6 ........ 7 a.....m..... The Business Center will be open during the following hours: Wednesday.........................m............................ A full schedule of presentations will be available on the Summer Academy Meeting 2011 website at www....m... – 5 p... – 6 p....................... 6:30 a......m.........................m.......... – 5 p...... 8 a...... August 7 ....... August 4..........m......... August 6 .................... Friday.m......................................m. August 4.m.....m.. and posted on-site at the meeting. – 5:30 p.... August 4.............m...... August 3 .............. August 6 ...

Should your needs require mobility service strictly during official meeting hours. When developing an educational program. the planning committee reviews applications and disclosure of interest forms. Please note. 30 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 . balanced.aad. This information is provided solely to assist Summer Academy Meeting 2011 participants. Potential participants are sent detailed guidelines that provide direction on necessary components to ensure independence in continuing medical education activities and to resolve conflict. You will be required to pick up and drop off your scooter in the AAD Convention Office.general information PRESS REGISTRATION: 2ND FLOOR PROMENADE Journalists who are working for and representing recognized news organizations are encouraged to register to attend the meeting as Press. The Academy has no control over and assumes no responsibility for the care provided through the hotels. The Academy has no control over and assumes no responsibility for the tours that are provided by independent tour operators. A comprehensive disclosure of financial relationships is published in the Program-At-A-Glance and is available online on the Academy’s Website at www. TOURS general information The concierge at your hotel can assist with arrangements for sightseeing tours. the Academy is dedicated to providing continuing medical education that is independent. check the “ADA Mobile” box under the Personal Information page of your online registration. Toll-free phone: E-mail: Fax: (888) 441-7575 info@scootaround. All freelancers must present a letter of assignment. patient care. The planning committee members submit and consider their own disclosure information and recuse themselves from planning educational activities should they have conflicts related to the subject area presented. along with needs assessment and evaluative data from past activities in order to develop programming. A PowerPoint-based slide with a disclosure template will be provided to the speaker for inclusion in the presentation prior to the meeting. and health care outcomes by maintaining. Failure to disclose will result in a denial of the opportunity to participate in the CME activity. developing and enhancing medical knowledge. as itemized below. directors/speakers are expected to make a verbal disclosure of relevant financial relationships or indicate no conflicts exist at the beginning of their presentation. you may reserve a scooter through the Academy. Gramercy Suite AB. objective and free of commercial bias.aad. CHILD CARE SERvICES Contact the Concierge Desk at your hotel to arrange for child care services. each meeting day. the individual is required to indicate such on the disclosure form. the Concierge Desk can be reached from any house phone or sleeping room. journalists must provide a business card and samples of their work. In addition. Inc.org. Handouts will no longer be distributed on site via DVD for Summer Academy Meeting 2011. the Academy will not be hosting a Press Office at the Summer Academy Meeting 2011. free of charge. interpersonal and communication skills and professionalism. 2011 on the Academy’s Website at www. Disclosure of Relevant Financial Relationships The Board of Directors requires that all participants in the Annual and Summer Meeting comply with all applicable laws and regulations governing disclosure. Should you require tour information after you have arrived at the hotel. Twenty-four hour mobility service is available by contacting ScootAround. Individuals who refuse to disclose relevant financial relationships are disqualified from participation in the educational program(s). This information is provided solely as a service to help registrants identify possible resources for child care services. MEETING HANDOUTS Meeting handouts will be available beginning July 1. Disclosure statements must include all financial relationships occurring within 12 months of the educational activity. fair. As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME) and in support of this mission. MOBILITy SERvICE AAD MEETING POLICIES Independence in CME The mission of the Academy’s continuing medical education program is to improve patient care.org/meetings-andevents/summer-meeting. Press may register to attend the Summer Academy Meeting 2011 in advance or at the On-site Press Registration Desk. The Academy employs several strategies to ensure these standards will be met. To register. Session directors and speakers are required to provide the Academy with a comprehensive disclosure of financial relationships with a commercial interest producing health care goods or services consumed by or used on patients. To do so. If no financial relationships exist. Arrangements should be made as early as possible prior to your anticipated arrival.com (204) 478-1172 Mobility service during Summer Academy Meeting 2011 official meeting hours is available.

ALCOHOLIC BEvERAGES The Academy’s official policy regarding the minimum age for alcohol consumption is the age applicable to the jurisdiction of the event venue. the Academy may review speaker presentations stored on the meeting servers to collect aggregate data regarding disclosure.aad. Session directors and room monitors will be closely monitoring adherence to this policy.) This ensures the audience that the recommendations are supported by the evidence and contributes to management of any potential conflicts of interest. for the lAteSt ProgrAm Book informAtion PleASe refer to www. BMJ 1996. These data are only used to determine effectiveness of the Academy’s policies and procedures regarding disclosure. and formal observers are all given the opportunity to evaluate the educational content and speaker performance. Session attendees are asked to turn off cell phones or place them on vibrate prior to entering a session room. In addition.312:71-2. This policy is due to the nature of some presentations and to ensure the safety of registrants’ children. and video cameras is prohibited in all educational sessions. CELL PHONES Cell phone usage during education sessions is disruptive and is therefore prohibited. Presentations and related materials must be based on scientific methods generally accepted by the medical community. Included in this process are measures to rate the success of the Academy’s policies regarding independence in continuing medical education activities with particular focus on the absence of commercial bias. if the presentation includes discussion of unlabeled or investigational use of a commercial product. and handouts cannot contain any advertising or product-group messages. attendees. Further. Violations of this policy will result in removal from the session and confiscation of equipment. this also must be disclosed to the participants.org | 31 . abstracts. speakers. Outcomes Measurement Several methods of evaluation are utilized in assessing the educational program. all speakers are required to complete the speaker attestation form indicating compliance with these policies. Please also comply with the smoking policy of each individual facility. camera phones. general information g SMOkING All AAD educational programs within meeting rooms and seated functions occurring during the meeting are smoke free. Educational materials such as slides.” the individual may not be asked to participate in future educational programs. trade names from several companies should be used where available. Violations of the policy will result in removal from the session room. (See Sackett et al. Content Validation Academy-sponsored educational activities are designed to promote improvements or quality in health care and not promote a specific proprietary business interest or a commercial interest.general information It is the responsibility of the session director to ensure balance with regards to disclosure of potential conflicts of interest. Use of generic names will contribute to this impartiality. CAMERA/vIDEO RECORDING Use of cameras. Presentations should be evidence-based and discuss the validity of the evidence upon which they base the opinion(s). In addition. CME must give a balanced view of therapeutic options. AGE LIMITS Infants and children under the age of 16 are not allowed into educational sessions or the Technical Exhibit Hall. Your support and compliance are appreciated. If CME educational material or content includes trade names. Directors and room monitors will be closely monitoring adherence to this policy. Session directors. as opposed to using trade names from just a single company. Should it be determined that a member of the Academy’s educational program violated the Academy’s “Policy to Ensure Independence in Continuing Medical Education.

........org.. Gist........ MEETING ROOM LOCATIONS AAD Staff MEETINGS AND CONvENTIONS DEPARTMENT The Meetings and Conventions Department administers the Summer Academy Meeting 2011....Senior Manager.... CMP.Design Manager Nicole Torling ........... Live Education Jennifer Wahl ........... Creative and Publishing Ed Wantuch .. please contact the following staff members by phone at (847)330-0230.... MPH................ Education Specialist Michelle Michelotti ... Senior Manager....... The Program-at-a-Glance will be distributed to all registrants in the meeting bag........... first-serve basis to eligible categories. CEM ....... Exhibits Amanda Sage.. When on site. Senior Manager............... Education Jennifer Thompson.......... general information EDUCATION DEPARTMENT The Education Department develops and administers the educational program for the Summer Academy Meeting 2011.............. Director...............Senior Manager........ the Program-at-a-Glance will have updated room changes................... MS ...... Production Manager Carrie Parratt ... Special Publications Nate Jenkins ............. Lara Lowery ............. fax (847) 330-1090 or e-mail mrc@aad... please contact the following staff members by phone at (847) 330-0230....... Exhibits Specialist Susan Jackson ...... Individuals attending sessions with a fee must have a ticket for admittance... or e-mail mrc@aad............................... Director.general information OFFICIAL LANGUAGE The official language of the Summer Academy Meeting 2011 is English....... Meetings Robin Downey ................ Timothy Moses..... For further information.... Lead Designer Joe Miller ... CMP ...... Administrative Specialist Krysten Zarembski ............................................Meetings Coordinator Rachel Jamieson . FACME................... Registration Sara Peterson.... seats will be available on a first-come....................... Registration Assistant Please be aware that the room locations listed in this program book may change prior to the meeting. SCIENTIFIC SESSIONS/TICkETED SESSION LATE ARRIvALS Tickets for sessions with no fee will hold a seat for a registered attendee until 15 minutes after the official start time of the session.............................................................................. Debra L...Production Specialist 32 | AmericAn AcAdemy of dermAtology • SUmmer AcAdemy meeting 2011 ............ Senior Manager.......aad............. Managing Editor..............org........ Director........ Meetings and Conventions Debra Barrett .............. For further information... and produces the Summer Academy Meeting 2011 Program Book. Education Coordinator CREATIvE AND PUBLISHING DEPARTMENT The Creative and Publishing Department designs............. Advertising Specialist Jon Dudek ...... Senior Manager.. After the first 15 minutes................Senior Meetings Specialist Joni Taylor .......................... edits... Publishing Dean Monti ........... Fax (847)330-1135........ Refer to the Program Book Update under the Summer Academy Meeting 2011 section of the AAD website at www...............org.................... Meetings Tamara Pundsack ...................Graphic Designer Katie Domanowski.

Thank you for Furthering Excellence in Dermatology…Today and Tomorrow! Visit the Leaders in Giving Recognition Module in the Level 3 Lobby. .The American Academy of Dermatology extends its most sincere appreciation to our Sustaining Fund Donors! Your support helps us expand and enhance our educational and humanitarian mission.

perfect for the job seeker! Save $25 on Save 25%-35% on magazines and professional journals with this NEW member benefit! the newest skin cancer and sun-safe presentation tool. Receive 5% off AAD Apparel including scrubs and lab coats! Personalize it! Pick up a FREE sample pack of AAD’s Patient Education Pamphlets! . Transition into Practice.Come visit the AAD Resource Center Save $25 on the Save $20 on the 2011 Coding and Documentation Manual! NEW PME Series Manual. the See SPOT CD.

Peer Communication Surveys coming soon! Save $40 with Demo the Clinical Performance Assessment Tool (CPA and learn how it satisfies Component 4 of MOC-D.Booth 906 to demo these new products and save! Save over 10% on the Dermatology Self-Assessment Program Volume 4! Satisfies Component 2 of MOC-D! NEw Patient Communication Surveys — learn how to improve your practice and help satisfy Component 4 of MOC-D. Great for iPods! Save $25 on Dermoscopy: A Guide for the Physician.000 slides and 400 cases! 1% CMS bonus! . view the Quality Reporting System and find out how to earn a Over 8. the new Dialogues in Dermatology online format.

P.. 2008. dryness and irritation2 Highly tolerable. Semin Cutan Med Surg. Galderma Laboratories. Galderma. Freeway. The epidermal barrier in atopic dermatitis.2: Ceramides help replenish the skin’s natural lipids Filaggrin technology helps restore moisture to help rebuild the damaged skin barrier Clinically proven to help soothe itch and reduce redness. Data on file. L.Now replenish skin at the structural level Visit Galderma BOOTH #5 06 to learn more! Cetaphil® RESTORADERM® Skin Restoring Moisturizer and Body Wash formulated for atopic dermatitis Patented technology helps restore hydration in atopic skin1. 14501 N. preservative and fragrance free2 cetaphil.P. L. Galderma Laboratories. 2.27:108-114. TX 76177 CETA-278 Printed in USA 03/11 . Fort Worth. Cetaphil and RESTORADERM are registered trademarks. © 2011 Galderma Laboratories.com References: 1. Sugarman JL.

..........................41 EHR Physician Demonstration .............m......... Nails ................ to 2:00 p... to 12:00 p.....m.......... to 5:00 p..49 U011 From the Dermatology-Rheumatology Clinic: Practical Tips and Advances in Management .....42 Forums — 12:00 p....m....... EADV/AAD Joint Symposium ................................. see page 24...........48 Smoking and the Skin .m..............44 Workshop — 12:00 p............m.........51 W004 Dermoscopy ................m........46 U007 Course — 2:00 p......45 U006 Bringing out the Best in Others ... Psoriasis.......m............43 F007 Case-Based Controversies: Procedural....................... to 2:00 p............................... S004 Leading High Performance Teams ....49 Forums — 3:00 p...........40 Face to Face: Management of Facial Dermatoses .....................m....scientific sessions For a description of session categories..40 Focus Sessions — 12:15 p.m............... to 8:45 a..................45 For the Latest Program Book InFormatIon PLease reFer to www..................... U005 Pitfalls in Dermatopathology ..50 F010 Legal Dilemmas in Dermatology .....................48 U009 U010 Skin of Color.. F009 Review and Update of Regional Reconstruction..................m.................................................m.......m....................38 U002 Asian American Skin .m...... Eczema and Inflammatory Dermatosis ............ to 4:00 p..........m.............. August 4 Workshop — 9:00 a......... C001 Live Patient Demonstration: Botulinum Toxin and Fillers ...................................................... A ticket is required for admittance M O C This activity has been approved by the ABD to satisfy component 2 of MOC-D Leadership Institute — addresses leadership competencies specific to dermatologists Practice Management Session open to eligible office staff/registered nurses Patient Safety Session Audience Response System Session Health Information Technology Sessions Thursday.............m.....50 Workshops — 3:00 p. F005 Infectious Disease and Infestation Update ....48 S005 Focus Sessions — 2:30 p... Thursday.m........42 Negotiating Your Way to Great Leadership..........................m... Restricted Session open to dermatologist and adjunct (researcher..........................m... to 11:00 a........................... to 5:00 p.............. W002 MOC Self-Assessment: Office-Based Safety . W001 MOC Self-Assessment: Skin Cancer ......47 Symposia — 2:00 p.. to 1:45 p............................................ to 5:00 p..........41 Symposia S001 S002 S003 — 9:00 a............... U008 Quality and Customer Service for a Better Practice .............. to 11:00 a....m........43 F006 What’s Boiling Over: Atopic Dermatitis and Other Eczematous Conditions .org | 37 .47 Medication Monitoring and Complications .............aad..................m.......38 Hidradenitis Suppurativa: An Update.......... W003 MOC Self-Assessment: Acne...............46 Neonatal Dermatology .........................m.44 F008 Case-Based Controversies: Medical .......m............................. corporate) members..... Please note: meeting room locations are subject to change....38 Forums — F001 F002 F003 F004 9:00 a.......................51 Scientific Sessions.................39 Photoprotection........39 Case-Based Challenges in Consultative Dermatology ....... See page 32 for more information...............m...........................................38 U003 U004 Medical Management of Actinic Keratoses . U001 Your True Colors: Know Yourself and Understand Others ......... August 4 Focus Sessions — 7:15 a......m... to 5:00 p.......... access and fees..

Ticket required for admission. 2. scarring inflammatory dermatosis. Bhatia. will be discussed. differentiate it from clinical simulator and categorize it based on severity. by 2050. u001 Your True Colors: Know Yourself and understand Others Room: Regent Parlor u003 Hidradenitis Suppurativa: An update Room: Clinton Suite DIReCTOR Robert A. scientific sessions FOCuS SeSSIOnS 7:15 a. DeSCRIPTIOn The medical management of actinic keratosis and the consequence of photodamage requires a fundamental understanding of the pathogenesis of mutations and the cutaneous neoplastic changes that occur over time. Furthermore. strong leadership skills allow a physician to meet these challenges with aplomb. immunomodulators. August 4. and summarize current therapies. Whether it be everyday staff management. Implement core leadership competencies into daily practice. 3. the attendee should be able to: 1. DeSCRIPTIOn The Asian American population is one of the fastest growing segments of the U. It is a common disease that is associated with considerable morbidity and often poses significant challenges for the practitioner. no tuition fee. to 8:45 a.50 Category 1 CME Credits 38 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . Lee. M.S. M. This session will introduce the diversity of Asian skin.m. Identify the importance of incorporating medical management of actinic keratosis into a treatment regimen. Its clinical presentation and corresponding histopathology will be reviewed.m. M.. involvement in organized medicine. this session will cover therapeutic considerations when managing skin disease in Asian Americans. Chiu. 1. the attendee should be able to: 1. Apply the mechanisms of action of therapeutics to the disease state and discuss current and future treatment options. LeARnIng OBjeCTIveS Following this focus session. They will be able to apply this information to develop a rational treatment algorithm for this often difficult to treat disease. 3. describe its natural history. LeARnIng OBjeCTIveS Following this focus session. An estimated 40 million Asian Americans will be living in the U. as well as a basic knowledge of the mechanisms of action of the many available therapeutic options. Ph. the attendee should be able to: 1. Formulate and prescribe a treatment plan based on current the medical literature. Please note: meeting room locations are subject to change. This session addresses the Leadership Institute Competencies Increasing Self-Awareness and Communicating Effectively. the audience will be able to diagnose and accurately stage the disease. or advancing an academic career. dermatologists are faced with leadership opportunities every day.D. Recognize the unique characteristics of Asian American skin. Discuss special considerations when treating Asian American skin.D. 1. practice promotion/expansion. 2.50 Category 1 CME Credits Thursday.For a description of session categories. After this presentation. surgical and laser procedures. Ticket holds seat for only 15 minutes after the official start time. Identify his/her own leadership strengths and weaknesses.D.50 Category 1 CME Credits DIReCTOR Neal D. recurrent.S. Diagnose hidradenitis suppurativa. population. The goals of the session are to review these concepts as well as discuss current and future treatments. the attendee should be able to: 1. Review the fundamental pathogenesis and progression of photodamage to actinic keratosis. including hormone therapy. LeARnIng OBjeCTIveS Following this focus session. 1. Scientific Sessions u002 Asian American Skin Room: Gibson Suite u004 Medical Management of Actinic Keratoses Room: Sutton South DIReCTOR Melvin W.D.50 Category 1 CME Credits DIReCTOR Elizabeth Shannon Martin. 1. LeARnIng OBjeCTIveS Following this focus session. How to improve communications with others using personality assessment will also be discussed. Describe the presentation of particular dermatologic conditions as they present in Asian Americans. M. Summarize current medical and surgical therapeutic options. 2. This interactive session will allow participants to perform a personality selfassessment and focus on how information learned allows the dermatologist to capitalize on his/her strengths and improve on his/her weaknesses. 2. access and fees. See page 32 for more information. DeSCRIPTIOn No matter the setting. 3.D. to serve as part of the clinician’s regimen. Improve the effectiveness of communications with others. its unique characteristics. and some of the dermatologic conditions that can manifest differently in Asian skin. Standard and newer therapeutic options. 3. both topical and systemic. see page 24. DeSCRIPTIOn Hidradenitis suppurativa is a chronic.

Halpern.D. M. Richard K. M. Fungus. Stern 9:25 a. InvITeD SPeAKeRS Zoe Diana Draelos. Detailed nail surgery know-how for the novice and experienced will round out the program. Osterwalder 9:25 a.m. Ticket holds seat for only 15 minutes after the official start time. The Latest and Greatest / Dr. Discuss the current regulation and future trends in sunscreens formulation. DeSCRIPTIOn This session covers nail diagnosis.aad. Please note: meeting room locations are subject to change.m. Draelos 10:45 a. There will be adequate time for questions and discussion. M. The Ideal Sunscreen . See page 32 for more information. 3.m. What You Need To Know About Nail Psoriasis and More / Dr.m. Recognize and treat cosmetic nail problems. Lim 9:45 a.D. Wang 9:05 a. 2. Halpern 10:05 a. M. 2. Lim.D. see page 24. The session will focus on the regulatory trends and scientific research in sunscreen formulation.m. Wang 10:25 a. M.D.D. Does Sunscreen Prevent Skin Cancer? / Dr. in photoprotection will also be presented. Introduction / Dr.scientific sessions For a description of session categories.D.m. Diagnose and manage nail psoriasis.m.m. specifically the role of sunscreen will be discussed by leading experts in the field. the attendee should be able to: 1.m. What You Need: A Nail Tool Kit / Dr. M. Questions and Answers / All faculty Scientific Sessions. What You Need To Know About Candida in the Nail / Dr. Rich 10:15 a.m. Nail experts will discuss common and uncommon nail problems with practical tips and strategies for management.00 Category 1 CME Credits SCHeDuLe 9:00 a. How To Do It: Nail Surgery Procedures / Dr. Wang. Apply techniques for performing a nail biopsy. such as skin cancer prevention and Vitamin D synthesis. Ralph Daniel. The Impact of Nanotechnology in Photoprotection / Dr. Jellinek.m.m. Questions and Answers / All faculty 10:00 a. 3. Allan C. 2. What is the Role of Antioxidants in Photoprotection? / Dr. M. 2. to 11:00 a. Dana W. Henry W. Scher 9:15 a. DeSCRIPTIOn Current technology and development in photoprotection. the attendee should be able to: 1.Tumors. M. A discussion of hot topics. Zoe Diana Draelos. access and fees. August 4 For the Latest Program Book InFormatIon PLease reFer to www.org | 39 .D.D. M.D.m. nail fungal infections and other nail conditions. Daniel 10:30 a. Draelos 10:45 a.K. surgery and therapy.D.m. from soup to nuts. Questions and Answers / All faculty LeARnIng OBjeCTIveS Following this forum. Jellinek 9:45 a. New Therapy / Dr. InvITeD SPeAKeRS C. Uli Osterwalder LeARnIng OBjeCTIveS Following this forum.Global Understanding. M. no tuition fee. F001 nails Room: Nassau Suite A/B F002 Photoprotection Room: Sutton North DIReCTOR Phoebe Rich.m. Hot Nail Topics . Evaluate the impact of sunscreens on skin cancer prevention and Vitamin D synthesis.m. Photoprotection and Vitamin D: What’s New? / Dr. DIReCTOR Steven Q. Thursday.00 Category 1 CME Credits SCHeDuLe 9:00 a. Ticket required for admission. FORuMS 9:00 a. Explain the role of nanotechnology and antioxidants in sunscreens formulation. Perspective and Direction on Sunscreen Regulation / Mr. Nathaniel J. Scher. Stern.m.

the lectures will focus on difficult to diagnosis cases and on unique presentations that predict response to specific therapies.D. Hughey.m. Zirwas Thursday. Eczematous Facial Dermatoses / Dr. Ph. Diagnosing Patients With Fever and Rash in the Bone Marrow Unit / Dr.D. Scientific Sessions 40 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . access and fees. Diagnose unusual or unique presentations of facial dermatoses. Instead. Lindy Peta Fox. Ticket required for admission. M. Follicularly Based Facial Dermatoses / Dr. August 4. Ethical Issues in Treatment of Hospitalized Patients with Skin Disease / Dr. atopic dermatitis. 2. Kanade Shinkai. see page 24. LeARnIng OBjeCTIveS Following this forum.D. DeSCRIPTIOn Inpatient dermatology offers us challenging cases. The lectures will not discuss typical presentations and therapies — it is assumed that attendees are competent to diagnose and treat these cases. Fox DIReCTOR Matthew Zirwas. Kroshinsky 9:30 a. we are making difficult decisions on rounds.00 Category 1 CME Credits SCHeDuLe 9:00 a. Please note: meeting room locations are subject to change. acne. LeARnIng OBjeCTIveS Following this forum. PCP Prophylaxis in Immunosuppressed Patient with Skin Disease / Dr.m. InvITeD SPeAKeRS Jonathan Cotliar. This session is designed to examine some of these challenging situations and consider options for approaching these cases. allergic contact. irritant contact. Shinkai 10:30 a.00 Category 1 CME Credits SCHeDuLe 9:00 a. Discuss controversies and challenges in the diagnosis of inpatient dermatology cases. pityrosporum folliculitis. M. Ticket holds seat for only 15 minutes after the official start time. scientific sessions FORuMS 9:00 a. to 11:00 a. DeSCRIPTIOn The session will consist of two lectures — one on follicularly based facial dermatoses (demodex.m.m.D. the attendee should be able to: 1. Treatment of Inflammatory Skin Disease in the Setting of Active Infection or Underlying Malignancy / Dr. no tuition fee. Bikowski 10:00 a.D. Identify controversies and challenges in the treatment of inpatient dermatology cases.m. etc) and one on eczematous facial dermatoses (seborrhea.For a description of session categories. M. rosacea. See page 32 for more information.. M. On a daily basis.m. InvITeD SPeAKeR Joseph B. 2.D. F003 Case-Based Challenges in Consultative Dermatology Room: Beekman Parlor F004 Face to Face: Management of Facial Dermatoses Room: Sutton Center DIReCTOR Lauren C. Bikowski. Develop unique treatment plans tailored to the presentation of each patient. the attendee should be able to: 1. M.D.m. M. 2. 2.m. etc). Cotliar 10:00 a.

m. www.D. DeSCRIPTIOn This session will focus on the completion of 25 questions.m. Baum. M.e.aspx SCHeDuLe 9:00 a. of the MOC-D program.m. 3. Oscar Colegio. M. will be covered. 10:20 a. LeARnIng OBjeCTIveS Following this symposium.org | 41 Scientific Sessions. Madan V. squamous cell carcinoma. Nemeth Questions on Merkel Cell Carcinoma / Dr. M.D. 9:40 a. See page 32 for more information. the attendee should be able to: 1. Camilleri.m. commitment to lifelong learning and periodic self-assessment. 10:00 a.m. Bolognia. W001 M O C MOC Self-Assessment: Skin Cancer Room: Rendezvous Trianon S001 eADv/AAD joint Symposium Room: Mercury Ballroom DIReCTOR Jerry D. Art. Nemeth Questions on Adnexal Tumors / Dr. to 12:00 p. Speakers representing the EADV will offer insights into the recent revisions in classification and prognoses of cutaneous B-cell lymphomas.D.edu/Reports/2010/Dietary-Reference-Intakes-forCalcium-and-Vitamin-D. access and fees. Lancet 2010. Sexually Transmitted Infections: Update on Rapid Diagnosis and Treatment / Mr. Cappel. the attendee should be able to: 1. see page 24. Brewer.m. Bullous Pemphigoid: Clinical Spectrum and Evidence-Based Practical Management / Dr. M. Lear JT.m. SYMPOSIuM 9:00 a. Baum Questions on Squamous Cell Carcinoma / Dr. Practice increased self-directed learning to remain up-to-date on current trends and information relating to cutaneous malignancy. Demonstrate commitment to lifelong learning and selfassessment. Identify strengths and weaknesses in knowledge of cutaneous oncology.D. Ph.m. M. CO-DIReCTOR Erwin Tschachler. Institute of Medicine’s Recommendations Regarding Vitamin D Requirements / Dr. Shari Nemeth. Specific topics that will be covered include: basal cell carcinoma. 9:20 a. to 11:00 a. no tuition or ticket.D. M.m. et al. M. 3. InvITeD SPeAKeRS Christian L.D. LeARnIng OBjeCTIveS Following this workshop. Issue 10.: CD002292.D. Michael J.375:673-85. 2. Lim www. Cappel This session will be submitted to the American Board of Dermatology for approval to satisfy Component 2. etc). Interventions for bullous pemphigoid. Lim.m. an evidence-based approach to the diagnosis and treatment of bullous pemphigoid will be presented. Questions on Basal Cell Carcinoma / Dr.m.D. Henry W. Tuition fee and ticket required for admission.m. speakers representing the AAD will provide an update on that topic in addition to a review and critique of the recent Institute of Medicine’s recommendations regarding vitamin D requirements. InvITeD SPeAKeRS Simon Barton. Cutaneous Lymphomas: What Dermatologists Should Know / Dr. 10:20 a. Open admission. Kirtschig G. based in large part upon the efforts of the EORTC.m. Luca Borradori. Mark A. Camilleri Questions on Rare Cutaneous Malignancy / Dr. Borradori 9:30 a. 2.D. WORKSHOP 9:00 a. Because MRSA is a significantly greater problem in the USA than in Europe. August 4 For the Latest Program Book InFormatIon PLease reFer to . 2. No. M. Barton 10:30 a.D. Merkel cell carcinoma.D. malignant melanoma. M. atypical fibroxanthoma. Kenneth J. from basal cell carcinomas to inflammatory diseases.scientific sessions For a description of session categories. Colegio Questions on Malignant Melanoma / Dr. 2.. as well as new light sources and photosensitizers currently available in Europe. Tomecki 10:00 a. Answers will be provided after the questions. 3. Cochrane Database of Systematic Reviews 2010. Szeimies 11:30 a. Thursday.iom. and rare cutaneous malignancy (i. M. Photodynamic Therapy: A European Perspective / Dr. dermatofibrosarcoma protuberans. Discuss new applications for photodynamic therapy. The session is structured in a question and answer format utilizing an audience response system (ARS) and will cover skin cancer as a topic specific to MOC SelfAssessment. Bad Bugs and New Drugs: MRSA Infections / Dr.D.aad. Participants will receive immediate feedback for each question and identify areas of weakness that require further selfdirected study.00 Category 1 CME Credits ReFeRenCeS 1. M. 3. CO-DIReCTOR Jean L. Rolf-Markus Szeimies. M. Szeimies R-M. Please note: meeting room locations are subject to change. Middleton P.D. DeSCRIPTIOn The EADV and AAD have joined forces in an effort to compliment one another and provide the audience with an expanded perspective of topics of interest to dermatologists. M. Tomecki. In addition to a review of newly developed rapid diagnostic tests for sexually transmitted infections.D. M.D.00 Category 1 CME Credits SCHeDuLe 9:00 a. adnexal tumors. Rein Willemze.m.m.m. Have an evidence-based treatment approach to bullous pemphigoid. Willemze 11:00 a. Appreciate the bases for the new classification scheme for cutaneous B-cell lymphomas. Non-melanoma skin cancer. The use of photodynamic therapy for a range of disorders. Bennett C.

This session will provide members with an enhanced understanding of the experiences of EHR dermatology champions.00 Category 1 CME Credits SCHeDuLe 9:00 a. Working in our universities.D. JD InvITeD SPeAKeRS David E. Getting the job done at a committee level. Kaufmann. 9:30 a. Thursday. Join our panel of experts to learn from experience how to be an effective negotiator and “get the job done. Open admission. M. Insight into skills that help you negotiate more effectively will be presented in this session.D. Negotiation may be necessary to accomplish what you need to get done with an insurance contract. 10:25 a. Eastern.m.m. 9:25 a. Goldberg. Scientific Sessions Save the Date Don’t miss the 2012 Volunteer Service Project at next year’s Annual Meeting in San Diego. the attendee should be able to: 1.H.aad. CA. Michael H. Cohen.m. Stone Questions and Answers / All faculty Negotiation In Academics: The Art and the Science / Dr.m. Building a team that works together to build strength. in our offices.m. 11:00 a. and participate in quality improvements through EHR systems. Davey Questions and Answers / All faculty Negotiating with Providers: Make It Fair / Dr. 11:30 a. the attendee should be able to: 1.m. 9:55 a. Davey. See page 32 for more information.org/dermatologyinaction 42 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . Gold. LeARnIng OBjeCTIveS Following this symposium. Assess how other dermatologists in various practice settings successfully adopted EHR systems. 3. William P. August 4. M. 2. DeSCRIPTIOn Live interactive physician-only (no vendors) demonstration of how EHR implementation was done and pearls on strategies that worked best. or even with industry.m. S002 eHR Physician Demonstration Room: Grand Ballroom East/West S003 negotiating Your Way to great Leadership Room: Regent Parlor DIReCTOR Mark D. a legislator. and even our patients.m. scientific sessions SYMPOSIA 9:00 a..m. Stephen P. 11:55 a. Stone. Joseph S. M. 11:25 a.m. Skills that help you get the job done effectively will be reviewed.00 Category 1 CME Credits DIReCTOR David J. use alternative approaches to reach an optimal outcome. M.D. 2. March 15.m. the academic setting requires constant negotiation.m. see page 24. 3. 10:30 a. LeARnIng OBjeCTIveS Following this symposium. no tuition or ticket. Demonstrate effective negotiation skills. a building manager.” 3. 10:55 a. 2012 More information coming soon! www. Identify skills that make participation in board/committee meetings productive. access and fees.D. 10:00 a.m. 3. Gold Questions and Answers / All faculty Negotiation with Patients: Control Your Day / Dr.D. Goldberg Questions and Answers / All faculty Negotiation to Simplify our Daily Practices / Dr. your office staff. communities and organizations we often serve on committees and boards. Principles of Negotiation / Dr. an academic department. Discuss how to enhance patient safety..m. M. Recognize the perspective of others involved in the negotiation process. Implement an EHR utilizing best practices.For a description of session categories. M. Cohen Questions and Answers / All faculty Thursday. on a board of directors. to 12:00 p. communication and efficiency for an effective outcome is necessary in all of our work. Eastern Questions and Answers / All faculty Negotiation with Influence on a Board of Directors / Dr.P. M.D. strengthen care coordination. Please note: meeting room locations are subject to change. industry.D. M. DeSCRIPTIOn “Getting the job done” in our daily lives requires that we negotiate every day.

to 2:00 p. Ronald P.D. 2. The Rest of the Story / Dr.m. 3.m. access and fees. resurgent diseases.m.P. Burdick. Recognize the appropriate use of systemic therapy in atopic dermatitis. Gasbarre 1:20 p. Germs And Steel: Antibiotics In Derm Surgery / Dr. 2.D.D. Presentations will emphasize trends and new developments. and changing patterns of disease. The Severely Affected Infant: What Should You Do Differently? / Dr. Tomecki. M. essentially an infectious “what’s new. Schaffer. Eichenfield 12:48 p.D.m. DeSCRIPTIOn This forum will update the learner on advances in the diagnosis and management of patients with atopic dermatitis and related conditions. M. Rosen 1:00 p. InvITeD SPeAKeRS Anne E. Rapini. Are There Bed Bugs in Your Bed? / Dr.scientific sessions For a description of session categories. M. DIReCTOR Robert Sidbury. leprosy.m. The Appropriate Use of Systemic Therapy / Dr. Eichenfield.D.m. Theodore Rosen.m. FORuMS 12:00 p. Please note: meeting room locations are subject to change. the role of patch testing and contact allergy in atopic patients. including bed bugs. August 4 For the Latest Program Book InFormatIon PLease reFer to www.m. Martinez 12:40 p.00 Category 1 CME credits SCHeDuLe 12:00 p. Travelers’ Buggy Maladies: The Americas / Dr. Contact Allergy and Patch Testing in Atopic Patients / Dr.aad. therapy. see page 24.org | 43 . M. Burdick 1:40 p. Chang 12:24 p. Thursday. Review the new NIAID food allergy guidelines and their relevance to AD care. Sidbury LeARnIng OBjeCTIveS Following this forum. selected travel-related afflictions from the Americas. Discuss the differential diagnosis and appropriate management of severe infantile eczema.D. M. 2 . Ticket holds seat for only 15 minutes after the official start time. 2. Tomecki Scientific Sessions. M. Rapini 12:20 p. Jose Dario Martinez. InvITeD SPeAKeRS Mary Wu Chang. the attendee should be able to: 1.m. Leprosy 2011 / Dr.H Christopher C. M. M. DeSCRIPTIOn This session. Julie V. DeLeo 1:12 p.m.D. and the appropriate use of systemic therapy. M. LeARnIng OBjeCTIveS Following this forum. We will specifically address the significance of new food allergy guidelines and how they relate to eczema patients.O.00 Category 1 CME Credits SCHeDuLe 12:00 p. M. and antimicrobials used in surgey.D. M. Gasbarre..m. Resurgent Diseases / Dr. Insect Assaults / Dr. the attendee should be able to: 1.D.D. F005 Infectious Disease and Infestation update Room: Nassau Suite A/B F006 What’s Boiling Over: Atopic Dermatitis and Other eczematous Conditions Room: Sutton Center DIReCTOR Kenneth J.m. Session will be clinically germane and directly applicable to patient care. Schaffer 1:36 p. See page 32 for more information. Lawrence F. the unique challenges presented by infants with severe eczematous eruptions. including diagnosis. Ticket required for admission. The New NIAID Food Allergy Guidelines: How Do They Affect my Practice? / Dr. Evaluate and treat affected patients more knowledgeably and effectively.m. Recognize recent trends and developments in infecttious diseases and infestations. Vincent Anthony DeLeo. no tuition fee.” will highlight the following topics: Selected infestations. D.

D.00 Category 1 CME Credits DIReCTOR Mark D.m. Davis..D. Newman 12:20 p.M.m. 2. This Male Patient Has Severe. Describe controversies in diagnosis of selected dermatologic conditions. M. He has a History of Psychiatric Illness: Should you Prescribe Isotretinoin? / Dr. LeARnIng OBjeCTIveS Following this forum. M. the use of adjuvant radiation in the treatment of SCC and role of dermatologists in treating Merkel cell carcinoma.D.D.D.m. Develop treatment strategies for challenging skin cancers. Amer Nizar Kalaaji.D. Kalaaji 12:40 p.m. Is Interstitial Granulomatous Dermatitis a Systemic Disorder? / Dr. no tuition fee.D. scientific sessions FORuMS 12:00 p. LeARnIng OBjeCTIveS Following this forum.m. InvITeD SPeAKeRS Dawn M. See page 32 for more information. Hectorne 1:40 p.m. DeSCRIPTIOn The session is divided in two parts. Discuss controversies in the management of selected dermatologic conditions. Manage reconstruction conundrums.m.D. Kathleen Julie Hectorne. access and fees. M. M. 2. M. to 2:00 p. DeSCRIPTIOn We will explore cases seen by medical dermatologists that led to some controversy either in diagnosis or management. The first part will focus on controversies in the management of melanoma.For a description of session categories. 2.m. the attendee should be able to: 1. R. Scientific Sessions 44 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . Davis. Recalcitrant Nodulocystic Acne. 2. the attendee should be able to: 1. The Patient is on Biologics for Rheumatoid Arthritis.00 Category 1 CME Credits SCHeDuLe 12:00 p. F007 Case-Based Controversies: Procedural Room: Sutton North F008 Case-Based Controversies: Medical Room: Beekman Parlor DIReCTOR Victor Allen Neel. David A. P. Ticket holds seat for only 15 minutes after the official start time. Wetter 1:00 p. Now He has Developed What Looks Like Psoriasis on the Hands and Feet: What to do Now? / Dr. Controversial Cases Seen by the Pediatric Dermatologist: A Pot-Pourri / Dr. The Patient is Starting Prednisone 30 mg Daily for Immunobullous Disease: Does PCP Prophylaxis Need to be Initiated? / Dr. M. August 4. Davis Thursday. Ticket required for admission. Davis 1:20 p. Wetter. The second part will highlight challenges in regional reconstruction. Ph. The Patient Clearly has Delusions of Parasitosis: What Now? / Dr. Catherine Clayton Newman. Please note: meeting room locations are subject to change. see page 24.

the attendee should be able to: 1. Identify strengths and weaknesses in one’s knowledge of issues in patient safety that are relevant to dermatology.O. The session focuses on histological mimickers: skin malignancies that resemble reactive conditions or benign neoplasms.m. M.50 Category 1 CME Credits DIReCTOR Hillary Johnson-Jahangir. W002 M O C MOC Self-Assessment: Office-Based Safety Room: Rendezvous Trianon u005 Pitfalls in Dermatopathology Room: Gibson Suite DIReCTOR Aleodor A. Wisco. to 1:45 p. Identify histological features that are useful in preventing pitfalls in diagnosis.00 Category 1 CME Credits * Self-assessment questions utilized in this session are the same as those used for Workshop W013 offered at Annual Meeting 2011 and Workshop W004 offered at Summer Academy Meeting 2010.D. DeSCRIPTIOn This session is directed towards residents.D.aad. Scientific Sessions.org | 45 . 1. Andea. benign conditions that masquerade as malignancies and tumors that are prone to be mistaken for other types of cutaneous malignancies. August 4 For the Latest Program Book InFormatIon PLease reFer to www. Oliver J. Please note: meeting room locations are subject to change.D. no tuition fee. The audience will be presented with the salient features of each entity and with tips to avoid misdiagnosis. M. LeARnIng OBjeCTIveS Following this focus session.m. M. Divya Srivastava. Ticket required for admission. M. WORKSHOP 12:00 p. LeARnIng OBjeCTIveS Following this workshop.scientific sessions For a description of session categories. James Selwyn Taylor. FOCuS SeSSIOn 12:15 p. Pitfalls in the diagnosis of cutaneous neoplasms that may result in diagnostic errors with significant clinical impact will be presented. to 2:00 p.D. 2.m. Ph. Tuition fee and ticket required for admission.. 3. see page 24. Ticket holds seat for only 15 minutes after the official start time. InvITeD SPeAKeRS Jacques Michael Casparian. D. DeSCRIPTIOn This session will be structured as a question-and-answer format using an automated response system.m.D. Physicians should not claim CME/MOC credit for attending this session if they attended Workshop W013 at Annual Meeting 2011 or Workshop W004 at Summer Academy Meeting 2010. the attendee should be able to: 1. Integrate and apply current concepts in patient safety to improve patient care. Current concepts in patient safety that are relevant for dermatologists will be highlighted. Recognize a variety of dermatopathology cases that are prone to be misdiagnosed. Determine appropriate ancillary studies that help arrive at the correct diagnosis. dermatologists with an interest in dermatopathology and dermatopathologists who enjoy challenging cases.D. access and fees. Thursday. 2. This session does not qualify as a Patient Safety Module for MOC Component 2: Commitment to Lifelong-Learning and Periodic Self-Assessment. M. Safety issues important in procedural and medical dermatologic practice will be addressed in order to better care for our patients. See page 32 for more information. 2.

m. and potentially difficult. to 1:45 p.D.For a description of session categories. One of the most rewarding. everyday office visit punctuated with only enough warnings to keep you on your toes. residents. Identify and nurture qualities in individuals that help your team grow. assistants. Included at no extra charge: Hints from 30 years of keeping my tie clear of poop and how to muffle ear-splitting cries. Grant-Kels. Jorizzo. with special emphasis on the normal. Shwayder. do they need imaging or follow up? Journey with me to explore the newborn skin. Perform an examination on newborn skin at the hospital or office. access and fees. August 4. practical. Identify abnormal newborn cutaneous variants and when to yell for help! 3.50 Category 1 CME Credits Develop the Leader Within! Leadership Institute sessions and events offer you an opportunity to strenthen your leadership skills to benefit you in your career. 46 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . Recognize normal newborn cutaneous variants so one can relax and reassure the parents.aad. and staff.D.D. See page 32 for more information. u006 Bringing out the Best in Others Room: Regent Parlor DIReCTOR Kathryn Schwarzenberger. 2. M. InvITeD SPeAKeRS Jane M. Join several dedicated mentor-leaders in our field as they share their pearls about how to help others reach their full potential. Please note: meeting room locations are subject to change. the attendee should be able to: 1. DeSCRIPTIOn Love seeing those babies. Ticket holds seat for only 15 minutes after the official start time. see page 24.m. DeSCRIPTIOn Regardless of practice setting. Ticket required for admission.D. Thursday. LeARnIng OBjeCTIveS Following this focus session. scientific sessions FOCuS SeSSIOnS 12:15 p. aspects of leadership is helping others mature and grow into their full potential. we all work closely with others: partners. visit www. no tuition fee. M.org/leadership to learn more. Joseph L. M. Describe and utilize mentorship skills to build teams at all levels. M. 1. 1. 2. LeARnIng OBjeCTIveS Following this focus session.50 Category 1 CME Credits In between meetings. All Leadership Institute sessions are marked with throughout the Program Book. Scientific Sessions u007 neonatal Dermatology Room: Sutton South DIReCTOR Tor A. the specialty and your personal life. Set aside time for you to enhance and engage your inner leader at this year’s Summer Academy Meeting. nurses. but dread being asked about a rash? Confused about normal newborn skin variations? How does one approach the cutaneous signs of rare genetic diseases? And those marks with rare systemic associations. the attendee should be able to: 1. Audience participation will be sought in this open-format session.

Roberta D. Botulinum Toxin in Procedures in Cosmetic Dermatologic Surgery Series. Jossey-Bass. CAE Jennifer Lucas. M. Carruthers A. Stratman Being a Star Team Player / Dr. InvITeD SPeAKeRS Karen Collishaw. Utilize team member skills for effective outcomes. 2008 3. 2. Parsons. The Five Dysfunctions of a Team. Filling the Temples / Dr. Matarasso. Lucas Getting the Work Done on Time / Dr. Lewis / Dr. M.m. Day. 3. see page 24.m. Arndt K. Amy B. Stratman Questions and Answers / Dr. Please note: meeting room locations are subject to change. access and fees. DeSCRIPTIOn Getting your team to work together for maximum performance requires insight. 3:30 p. Parsons Questions and Answers/Conclusion / Dr. 4:30 p. Marks.aad. M. InvITeD SPeAKeRS Diane S. 4:05 p. M.D. Introduction / Dr. and leadership. Philadelphia: Elsevier. to 5:00 p.D. Marmur / Dr. 2002 SCHeDuLe 2:00 p.m. Lisa M. Kaminer M. Plan and execute effective team goals.m. Lewis. Erik J. Join our experts in this area to learn concrete concepts and valuable insight and ideas on how to maximize your team’s performance for an optimal result with a group that feels that they have worked together and enjoyed the process to achieve success.m.m.Collishaw Questions and Answers / Ms. Rohrer. Introduction 2:05 p.D. preparation.00 Category 1 CME Credits ReFeRenCeS 1.D. the attendee should be able to: 1.m. Lucas Questions and Answers / Dr.D.m. Volumizing the Mid Face / Dr. Sengelmann.m.D. M. Carruthers A. Carruthers J.m. DIReCTOR Thomas E. Alan Matarasso / Dr. Michael Kane. Creating the Perfect Lip / Dr.scientific sessions For a description of session categories. M. M. SYMPOSIuM 2:00 p. 2:40 p.D. Marmur 3:20 p. See page 32 for more information. Doris J. Philadelphia: Elsevier. Day 4:30 p. P. Atlas of Cosmetic Surgery. Lower Face Rejuvenation / Dr.00 Category 1 CME Credits ReFeRenCeS 1. eds.org | 47 . M.D.m. 4:35 p. 3. 2:35 p. Seth Matarasso / Dr.D. to 5:00 p.m.m.m. Identify soft tissue fillers appropriate for a variety of facial areas and applications. 4:00 p.m. Upper Face Rejuvenation / Dr. Berson / Dr. 2. 3. Open admission.Collishaw Leading Teams / Dr. Seth Matarasso 2:30 p. Assess the aging face and choose the most appropriate injection techniques. M.m. 2008 2. Soft Tissue Augmentation In Cosmetic Dermatology Series.m. Questions and Answers LeARnIng OBjeCTIveS Following this symposium. August 4 For the Latest Program Book InFormatIon PLease reFer to www. Victor J. Berson 4:10 p. Marks Knowing the Personalities on Your Team / Dr. COuRSe 2:00 p. Donofrio / Dr. Rejuvenating the Neck and Hands / Dr. 2:05 p.D.m. Tuition fee and ticket required for admission. Ellen S. interact with. DeSCRIPTIOn This live interactive session will feature experts from around the country demonstrating and commenting on soft tissue filler and botulinum toxin injections. Marks Questions and Answers / Dr. 3:20 p.D. Kane / Dr.m. 4:55 p. Lencioni. thought. Alan Matarasso. Day 2:55 p. Carruthers J.m. Donofrio 4:55 p.D.m. C001 Live Patient Demonstration: Botulinum Toxin and Fillers Room: Trianon Ballroom S004 Leading High Performance Teams Room: Regent Parlor DIReCTOR Margaret E. and inject their patients. 2008 SCHeDuLe 2:00 p. Lewis 3:45 p. M. no tuition or ticket. It is an opportunity for attendees to virtually step into the office of these expert injectors and see how they assess. LeARnIng OBjeCTIveS Following this course. Seth L. Berson. Marmur.m. Parsons Scientific Sessions. Donofrio. M. Each region of the face will be addressed by two faculty members and audience interaction is encouraged. 3. Identify new concepts in facial aging and how that applies to rejuvenating procedures. the attendee should be able to: 1. M. Parsons Managing Teams: Principles / Ms.m. Identify key concepts of team-building. Dover J.D. Rohrer T. Philadelphia: Elsevier. M. Stratman.m. M. Rejuvenating the Eyes and Tear Troughs / Dr. Thursday.D.

Questions and Answers / Dr. Ph.. See page 32 for more information. to 4:00 p. Service Excellence forms a foundation for other projects and safety improvements. there is a high risk of developing skin cancers among first. M. Open admission.m. (entire issue) SCHeDuLe 2:00 p.D. Diagnose smoking-related skin and mucosal changes.O. Increased skin cancer rate and precocious skin aging in smokers are the two arms of the same pathophysiologic mechanism. as well as relevant controversies and difficult questions concerning four common areas of systemic dermatologic therapy. John A. Drug Causation: How Do We Know the Drug Did the Deed? / Dr. the attendee should be able to: 1. such as psoriasis and hidradenitis suppurativa. 2009 Sep-Oct. 2. Harper 4:10 p.m.D. Julie Claire Harper. scientific sessions SYMPOSIuM 2:00 p.and second-hand smokers. Identify the safety issues concerning common systemic therapies in acne and rosacea. Wolverton SE editor. 3. Wolverton 4:55 p. Evaluate great service in the office setting. Recognize why Service Excellence is important and how it represents quality in medicine. DeSCRIPTIOn Service Excellence (also called customer service) is a critical competency for dermatologists. LeARnIng OBjeCTIveS Following this symposium. 2. (For all practitioners). There is evidence that patient satisfaction and quality medicine are one and the same. even more than patient outcomes. On the other hand. August 4. 3. After instituting Service Excellence. Experts in each of the four areas will inform and challenge the audience concerning both the important complications and monitoring required in order to maximize drug safety. no tuition fee. The dichotomous effect of smoking can be explained through the nicotinic receptormediated action of nicotine on different cutaneous cell types involved in a particular disease.50 Category 1 CME Credits Thursday. practitioners spend more time in medical care and less in office problem-solving.m. Chemotherapy and Dermatologist: Some Dermatology Uses and Unique Skin Complications / Dr. Controversies in Dermatologic Drug Therapy. Questions and Answers / All faculty DIReCTOR Charles N. Zic. Please note: meeting room locations are subject to change. Assess the most current scientific information on the most serious isotretinoin complications. Describe the clinical relevance of selected chemotherapy drugs in dermatology and the cutaneous risks of these drugs. LeARnIng OBjeCTIveS Following this focus session.50 Category 1 CME Credits 48 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . 1.D. Ellis. InvITeD SPeAKeRS James Q.00 Category 1 CME Credits ReFeRenCeS 1. Scientific Sessions u009 Smoking and the Skin Room: Sutton South DIReCTOR Sergei A.m. LeARnIng OBjeCTIveS Following this focus session. the attendee should be able to: 1.m.m.m. Zic 3:25 p. Questions and Answers / All faculty 2:45 p.D. Zic 3:30 p. M. see page 24.D.D. FOCuS SeSSIOn 2:30 p. Del Rosso 2:40 p. DeSCRIPTIOn In addition to a well known harmful role of smoking in several inflammatory skin diseases. Studies show patient satisfaction is driven by patient experiences. Questions and Answers / All faculty 4:15 p. Isotretinoin Adverse Effects: An Update on the Most Worrisome Complications / Dr. DeSCRIPTIOn This highly interactive symposium will address important up-todate scientific information. M. Systemic Agents Used to Treat Acne and Rosacea: Monitoring and Safety Consideration / Dr. Understanding how to provide great service will be the best thing you ever did for yourself. to 5:00 p. access and fees. the attendee should be able to: 1.m. M. Del Rosso. Ticket required for admission. M. Ticket holds seat for only 15 minutes after the official start time. focusing most on the theoretical risk of inflammatory bowel disease. Training in providing great service leads to a more efficient and happier workforce. there is a negative association of smoking with certain skin diseases. 1. Wolverton. Implement Service Excellence in dermatology offices.m. Grando. no tuition or ticket.For a description of session categories. D. Dermatol Ther 22(5):397. such as pyoderma gangrenosum and pemphigus. S005 Medication Monitoring and Complications Room: Grand Ballroom East/West u008 Quality and Customer Service for a Better Practice Room: Gibson Suite DIReCTOR Stephen E. 3. The schedule allows more than adequate time to answer questions from the audience.m.m.m. 2. Diagnose skin and mucosal diseases related to smoking.

the attendee should be able to: 1.. dermatomyositis.org | 49 . LeARnIng OBjeCTIveS Following this forum. Review the current peer reviewed literature in Ethnic Skin of Color. case studies from our multidisciplinary clinics will be presented emphasizing management and decision making process and referral back to the referring dermatologist.D. Qureshi. scleroderma/fibrosis and psoriasis/psoriatic arthritis in a multidisciplinary clinic environment. pyoderma gangrenosum.50 Category 1 CME Credits From the Dermatology-Rheumatology Clinic: Practical Tips and Advances in Management Room: Madison Suite DIReCTOR Abrar A. Please note: meeting room locations are subject to change. no tuition fee. We will spend time on off-label treatment options and therapeutic pearls mainly. dermatomyositis. scleroderma/fibrosis and psoriasis/ psoriatic arthritis. The CD includes: • Scripts that follow along with each presentation.m. alopecia and inflammatory disorders in Ethnic skin of Color. DeSCRIPTIOn This session will consist of a summary of clinic set-up with a discussion of operational. the attendee should be able to: 1. to 4:00 p. 2. Treat patients with cutaneous lupus.scientific sessions For a description of session categories. Fact vs. 1. Thursday. Adults Pre-teens and Teens Children Grades 3-5 Perfect for school presentations and screening events! Children Grades K-2 For the Latest Program Book InFormatIon PLease reFer to www. August 4 Teach the fundamentals of skin cancer and sun-safety! The See SPOT CD contains four dynamic PowerPoint™ slide presentations. M. emphasizing the treatment of skin disease in patients who also have multi-organ disease. u010 Skin of Color Room: Clinton Suite u011 DIReCTOR Wendy E. See page 32 for more information.aad. patient flow and billing practices. dermatomyositis. see page 24.H. Ticket required for admission. LeARnIng OBjeCTIveS Following this focus session. As examples.D. access and fees. The session is targeted as a data resource for those who teach. pyoderma gangrenosum. 2. slide by slide • Pre. I will discuss approaches to the patient with cutaneous lupus. detection and treatment options in persons with darker skin types. research.m. Ticket holds seat for only 15 minutes after the official start time. FOCuS SeSSIOnS 2:30 p. Discuss skin cancer. 3. pyoderma gangrenosum. laboratory investigations and therapy.50 Category 1 CME Credits Scientific Sessions. 1.and post-presentation evaluations to test your audience’s sun safety knowledge • Printable coloring pages and word finds – great giveaway for your waiting room Visit the Academy Resource Center Booth 906 to demo. Therapeutic approaches will focus on case examples to illustrate choice of systemic therapies including biologics. DeSCRIPTIOn This session will overview pertinent and current peer review literature present regarding Skin and Hair of Color. or treat skin of color. 3. Evaluate and work up patients with cutaneous lupus. Update our medical knowledgebase and treatments in Ethnic Skin of Color. Roberts. Design a combined clinic with physicians from multiple specialties working together. each specially targeted to a different age group. M. fiction will be reviewed regarding description. scleroderma/fibrosis and psoriasis/psoriatic arthritis including taking a history and physical examination. M.P.

D. 3:05 p.m.m.m. see page 24.00 Category 1 CME Credits SCHeDuLe 3:00 p. 4:20 p. What is your liability? You see a patient who adamantly insists that his sutures be removed one week after they have been placed. Carucci.D.D. DeSCRIPTIOn You are online in a social Internet site and one of the other people starts to discuss the treatment of his unusual skin condition.. Ticket holds seat for only 15 minutes after the official start time. 2. scientific sessions FORuMS 3:00 p. Identify important recent literature related to regional reconstruction. 3. J.m. J. Gladstone.. 4:45 p. You can’t resist giving advice. Gladstone Staged Reconstruction: Regional Approach / Dr. M. lip/ perioral area as well as staged procedures for these same locations. ear. Recognize legal implications of treatment alternatives. but you know medically that the patient will have an unsatisfactory result if you comply with his demand. Campen. Questions and Answers / All faculty 4:15 p. Carucci Questions and Answers / All faculty 50 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 .D. Brian Jiang. InvITeD SPeAKeRS Murad Alam. 3:55 p.D. InvITeD SPeAKeRS Rebecca B. access and fees. See page 32 for more information. Jiang Reconstruction of Nasal Defects / Dr. J.D.D. the attendee should be able to: 1. to 5:00 p. Unfortunately. Scientific Sessions DeSCRIPTIOn This session will focus on regional reconstruction for Mohs surgery defects..m. all of whom are practicing dermatologists.For a description of session categories. the attendee should be able to: 1.m. Ticket required for admission. M. Jiang Reconstruction of the Lip and Perioral Area / Dr.. Ph. M. M. Introduction / Dr.m. Recognize the best reconstruction options for difficult anatomic areas. Presentation and Analysis of Legal Dilemmas / All faculty 4:00 p.m. August 4. 2. Hayes B. M.D. 2. Jonathan Scott Sanders. LeARnIng OBjeCTIveS Following this forum.D. 3:30 p. no tuition fee. your advice is grossly incorrect.m. M.00 Category 1 CME Credits SCHeDuLe 3:00 p. Presentation and Analysis of Legal Dilemmas / All faculty 4:45 p. M.m. The speakers will review and update different repair options for difficult anatomic locations such as the nose.m. What should you do? These and other legal dilemmas will be discussed by a panel of MD/JDs. 2. Thursday. John A. LeARnIng OBjeCTIveS Following this forum.D. Questions and Answers / All faculty DIReCTOR Shang I. Identify different reconstructive options for various anatomic locations. F009 Review and update of Regional Reconstruction Room: Sutton Center F010 Legal Dilemmas in Dermatology Room: Nassau Suite A/B DIReCTOR Clifford Warren Lober. Analyze legal dilemmas to facilitate appropriate patient care. Alam Reconstruction of the Ear / Dr.D. Please note: meeting room locations are subject to change.m.

Apply the two step method to identify melanocytic and nonmelanocytic skin lesions with dermoscopy. InvITeD SPeAKeR Ana M. with emphasis on melanoma and dysplastic nevi. Martini 4:30 p. Ciurea 3:30 p. Martini 4:20 p.m. to 5:00 p. LeARnIng OBjeCTIveS Following this workshop. The forum will cover topics in acne.m.D. Ciurea 3:20 p.m.scientific sessions For a description of session categories. Demonstrate commitment to lifelong learning and selfassessment via completion of 25 questions and answers with discussion. Martini.000 slides and 400 cases • Identify and diagnose lesions of the skin • Includes two DVDs – basic and advanced A Guide for the Physician Visit the Academy Resource Center Booth 906 to purchase! For the Latest Program Book InFormatIon PLease reFer to www. Questions / Dr.00 Category 1 CME Credits This session will be submitted to the American Board of Dermatology for approval to satisfy Component 2. M. Martini DIReCTOR Joslyn S. Martini 4:50 p. This forum will allow for self-assessment with immediate feedback and allows for identification of areas that require further self-directed study. LeARnIng OBjeCTIveS Following this workshop. Questions / Dr. Thursday. Kirby. psoriasis. M. access and fees.m. Ciurea. Identify the strengths and weaknesses in the attendee’s dermatology knowledge and to make improvements as needed. M. Psoriasis. M. Ciurea 4:00 p.D. Questions / Dr. Questions / Dr. commitment to lifelong learning and periodic self-assessment. The two Step Algorithm: Defining Melanocytic and Non-Melanocytic Lesions / Dr. 2. Dermoscopy Unknowns / Dr. of the MOC-D program. 2. The session will conclude with a series of dermoscopy unknowns. DeSCRIPTIOn This session is geared for both the beginner dermoscopist and also offers a good review for clinicians who incorporate dermoscopy in their practices. WORKSHOPS 3:00 p. Dermoscopy Basics: Equipment and Terminology / Dr. InvITeD SPeAKeRS Mark Lebwohl. DeSCRIPTIOn This session is structured as a question and answer forum using an audience response system. Joshua Zeichner.D.00 Category 1 CME Credits SCHeDuLe 3:00 p.D. The session will review terminology. 3. • View over 8. Please note: meeting room locations are subject to change. Tuition fee and ticket required for admission. Dysplastic Nevi and Melanoma / Dr. M.m.m. see page 24.m. the attendee should be able to: 1. and other inflammatory dermatoses. Misha Rosenbach. eczema and Inflammatory Dermatosis Room: Rendezvous Trianon W004 Dermoscopy Room: Sutton North DIReCTOR Mary C. both of which benefit the patient. eczema. Identify melanoma on dermoscopy. August 4 DERMOSCOPY Learn a technique that is less invasive and yields faster results. M. please arrive on time. current dermatoscopes: polarized and non-polarized and the two step algorithm. Mowad.org | 51 . Christen M. Distinguish benign and malignant melanocytic lesions using dermoscopy. the attendee should be able to: 1.D. Non-melanocytic lesions will also be covered.D.D.m. 2. Ciurea 3:50 p. W003 M O C MOC Self-Assessment: Acne.aad.m. the attendee will view numerous images of benign and malignant melanocytic lesions.m. Following these presentations. See page 32 for more information. 2. M. Scientific Sessions. Due to the timed framework of this session.

. .m. . . . . . . . .m. . Hwang. . to 4:00 p. . . . . . .m.m. . . . . . . . . . . . U014 Mastering Moles in Pediatric Patients . . . . Update in CTCL: A Tale of Two Kinds of T-Cells / Sam T..m. . Non-Ablative and Ablative Fractional Resurfacing: Cosmetic and Medical Indications / Roy G. . M. . . . . . . . . 54 9:20 a. . to 12:00 p. . . . .m.D. . . to 8:45 a. 62 52 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . . . Stratman. You Decide / Timothy M. . . .m. . . . U012 Patients Satisfaction: Measurement and Improvement . Using Technology to Improve Dermatology Access . Ph. . 61 Workshop — 3:00 p. . . Lim. . . . . . Please note: meeting room locations are subject to change. . . . . . . . . . .59 Case-Based Challenges for PA/NPs . Chair’s Welcome / Henry W. . . . . . .m. . . . . C002 Live Patient Demonstration: Neurotoxins and Soft Tissue Augmentation . M. . U013 What’s New in Non-Melanoma Skin Cancer . . . Scientific Sessions Plenary Session — 9:00 a. . M. . . . . . .D. . . to 5:00 p.D. . . .m. . . Johnson. . Restricted Session open to dermatologist and adjunct (researcher. . . . . . 55 11:15 a. . . 54 9:50 a. . . . . . .D. . .m. . . .m. . . . . . . . . See page 32 for more information. . . August 5 53 53 53 53 Symposia — 2:00 p. . Geronemus.m. .m. W005 MOC Self-Assessment: Pediatric Dermatology . . .m. see page 24. . Maps.D. . . 54 10:30 a. . . . . . . M. . . . . . . . 58 Focus Sessions — 2:30 p.D. . . . . M. . U015 Laser Update . . . .m. . . access and fees.m. M. . . . S006 What’s Hot in Dermatopathology .D. . Memorial Lectureship: Sentinel Node Biopsy: Just the Facts.m. 57 S007 Effective Communications: Delivering Key Messages . . . . . Margolis.m. . . . . Fox. . . Friday. . . Contact Dermatitis / David Eric Cohen.m. .. to 5:00 p. .D. .m. . . . . . . . . . 56 Course — 2:00 p. Comparative Effectiveness / David J. . . . . . . . . 57 58 58 59 59 3:00 p. . . . .m. and Traps / Erik J. . . . . . . to 5:00 p. . . . . . . . . . President’s Address / Ronald L. . . . Gaps. . . . . .m. . . . . . Moy. . M.D. . 55 10:45 a. . . M. . . . . . . . . . . A ticket is required for admittance M O C This activity has been approved by the ABD to satisfy component 2 of MOC-D Leadership Institute — addresses leadership competencies specific to dermatologists Practice Management Session open to eligible office staff/registered nurses Patient Safety Session Audience Response System Session Health Information Technology Sessions Focus Sessions — 7:15 a. . M. . .55 11:00 a. . . . . . Guest Speaker / Don Tapscott . . . . . .D. . 60 Melanoma . .m. Cellulitis: A Common (Mis)Diagnosis? . August 5. . . . . . . . . to 5:00 p. 55 11:30 a. 54 9:05 a. . . . . . . . U018 Dermoscopy for the Non-Dermoscopist . . . . . . Everett C. . . . . . . . . 60 Finessing Surgical Technique . . . . . . . . . . . . . 9:00 a. . . . . . . . U019 Forums — F011 F012 F013 F014 Friday. . . U016 From Bench to Bedside: Important Clinical Advances . U017 Photodynamic Therapy . . . . . corporate) members. . . .scientific sessions For a description of session categories. . . . . . . Overhauling CME and Dermatology Education: Laps.

A greater skill as how to approach the patient will be developed. Schaffer. including variants such as spitz. 1. Please note: meeting room locations are subject to change. See page 32 for more information.org | 53 . Recognize clinicopathologic variants of acquired and congenital melanocytic nevi in children and their typical patterns of evolution. Identify and analyze new and important studies in nonmelanoma skin cancer. and management of melanocytic nevi in children. 1.D. 2. DeSCRIPTIOn This session will review the clinical spectrum. natural history. August 5 u013 What’s new in non-Melanoma Skin Cancer Room: Sutton South DIReCTOR Gary Goldenberg. Determine a practical and safe approach for everyday practice. Friday.50 Category 1 CME Credits u015 Laser update Room: Clinton Suite DIReCTOR Jerome M. M. DeSCRIPTIOn This session will focus on non-melanoma skin cancer. LeARnIng OBjeCTIveS Following this focus session. DeSCRIPTIOn This session will focus on raising awareness of the importance of an exceptional experience by patients as the basis for office success. LeARnIng OBjeCTIveS Following this focus session. Formulate an individualized approach to management of melanocytic nevi in children. numbers. Data on clinical presentations and biologic behavior of prepubertal melanoma will also be presented. the attendee should be able to: 1. basal cell carcinoma. 3.g.aad. Recognize the difference between patient and physician perception of excellence in care. DeSCRIPTIOn With so many devices being promoted for the treatment of the skin. highlighting insights into pathways of melanocytic tumorigenesis. 3. Identify the latest developments in laser therapy. histopathology. 2.D. outline principles of service excellence. and Kaposi’s sarcoma.D. see page 24.D. Identify behavioral standards that can be adopted as office standards. the attendee should be able to: 1. Choose appropriate laser systems for various conditions. 2.50 Category 1 CME Credits Scientific Sessions.m. 2. 3. blue. squamous cell carcinoma. Identify new treatment approaches to non-melanoma skin cancer. including actinic keratosis. LeARnIng OBjeCTIveS Following this focus session. August 5 Scientific Sessions. no tuition fee. M. We will review and analyze new studies. M. the attendee should be able to: 1.m. We will discuss patient versus physician perceptions of care. Ticket holds seat for only 15 minutes after the official start time. Apply Principles of Service Excellence to your practice setting. 1. FOCuS SeSSIOnS 7:15 a. Current concepts of the risks associated with congenital melanocytic nevi of different sizes. epidemiology. and speckled lentiginous nevi. the attendee should be able to: 1. considering cosmesis and ease of monitoring) will be discussed. and treatment. 1. Describe new findings in dermatopathology in relation to nonmelanoma skin cancer. Ticket required for admission. and locations as well as individualized strategies for their management (e.scientific sessions For a description of session categories. Recent observations on the dermatoscopic features and molecular hallmarks of childhoodacquired and congenital melanocytic nevi will be examined. 3. Identify and monitor children at risk for the development of melanoma or neurocutaneous melanocytosis. access and fees. focusing on pathogenesis. Friday. LeARnIng OBjeCTIveS Following this focus session.50 Category 1 CME Credits For the Latest Program Book InFormatIon PLease reFer to www. Merkel cell carcinoma. this forum will give an understanding to the science and clinical outcome including the latest developments.50 Category 1 CME Credits DIReCTOR Victor James Marks. Garden. to 8:45 a. u012 Patients Satisfaction: Measurement and Improvement Room: Gibson Suite u014 Mastering Moles in Pediatric Patients Room: Regent Parlor DIReCTOR Julie V. M. and elucidate the concept of behavioral (service) standards as a means of ensuring consistently personal service delivery by all personnel in the office.

You Decide! Timothy M. Dr. No CME Credit 54 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 .scientific sessions P151 PLenARY SeSSIOn For a description of session categories.D guest Speaker Don Tapscott Sentinel node biopsy for melanoma remains controversial within dermatology. 9:50 a. This presentation will summarize the contemporary data.m. Fox. Dr. Tapscott has authored or coauthored fourteen widely read books on technology. His other books include Grown Up Digital: How the Net Generation is Changing Your World and Wikinomics: How Mass Collaboration Changes Everything – an international bestseller.m. business and the Net Generation. Chair. everett C. It should be appreciated that variable interpretation of existing evidence is certain. Room: Grand Ballroom East/West Open admission. See page 32 for more information. Please note: meeting room locations are subject to change. and final interpretations and opinions may respectfully differ from one person to another.m. Williams. no tuition or ticket. No CME Credit Friday.” Dr. and update attendees on plans for influencing positive change for the future. the Academy has developed a detailed plan of strategic priorities aligned with our members’ top concerns … including addressing challenges and opportunities that emerge as we work through the impending health care revolution.m. to 12:00 p. Moy.D. Scientific Sessions 9:20 a. access and fees. M.00 Category 1 CME Credits 9:05 a. including his newest book. Lim. For the Summer Academy Meeting 2011 in New York. 9:00 a. marketing and talent..50 Category 1 CME Credits Don Tapscott is an internationally renowned authority on the strategic impact of information technology on innovation. appearing on the New York Times and BusinessWeek bestseller lists.D.D. M. Up to 2.m. 9:00 a. co-authored with Anthony D. found by and large outside the core dermatology literature. Scientific Assembly Committee President’s Address Ronald L.m. No CME Credit “To help us succeed in today’s dynamic health care environment. M. Tapscott consistently identifies and explains the next business imperatives and defines the business models and strategies required for success. Moy will discuss how the Academy is helping its members manage change. see page 24. Moy stated earlier this year. August 5. Moy will discuss the progress of these efforts and address current issues affecting the profession. Macrowikinomics: Rebooting Business and the World. 0. Welcome Henry W. Johnson. M. Memorial Lectureship: Sentinel node Biopsy: just the Facts.

scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.

P151

9:00 a.m. to 12:00 p.m. Room: Grand Ballroom East/West Open admission, no tuition or ticket. Up to 2.00 Category 1 CME Credits 10:45 a.m.

PLenARY SeSSIOn

10:30 a.m.

Overhauling CMe and Dermatology education: Laps, gaps, Maps, and Traps
Erik J. Stratman, M.D.

Contact Dermatitis
David Eric Cohen, M.D.

Over 3 billion dollars is spent annually delivering CME education to physicians in the United States, or just over $3700 per US physician. Despite the expenditure, data suggest that the traditional lecture-based CME does little to change physician behavior when delivering subsequent patient care. With pressure mounting to provide more outcomes-driven impactful education during residency and during the continuing professional development of the practicing physician, medical education has begun to evolve. Residency training now has milestones in addition to competencies. In CME education, we see shifts in education delivery and focus, now with much greater emphasis in performance improvement, point of care education, and Maintenance of Certification. In many cases, these education changes are becoming less optional and an expected means to acquire education to maintain licensure and/or certification. This session will provide the dermatologist with a glimpse at changes underway and changes coming, and will explain how we all will be impacted through CME sessions of the near future. 0.25 Category 1 CME Credit 11:00 a.m.

The evaluation of contact dermatitis presents an often harrowing challenge in the daily care of patients with eczematous dermatitis. While the technique of patch testing has changed little in the past decades, our recognition of important provocative allergens and groups of chemicals regularly transforms and evolves, a consequence of the great flux in exposure patterns that patients experience through their work and routine daily activities. Consequently, we have seen the emergence of important and relevant allergens as participants in the genesis of cutaneous delayed type hypersensitivity and the vanishing role of previously commonly implicated chemicals. We will review the epidemiologic journey of contact dermatitis and current perspectives on the importance and relevance of patch testing. 0.25 Category 1 CME Credit

Scientific Sessions, Friday, August 5 Scientific Sessions, Friday, August 5

11:15 a.m.

update in CTCL: A Tale of Two Kinds of T Cells
Sam T. Hwang, M.D., Ph.D.

Comparative effectiveness
David J. Margolis, M.D.

In the dermatologic literature, Sézary syndrome (SS) is often described as a variant of mycosis fungoides (MF). New immunological data indicate that the malignant T cells in SS and MF are derived from two distinct populations of T cells. This information can help explain the clinical manifestations of these two diseases and provide avenues for selective therapy. 0.25 Category 1 CME Credit

Comparative effectiveness research is the comparison of existing therapeutic options in order to determine which therapy provides the greatest benefits, often in a real world setting. His presentation will include a basic primer on comparative effectiveness research and discuss why this type of research will impact the provision of healthcare. 0.25 Category 1 CME Credit

For the Latest Program Book InFormatIon PLease reFer to

www.aad.org

|

55

scientific sessions
P151 PLenARY SeSSIOn

For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information. 9:00 a.m. to 12:00 p.m. Room: Grand Ballroom East/West Open admission, no tuition or ticket. Up to 2.00 Category 1 CME Credits

11:30 a.m.

non-Ablative and Ablative Fractional Resurfacing: Cosmetic and Medical Indications
Roy G. Geronemus, M.D.

Friday, August 5, Scientific Sessions

Fractional resurfacing was developed in response to complications and prolonged healing associated with non fractional resurfacing for cosmetic conditions. Non-ablative fractional resurfacing involves the delivery of thousands of microthermal zones extending to various depths depending on the laser wavelength and energy. The non-ablative treatments have shown dramatic clinical benefit for rejuvenation, acne and surgical scars, dyschromia and actinic keratoses. 0.25 Category 1 CME Credit

The American Academy of Dermatology is pleased to announce a Call for Nominations for the 2013 Named Lectureships. These distinguished awards are given in recognition of outstanding dermatologic research. Recipients receive cash awards and will present their lecture at the 2013 Annual Meeting in Miami, Fla. Nominations are currently being accepted for the following awards:
• Clarence S. Livingood, MD,

11:45 a.m.

Questions and Answers

Award and Lectureship

• arion B. Sulzberger, MD, M

Memorial Award and Lectureship Award and Lectureship

• ila Gruber Memorial Cancer Research L

• ugene J. Van Scott Award for Innovative E

Therapy of the Skin and Phillip Frost Leadership Lecture

If you would like to apply or nominate someone visit the Academy Resource Center Booth 906 or visit www.aad.org/namedlectureships

56

|

amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011

scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.

COuRSe

2:00 p.m. to 5:00 p.m. Tuition fee and ticket required for admission.

SYMPOSIuM

2:00 p.m. to 5:00 p.m. Open admission, no tuition or ticket.

C002

Live Patient Demonstration: neurotoxins and Soft Tissue Augmentation
Room: Trianon Ballroom

S006

What’s Hot in Dermatopathology
Room: Mercury Ballroom

DIReCTOR Shane A. Meehan, M.D. InvITeD SPeAKeRS Tammie C. Ferringer, M.D. Gary Goldenberg, M.D. Rishi R. Patel, M.D. LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Discuss new developments in the understanding of various disease processes from the perspective of dermatopathology as they pertain to clinical practice of dermatology. 2. Describe advances in diagnostic studies as they pertain to the diagnosis and pathogenesis of a variety of infectious, neoplastic and inflammatory disease processes. DeSCRIPTIOn This course is designed to provide dermatologists and dermatopathologists with an overview of recent developments in the diagnosis and pathogenesis of a wide variety of neoplastic and inflammatory processes. Recently devised immunoperoxidase markers for the diagnosis of melanoma, non-melanoma skin cancers, and certain infectious diseases will be discussed. In addition, advances in molecular diagnostic studies as they pertain to the understanding and diagnosis of melanocytic neoplasms will be reviewed. The session will also encompass newly recognized inflammatory processes, such as cocaine-related retiform purpura and challenges pertaining to the diagnosis of pustular psoriasis versus acute generalized exanthematous pustulosis. 3.00 Category 1 CME Credits SCHeDuLe 2:00 p.m. 2:40 p.m. 2:45 p.m. 3:25 p.m. 3:30 p.m. Inflammatory Skin Disorders / Dr. Patel Discussion / Dr. Patel Today’s Immunohistochemistry / Dr. Ferringer Discussion / Dr. Ferringer What’s New In Non-Melanoma Skin Cancer? / Dr. Goldenberg 4:10 p.m. Discussion / Dr. Goldenberg 4:15 p.m. Atypical Melanocytic Nevi And Melanoma / Dr. Meehan 4:55 p.m. Discussion / Dr. Meehan

DIReCTOR Heidi A. Waldorf, M.D. InvITeD SPeAKeRS Rebecca L. Fitzgerald, M.D. Jeannette O. Graf, M.D. Michael Kane, M.D. Seth L. Matarasso, M.D. Cameron K. Rokhsar, M.D. Neil S. Sadick, M.D. Susan H. Weinkle, M.D.

LeARnIng OBjeCTIveS Following this course, the attendee should be able to: 1. Evaluate the aging face. 2. Develop a therapeutic rejuvenation plan utilizing a combination of neurotoxin and soft tissue fillers and collagen stimulators. 3. Avoid and manage complications. DeSCRIPTIOn This session consists of live demonstrations of injectables for facial rejuvenation including neuromodulators, soft tissue fillers and collagen stimulators. During the demonstrations, the faculty will review patient evaluation, anatomic considerations, product selection, injection techniques and complications. Combination therapies to enhance outcomes will be discussed. 3.00 Category 1 CME Credits SCHeDuLe 2:00 p.m. Introduction / Dr. Waldorf 2:05 p.m. The Upper Face: Shaping the Brow / Dr. Kane / Dr. Graf 2:25 p.m. The Upper Face: Focus on the Eyes and Tear Trough / Dr. Graf / Dr. Matarasso 2:45 p.m. The Upper Face: The Atrophic Temple / Dr. Fitzgerald / Dr. Kane 3:05 p.m. The Mid-Face: Volumizing the Cheeks / Dr. Sadick / Dr. Fitzgerald 3:25 p.m. Questions and Answers / Faculty 3:35 p.m. The Mid-Face: Approaching the Perioral Area and Lips / Dr. Matarasso / Dr. Waldorf 3:55 p.m. The Lower Face: Managing Jowls and Jawline / Dr. Waldorf / Dr. Weinkle 4:15 p.m. The Hands: Rejuvenation / Dr. Weinkle / Dr. Rohksar 4:25 p.m. Refining the Nose / Dr. Rohksar / Dr. Sadick 4:45 p.m. Questions and Answers / Faculty

Scientific Sessions, Friday, August 5 Scientific Sessions, Friday, August 5

For the Latest Program Book InFormatIon PLease reFer to

www.aad.org

|

57

see page 24. from practicing dermatologists to basic scientists. Learning how to successfully craft and deliver key messages will help you communicate effectively in any situation.50 Category 1 CME Credits Friday. concisely and effectively. 3. basal cell carcinoma and dermatofibrosarcoma protuberans. 2.scientific sessions SYMPOSIuM 2:00 p. Scientific Sessions u017 Photodynamic Therapy Room: Regent Parlor DIReCTOR Mollie A. Describe the mechanism of action of photodynamic therapy.m..m. Ticket holds seat for only 15 minutes after the official start time.D. dermatofibrosarcoma protuberans and Kaposi’s sarcoma will be reviewed. Ph. 2.m. DeSCRIPTIOn The Academy has identified effective communication as a core competency for leadership in dermatology. DeSCRIPTIOn Systemic and topical targeted therapies are emerging as a rational approach to the management of skin cancers. Farris Key Message Training / Dr. M. no tuition fee. as with any recent advance. Incorporate photodynamic therapy into his or her practice. Mugalian Develop Key Messages / Ms. She will be assisted by a communications consultant. the attendee should be able to: 1. actinic keratoses. InvITeD SPeAKeR Ruth Mugalian LeARnIng OBjeCTIveS Following this symposium. In this session. access and fees. Communicate key messages clearly.m. S007 effective Communications: Delivering Key Messages Room: Mercury Rotunda u016 From Bench to Bedside: Important Clinical Advances Room: Gibson Suite DIReCTOR Patricia Farris. Introduction / Dr. Apply strategies for staying focused on key messages in challenging situations such as media interviews. 2. 2:40 p. Seating will be limited to 30 and available on a first-come first-served basis. FOCuS SeSSIOn 2:30 p. Prepare compelling and relatable key messages. 2:05 p. This session will cover the science behind photodynamic therapy. M. Summarize the efficacy of recently approved therapies or therapies currently in trials for the treatment of skin cancers. Farris Basics/Expectations of an Interview / Ms.D.m. no tuition or ticket.m. LeARnIng OBjeCTIveS Following this focus session. the rationale behind and effectiveness of new molecules used in the treatment of melanoma.m. 3:20 p. the attendee should be able to: 1. confusion exists regarding its actual efficacy for treating a variety of skin diseases. 1. 4:50 p.D. to 4:00 p. Identify conditions that respond well to photodynamic therapy as well as those that do not. 3:00 p.m. Mugalian Questions and Answers / All Faculty DIReCTOR Oscar Colegio.m. the attendee should be able to: 1. 3. to 5:00 p. DeSCRIPTIOn Photodynamic therapy is rapidly becoming a mainstay of dermatologic therapy. Ticket required for admission. 3. Describe molecular pathways recently discovered to be effective targets for treating melanoma. See page 32 for more information. MacCormack. This session is designed for a broad audience. Mugalian On-Camera Mock Media Interviews / Ms. 1. Attendees will have the opportunity to practice what they’ve learned about message development in mock media interviews designed to challenge participants to stay focused while delivering their message.m. For a description of session categories. LeARnIng OBjeCTIveS Following this focus session. This session is recommended for dermatologists and graduate members.00 Category 1 CME Credits SCHeDuLe 2:00 p.D. Open admission. Yet. basal cell carcinoma.50 Category 1 CME Credits 58 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . The course director is a previous chair of the council on communications. Easily incorporated into clinical practice it adds a new dimension to dermatologic care. August 5. Please note: meeting room locations are subject to change. M. details on how the procedure is performed and how you can easily incorporate it into your own practice as well as an extensive review of the data supporting its efficacy in treating a wide range of dermatologic conditions.

Friday.D. Ph. M. when the clinical presentation is somewhat atypical. see page 24. Identify those who may have limited access to dermatologic care and to identify possible barriers to providing this care. to 4:00 p. Jeffrey A. William D.D. August 5 u019 Cellulitis: A Common (Mis)Diagnosis? Room: Clinton Suite DeSCRIPTIOn Though the problem of inequality of dermatologic care has been recognized. By incorporating dermoscopy into everyday practice. 3. the attendee should be able to: 1. to 5:00 p. with an emphasis on the differential diagnosis of cellulitis in both healthy and immunocompromised patients. FORuM 3:00 p.D.00 Category 1 CME Credits DIReCTOR Daniela Kroshinsky. including use of online educational databases. 2. Scientific Sessions. 2.. 1. Please note: meeting room locations are subject to change. For routine cellulitis. no tuition fee. the differential diagnosis should be rapidly expanded. Use dermoscopy to distinguish benign from suspicious lesions that require biopsy. Discuss access to care issues and consider future means for providing dermatologic care to underserved populations. this manual will guide you every step of the way into your new job. Define the clinical patterns and symptoms associated with the different forms of true cellulitis. ! NEW • Assessing Practice Options • Interview Process • Structuring Your Contract • Co-ownership/Buy-in • Marketing Yourself to Patients Visit the Academy Resource Center Booth 906 to purchase! www. Benabio. 3. or if the patient fails to respond to appropriate therapy for common bacterial cellulitis. Armstrong. Recognize the features that suggest another diagnosis.scientific sessions For a description of session categories. DeSCRIPTIOn Dermatologists are often consulted to evaluate a patient with presumed cellulitis. Amit Pandya. Ticket holds seat for only 15 minutes after the official start time. Formulate a broad differential diagnosis for healthy and immunosuppressed patients. DeSCRIPTIOn Novice dermoscopists will be taught recognizable dermoscopic patterns to assist in the diagnosis of pigmented lesions. M. However. Ticket required for admission. Noah A. Stein. the attendee should be able to: 1. including the face and acral surfaces. LeARnIng OBjeCTIveS Following this focus session. This course will provide professional development to the attendees via new information on methods of providing care to those in need. 2. Participants will be shown unknown cases throughout the session for self-assessment and the approach to diagnosis of these cases will be reviewed. u018 Dermoscopy for the non-Dermoscopist Room: Sutton South F011 using Technology to Improve Dermatology Access Room: Sutton North DIReCTOR Jennifer A. Ticket required for admission.D. an accurate diagnosis can be obtained from the patient’s symptoms and clinical appearance. With the increase in usage of teledermatology and other new technologies. InvITeD SPeAKeRS April W. Friday. Inequality of care in different regions of the United States and globally needs to be addressed.D. no tuition fee. LeARnIng OBjeCTIveS Following this forum. M. specifically in atypical presentations or in patients who fail to respond to routine therapy. James.50 Category 1 CME Credits DIReCTOR Claudia Hernandez. there is still a shortage of care. Craft.D. Understanding the tools available to dermatologist will help in closing this gap. The session will also include dermoscopy of special sites. and teledermatology.D. August 5 Scientific Sessions. See page 32 for more information.m. 1. New technologies will aid in delivery of care for underserved patients and communities. We will discuss a simple pattern recognition system that can be incorporated into routine dermatologic practice.aad. M. Formulate a simple pattern recognition system that can be used in general dermatologic practice to minimize unnecessary biopsies and improve detection of malignant lesions. M.50 Category 1 CME Credits Transition into Practice: A Toolkit for Dermatologists Entering into the Workforce Whether you’re fresh out of residency or changing practices mid-career.m. access and fees. the attendee should be able to: 1. participants will be able to improve their diagnostic accuracy in detecting melanoma and other skin cancers.D. Recognize characteristic dermoscopic structures of benign and malignant lesions. Review innovative means for providing dermatologic care to those in need. 2.D. This session will discuss the approach to the patient with presumed cellulitis.org | 59 For the Latest Program Book InFormatIon PLease reFer to .m. M. LeARnIng OBjeCTIveS Following this focus session. M. Ticket holds seat for only 15 minutes after the official start time. access to care should increase. V. 3. FOCuS SeSSIOnS 2:30 p.m. M.

Identify the most appropriate management strategies and formulate a practical treatment plan. and issues in its control. DeSCRIPTIOn This session will focus on the interaction of technology and melanoma.00 Category 1 CME Credits SCHeDuLe 3:00 p. Using challenging case examples. Halpern. Nancy E. Morel 3:35 p. participants will be guided through differential diagnoses and therapeutic plans for a variety of complex cases. Nunley 4:45 p. Introduction and Objectives / Dr. Technological Aids to Melanoma Diagnosis / Dr. no tuition fee.D.D.m. Ticket required for admission. its use in diagnosis.m. InvITeD SPeAKeRS Lynn Anne Cornelius. Kara S. Perform a broad differential diagnosis based on clinical findings and lesion morphology. Rigel Friday. Thomas 4:06 p. Melanoma is now recognized as a collection of diseases. M. See page 32 for more information. Identify clinical and pathologic features of common and challenging dermatologic diseases. August 5. M. Identify the clinical features of genetically distinct types of melanoma. Assess and use technologies relevant to melanoma. and complex medical dermatology cases. Kimberly Dawn Morel.m. Pediatric Dermatology Case Challenges / Dr. to 5:00 p. Hurst. LeARnIng OBjeCTIveS Following this forum. Hurst 3:10 p. 3:00 p. An audience response system will be used to facilitate learning. BRAF and NRAS Mutant Melanomas: Clinical Features.m. Patel 4:20 p. M.m. the attendee should be able to: 1.m.m. Complex Medical Dermatology Case Challenges / Dr. Assessing Impact of New Technology on Melanoma Risk / Dr. thought processes leading to the differential diagnoses will be described.D.00 Category 1 CME Credits SCHeDuLe 3:00 p. Thomas. Scientific Sessions 60 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . Nunley.D. the attendee should be able to: 1.m. F012 Case-Based Challenges for PA/nPs Room: Beekman Parlor F013 Melanoma Room: Sutton Center DIReCTOR Eva A. Halpern 3:39 p.m. including assessing its effect on risk.m. 3. 2.m. M. M. M. transplant dermatology. see page 24. DIReCTOR Martin A. Indoor Tanning: Current Issues and Future Challenges / Dr. Rigel. and Outcome / Dr. Weinstock. M.D. and management will be discussed. Darrell S. Please note: meeting room locations are subject to change. Ticket holds seat for only 15 minutes after the official start time. 2.D. M.D. Risk.m. Allan C. 2. Decribe new therapies for metastatic melanoma. InvITeD SPeAKeRS Richard Carvajal. Manisha J. pediatric dermatology. 3. this session will review advances and practical approaches to treatment. DeSCRIPTIOn This forum is designed for NPs and PAs practicing dermatology.m. laboratory testing and dermatopathology will be reviewed. Cornelius 3:55 p.D. Question and Answer / All faculty LeARnIng OBjeCTIveS Following this forum.. Transplant Dermatology Case Challenges / Dr. M. and we will also discuss their clinical features and therapy in the metastatic setting. M.D. 2. Specifically. Patel.D. Related to presented cases. Weinstock 3:12 p. access and fees. A New Era in the Management of Metastatic Melanoma / Dr. Topic highlights include pigmented lesions and melanoma.scientific sessions FORuMS For a description of session categories.D. Pigmented Lesion and Melanoma Case Challenges / Dr. Carvajal 4:33 p. Ph.

scientific sessions
FORuM
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information. 3:00 p.m. to 5:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.

F014

Finessing Surgical Technique
Room: Nassau Suite A/B

DIReCTOR David M. Ozog, M.D. InvITeD SPeAKeRS Brett M. Coldiron, M.D. Emily J. Fisher, M.D. Hayes B. Gladstone, M.D. Hugh M. Gloster Jr., M.D. Christopher James Miller, M.D. Suzanne Olbricht, M.D.

The new www.AAD.org is built around you!
Your feedback helped us design a website that makes your job easier. Enjoy some of these new features: • Dermatology A to Z, which offers easy-todigest text and images for your patients. • Easier navigation around the website to get to the information you need quickly. • An improved search function that yields accurate results faster than ever before. These are just a few of the improvements; be sure to visit often to explore new content and continuing improvements.

LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Demonstrate simple yet essential surgical techniques to achieve optimal cosmetic and functional outcomes. 2. Utilize proper surgical instruments and materials to enhance healing and repair outcomes. 3. Assess common mistakes made when coding for surgical procedures and how to avoid them. DeSCRIPTIOn This session provides essential surgical pearls for the general dermatologist and intermediate dermatologic surgeon. A myriad of topics will be discussed including tips for anesthesia, optimizing suturing techniques and wound aversion, and the best use of surgical instruments, wound dressings and suture materials. Practical topics will be discussed, including surgical coding and tips to avoid and treat wound complications. 2.00 Category 1 CME Credits SCHeDuLe 3:00 p.m. Painless Anesthesia Before Difficult Closures Made Simple / Dr. Ozog 3:15 p.m. Instruments That Make My Day Easier / Dr. Gloster 3:30 p.m. When Aversion Ain’t Happening: Tips for Optimal Suture Placement / Dr. Miller 3:45 p.m. The Ear of the Dog: Hangover Remedies / Dr. Olbricht 4:00 p.m. Essential Suturing Techniques: Beyond The Simple Interrupted Stitch / Dr. Gladstone 4:15 p.m. Good Closures Gone Bad: A Short Story Of Blood, Pus, And Tears / Dr. Fisher 4:30 p.m. I Can Get Paid for That? Tips To Optimize Surgical Coding / Dr. Coldiron 4:45 p.m. Questions and Answers / All faculty

Scientific Sessions, Friday, August 5 Scientific Sessions, Friday, August 5

Tell us what you think at www.aad.org/ feedback today!

Make www.AAD.org your home page.

For the Latest Program Book InFormatIon PLease reFer to

www.aad.org

|

61

scientific sessions
WORKSHOP

For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information. 3:00 p.m. to 5:00 p.m. Tuition fee and ticket required for admission.

W005
M O C

MOC Self-Assessment: Pediatric Dermatology
Room: Rendezvous Trianon

DIReCTOR Katherine B. Puttgen, M.D. InvITeD SPeAKeRS Bernard Cohen, M.D. Moise L. Levy, M.D. Teresa S. Wright, M.D. LeARnIng OBjeCTIveS Following this workshop, the attendee should be able to: 1. Identify features of neurofibromatosis type 1 in the pediatric population. 2. Differentiate among treatment options for function-threatening infantile hemangiomas. 3. Discuss causes of and therapies for tinea capitis.

Need Self-Assessment Points? Try the AAD’s Dermatology Self-Assessment Program
• atisfies part of Component 2 of S Maintenance of Certification (MOC-D) • 00 Self-assessment questions and 1 points per volume • earning formats in print, online, L and CD -ROM

Friday, August 5, Scientific Sessions

DeSCRIPTIOn Attendees will review clinical findings of important genodermatoses in children including tuberous sclerosis, neurofibramotosis type 1, and Rothmund-Thomson. An update on vascular anomalies in children including infantile hemangiomas and congenital hemangiomas will be reviewed. Epidemiology of important pediatric dermatology infections and infestations will be discussed. 2.00 Category 1 CME Credits SCHeDuLe 3:00 p.m. 3:30 p.m. 4:00 p.m. 4:30 p.m. Questions and Answers: 1st Portion / Dr. Wright Questions and Answers: 2nd Portion / Dr. Puttgen Questions and Answers: 3rd Portion / Dr. Cohen Questions and Answers: 4th Portion / Dr. Levy * Self-assessment questions utilized in this session are the same as those used for Workshop W002 and W005 offered at Annual Meeting 2010 and 2011 and Workshop W008 at Summer Academy Meeting 2010. Physicians should not claim CME/MOC credit for attending this session if they attended any of the sessions listed above.

! NEW

Volume 4

Volume 3
Dou que ble th stio e ns!

Voluime 2 – Online only

Visit the Academy Resource Center Booth 906 to purchase.

62

|

amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011

scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
Restricted Session open to dermatologist and adjunct (researcher, corporate) members. A ticket is required for admittance
M O C

This activity has been approved by the ABD to satisfy component 2 of MOC-D Leadership Institute — addresses leadership competencies specific to dermatologists

Practice Management Session open to eligible office staff/registered nurses Patient Safety Session Audience Response System Session

Health Information Technology Sessions

Saturday, August 6

Focus Sessions — 7:15 a.m. to 8:45 a.m. Exploring Evidence-Based Cosmeceuticals.............. 64 U020 Controversies in “Dysplastic” Nevi ......................... 64 U021 Patch Test Allergens 101: A Detective’s Toolkit....... 65 U022 U023 Use of Light for Diagnosis and Treatment in Dermatology ..................................... 65 Forums — F015 F016 F017 9:00 a.m. to 11:00 a.m. Alopecia and Hair Loss........................................... 66 Consultative Dermatology ...................................... 66 Case-Based Controversies: Dermatopathology.................................................. 66

Focus Session — 12:15 p.m. to 1:45 p.m. U024 When Clinical and Histological Findings Converge: Great Cases From a Dermatopathologist’s Perspective .............................................................. 71 Impact of Nanotechnology and Dermatology......... 71 U025 Pediatric Dermatology Jeopardy ............................. 71 U026 Symposium — 2:00 p.m. to 5:00 p.m. S010 Cutting Edge Surgery and Oncology ...................... 72 Focus Sessions — 2:30 p.m. to 4:00 p.m. U027 Practical Dermoscopy ............................................. 72 Morphea: Not Just for Adults Anymore.................. 72 U028 Forums — 3:00 p.m. to 5:00 p.m. F021 New Technologies in Minimally Invasive Skin Rejuvenation ..................................... 73 F022 Psoriasis Guidelines: Implementing them in Your Practice ............................................. 73 Workshop — 3:00 p.m. to 5:00 p.m. W007 Coding and Documentation ............................ 74

Scientific Sessions, Saturday, August 6

Symposia — 9:00 a.m. to 12:00 p.m. S008 What’s Hot in Women’s Dermatology .................... 67 S009 Dermatology Grand Rounds: A Discussion of Case-Based Dilemmas ............................................ 68 Course — 9:00 a.m. to 5:00 p.m. C003 Derm Exam Prep Course: Refresher ....................... 68 Forums — 12:00 p.m. to 2:00 p.m. F018 Hypercoagulability, Purpura and the Skin .............. 69 F019 Oral Disease ........................................................... 69 F020 Tumor Board .......................................................... 70 Workshop — 12:00 p.m. to 2:00 p.m. W006 Practical Approaches to Patient Problems .............. 70

For the Latest Program Book InFormatIon PLease reFer to

www.aad.org

|

63

” Clark’s. “atypical” nevus. DeSCRIPTIOn Cosmeceuticals can be of value in dermatology for the prevention and maintenance of skin disease. 1. and degrees of “atypia” will be explored through historical review. LeARnIng OBjeCTIveS Following this focus session. Examine historically the concept of the “lentiginous” and “dysplastic” nevi. which have emerged over the last 30 years. u020 exploring evidence-Based Cosmeceuticals Room: Sutton South u021 Controversies in “Dysplastic” nevi Room: Gibson Suite DIReCTOR Payam Abrishami. the AAD Buyer’s Guide allows members to quickly find what they need without the clutter of general purpose search engines. see page 24. and architecturally disordered nevi. access and fees. architecturally disordered nevus. Recognize the different categories of cosmeceuticals and their efficacy parameters. no tuition fee. Discuss recommendations for terminology to be adopted by our specialty. 2. FOCuS SeSSIOn 7:15 a. LeARnIng OBjeCTIveS Following this focus session.aaddermatologybuyersguide. this session will promote a new direction in the understanding of these common melanocytic nevi. Analyze the criteria for the “lentiginous. Examine new research directing development of cosmeceuticals. the attendee should be able to: 1.m. Scientific Sessions Search with Ease! With a database of goods and services that are continually purchased by dermatologists. Clark’s nevus.m. 3. in addition to addressing photoaging issues.scientific sessions For a description of session categories. The attendee will be empowered to decide the legitimacy of these concepts. Ticket holds seat for only 15 minutes after the official start time. M. 1. See page 32 for more information.” “dysplastic.D. This session will examine the evidence behind cosmeceuticals in the current marketplace while presenting new research leading to cosmeceutical development in the future.com 64 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . Please note: meeting room locations are subject to change. Each of the basic categories of cosmeceuticals will be discussed with attention to the efficacy of individual technologies. the attendee should be able to: 1. DeSCRIPTIOn Through a series of original photomicrographs the session will validate the concept of the “lentiginous” nevus for the attendee. to 8:45 a.D. The terms “dysplastic” nevus. Ticket required for admission.50 Category 1 CME Credits DIReCTOR Zoe Diana Draelos. Demonstrate an understanding of how cosmeceuticals can be used meaningfully in dermatology. August 6. 2. M. Start searching today at www. 3.50 Category 1 CME Credits Saturday.

scientific sessions For a description of session categories.U. Lastly. August 6 aa Measurement Tools u For the Latest Program Book InFormatIon PLease reFer to www. Recognize common allergens on product labels. access and fees. Illustrative questions and cases will be discussed.m. to 8:45 a. Hamzavi. Please note: meeting room locations are subject to change. A basic understanding of skin optics is needed to implement light based treatments in any practice. See page 32 for more information. M. 1. FOCuS SeSSIOn 7:15 a. the attendee should be able to: 1.R. suggestions will be made on how to organize an office to start or improve phototherapy options.D. 2.50 Category 1 CME Credits Scientific Sessions. the attendee should be able to: 1. We will review the T. Saturday.aad. Counsel patients on likely sources of allergen exposures. DeSCRIPTIOn Light has become a more important part of treatment options for dermatologists. no tuition fee. Determine an appropriate array of allergens to adequately test your patients. With this understanding complex diseases can be managed more effectively with phototherapy. Ticket required for admission. DeSCRIPTIOn The baseline series of patch tests encompass many compounds to which patients are exposed on a daily basis. LeARnIng OBjeCTIveS Following this focus session. Identify the staff and skills needed to administer light-based treatments in your office. Schalock.50 Category 1 CME Credits DIReCTOR Iltefat H.D. Demonstrate a basic understanding of skin optics. Ticket holds seat for only 15 minutes after the official start time. Test as well as the 50 Chemotechnique North American Standard Series allergens. 3. see page 24. 1.E. LeARnIng OBjeCTIveS Following this focus session.org | 65 . This course will explain the theory behind photomedicine and then develop an approach to customize treatment modalities to the needs of the patient. PDT and lasers.m. This session is for those interested in learning more about the most common allergens. Demonstrate the ability to formulate treatment plans using different light sources. u022 Patch Test Allergens 101: A Detective’s Toolkit Room: Clinton Suite u023 use of Light for Diagnosis and Treatment in Dermatology Room: Regent Parlor DIReCTOR Peter C. Having knowledge of potential allergens and their prospective sources of exposure is essential for assessing those with suspected allergic contact dermatitis in a general dermatology practice. 3. M. Sources of these allergens and patient counseling tips will be suggested. 2.

2. DeSCRIPTIOn The evaluation and management of hair disorders can be challenging. M. Daniela Kroshinsky.m. InvITeD SPeAKeRS Lindy Peta Fox. 9:55 a.m.D. 2. Perform an appropriate evaluation for scarring alopecia.scientific sessions For a description of session categories. 2. Carlson Case Presentation / Dr.m. John Andrew Carlson. Special attention will be paid to unique reactions to cancer therapy.D. to 11:00 a.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. will be discussed by a panel of experienced dermatopathologists. 10:00 a. Fox 9:50 a. Cotliar 66 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . Scientific Sessions F016 Consultative Dermatology Room: Sutton Center DIReCTOR Jonathan Cotliar. Carlson Questions and Answers / Dr.00 Category 1 CME Credits SCHeDuLe 9:00 a. Selected topics. Sperling.m. Perform an appropriate evaluation for non-scarring alopecia. the attendee should be able to: 1. M. no tuition fee. Ph.D. F015 Alopecia and Hair Loss Room: Sutton North F017 Case-Based Controversies: Dermatopathology Room: Rendezvous Trianon DIReCTOR Dirk Michael Elston. 9:25 a.m. 2. 9:30 a. See page 32 for more information. Andea. M. 2. Lauren C. M.m. Many of these issues have an impact on patient management. Audience participation is welcomed and encouraged. Recognize unique paraneoplastic dermatoses. 3. Identify management options for cases with problematic histopathologic findings. reporting and/or recommendations supplied by the dermatopathologist. 1.D. Identify controversial topics that may be encountered in Dermatopathology. see page 24. 3. Ticket holds seat for only 15 minutes after the official start time. M. LeARnIng OBjeCTIveS Following this forum. Andea Case Presentation / Dr.m. 10:30 a. M. InvITeD SPeAKeRS Aleodor A. Shinkai 10:40 a. LeARnIng OBjeCTIveS Following this forum. Neutrophilic Dermatoses / Dr. Case Presentation / Dr. Manage alopecia effectively. DeSCRIPTIOn This case-based session is intended for physicians with an interest in the consultative care of cancer in patients with skin disease.m.00 Category 1 CME Credits DIReCTOR Jacqueline M. Unusual Dermatoses in Cancer Patients / Dr.D. M. Andea Questions and Answers / Dr. the attendee should be able to: 1. Please note: meeting room locations are subject to change. Sperling Case Presentation / Dr. 10:55 a.m. Sperling Questions and Answers / Dr. 10:25 a.D. atypical spindle cell tumors. M. 2.m. new and unusual paraneoplastic dermatoses. LeARnIng OBjeCTIveS Following this forum.m.D. 3.m. August 6.D.m.D. Kanade Shinkai. Recognize cutaneous complications of stem cell transplantation. efficient and costeffective approach to the evaluation and management of alopecia and hirsutism. the attendee should be able to: 1. as well as common and uncommon complications of stem cell transplantation. Junkins-Hopkins. and atypical dermal lymphocytic infiltrates. such as alopecia biopsies. Hughey. Unique Paraneoplastic Dermatoses / Dr. This session will benefit both dermatologists and dermatopathologists.D. Unique Reactions to Cancer Therapy / Dr. Recognize unique cutaneous toxicities associated with cancer therapy.. Leonard C. M. FORuM 9:00 a. This session presents a practical. Junkins-Hopkins Questions and Answers / Dr. management and reporting of atypical but non-malignant proliferations. Junkins-Hopkins Saturday. unique presentations of neutrophilic dermatoses. Kroshinsky 10:15 a. DeSCRIPTIOn Some entities in Dermatopathology may be considered controversial with regard to diagnosis. Recognize limitations in the histopathologic assessment of certain entities.m. Hughey 9:25 a. access and fees. Dermatoses Associated with Stem Cell Transplantation / Dr. including melanocytic lesions. Ticket required for admission.D. M.

m.m. Elewski Nail Tips for Women / Dr. Mark Lebwohl. Additionally. LeARnIng OBjeCTIveS Following this symposium. there will be a discussion of vulvodynia and vulvar dermatoses as well as contact dermatitis in women.D. Lebwohl Dermatoses of Pregnancy / Dr. SYMPOSIuM 9:00 a.associationarchives. See page 32 for more information. Scher.D. 3. Rigel Scientific Sessions. 9:30 a. M. and treatment. Northington 10:45 a. Management of Vulvodynia and Vulvar Dermatoses / Dr. DeSCRIPTIOn Certain skin diseases occur more commonly in women.m.D. Scher Treating Psoriasis in Women / Dr. Introduction / Dr. Elmets. Marian Elizabeth Northington. InvITeD SPeAKeRS Craig A. Saturday. August 6 Annual Meeting 2011 Conference Recordings available on DVD! Enjoy the virtual attendee experience and convenience! • ver 700 speakers recorded with topics covering O most every aspect of dermatology • peaker’s slides synchronized with audio of select talks S • ccess to online version for easy listening A anytime. Contact Dermatitis in Women / Dr.org | 67 . Rigel. 2.m. melanoma. Effectively diagnose and treat women with nail disorders. and psoriasis will be highlighted.D.scientific sessions For a description of session categories. 9:55 a. Vlada Groysman. Richard K. Please note: meeting room locations are subject to change. Open admission. This symposium will focus on select skin disorders emphasizing diagnostic clues. 3.m. 9:05 a. M. Melanoma in Women: Special Concerns / Dr. to 12:00 p. diseases of pregnancy. access and fees. Select the best medical and aesthetic approach for management of the aging female face. the attendee should be able to: 1. Darrell S. M. 10:20 a.m.m. Mary Gail Mercurio. Elmets 11:30 a. nail disorders.m. M.D.D. no tuition or ticket. Mercurio A Medical and Aesthetic Approach to the Aging Face / Dr. best medical and aesthetic approach for the aging face. recognize contact dermatitis in women and pregnancy related dermatoses.D. M.com/AAD Visit the Academy Resource Center Booth 906 to order.aad. Elewski. S008 What’s Hot in Women’s Dermatology Room: Nassau Suite A/B DIReCTOR Boni E.m. For the Latest Program Book InFormatIon PLease reFer to www.D.00 Category 1 CME Credits SCHeDuLe 9:00 a. Discuss management of melanoma in women. Finally.m. M. L or iTunes playlist • Both MAC and PC Compatible To place an order call Association Archives at (858) 704-8612 or visit www. see page 24. iPod. M. therapeutic challenges. M. Groysman 11:05 a. anywhere • oad talks directly to any MP3 playing device. vulvodynia and vulvar dermatoses.

m. See page 32 for more information. COuRSe 9:00 a. Zaenglein. Evidenceand experience-based commentary among panelists and audience members will be presented to offer practical considerations in the diagnosis. Grant-Kels. Tuition fee and ticket required for admission. SYMPOSIuM 9:00 a. 6. access and fees. and advanced therapeutic management of challenging clinical cases and representing a breadth of complex diseases. Fiona O’Reilly Zwald.D. Christopher James Miller.D. S009 Dermatology grand Rounds: A Discussion of Case-Based Dilemmas Room: Grand Ballroom East/West C003 Derm exam Prep Course: Refresher Room: Trianon Ballroom DIReCTOR Jeffrey J. Saturday.D. M.00 Category 1 CME Credits LeARnIng OBjeCTIveS Following this course. 68 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 .scientific sessions For a description of session categories. 3. 3. Recognize the format used on the MOC-D exam. Review the 150 dermatologic diseases and conditions listed by the American Board of Dermatology (ABD) as required for the General Dermatology module of the Maintenance of Certification in Dermatology (MOC). specific evaluation. M. InvITeD SPeAKeRS Bryan Erik Anderson. M. M. Andrea L. DIReCTOR Amit Garg. Identify areas needing additional study in preparation for the General Dermatology module of the MOC-D exam. 2011 • Orlando. Visit the Academy Resource Center Booth 906 for more information. M. no tuition or ticket.D. Discuss the use of advanced systemic therapies for the management of refractory dermatologic conditions.D.m. August 6.D. M. Residents preparing for their Board exam may also benefit. Jennie T. see page 24. M. the attendee should be able to: 1.D.m. Fla. Miller.m. Scientific Sessions DeSCRIPTIOn This session will offer a Grand Rounds style discussion. M. Jane M.D. Please note: meeting room locations are subject to change. to 5:00 p.00 Category 1 CME Credits Save the Date Derm Exam Prep Course THE ONLY preparatory course available for the American Board of Dermatology’s Maintenance of Certification exam! A M E R I C A N A C A D E M Y O F D E R M AT O L O G Y November 18 – 20. M. the attendee should be able to: 1. Marks. to 12:00 p. LeARnIng OBjeCTIveS Following this symposium. Victor J. 2. Open admission.D. Clarke. M. 2.D. InvITeD SPeAKeRS Jeffrey Phillip Callen. M. Bethanee Jean Schlosser. Develop skills in differential diagnosis and evaluation of complex dermatologic diseases. The course will review the 150 diagnoses listed as covered in the General Dermatology module of the MOC-D exam in a format similar to the one used on the exam.D. DeSCRIPTIOn This course is targeted to dermatologists preparing for the American Board of Dermatology (ABD) Maintenance of Certification in Dermatology (MOC-D) exam. Lindy Peta Fox. many with interdisciplinary considerations. An interactive case-based approach will be utilized to highlight relevance for the experienced clinician.D. M.

3. The faculty will share with the audience their approach and treatment of many common oral dermatoses including oral ulcers.D. D. FORuM 12:00 p. Saturday. inflammatory hemorrhage. 1:20 p.m. A brief discussion of relevant clotting and clot inhibition pathways is followed by a targeted review of pertinent laboratory testing.00 Category 1 CME Credits DIReCTOR Ginat W. F018 Hypercoagulability. M. and occlusion.D.m. Bethanee Jean Schlosser. to 2:00 p.scientific sessions For a description of session categories. Torgerson Tongue Lesions / Dr.00 Category 1 CME Credits SCHeDuLe 12:00 p. the attendee should be able to: 1. Ticket required for admission. Rochelle R. Smith Challenging Oral Cases / Dr. Evaluate the various presentations of challenging conditions in immunocompromised hosts. Ph. LeARnIng OBjeCTIveS Following this forum. M. oral erosive lichen planus. DeSCRIPTIOn The session will cover the evaluation and treatment of numerous oral conditions. access and fees. 2. as well as tongue lesions. Fazel Oral Lichen Planus / Dr. the attendee should be able to: 1.M. August 6 For the Latest Program Book InFormatIon PLease reFer to www. M.m. Purpura and the Skin Room: Beekman Parlor F019 Oral Disease Room: Sutton North DIReCTOR Warren W.org | 69 . Acute Oral Ulceration / Dr. 3.D.m. Define mechanisms of cutaneous occlusion. 2.D.D.m. Recognize typical presentations of microvascular occlusion syndromes in the skin. Choose relevant laboratory screening exams critical for diagnosis. Schlosser Update on Burning Mouth Syndrome / Dr.m. See page 32 for more information.D. 12:40 p. oral conditions in the immunocompromised host. 1:00 p.m.D. LeARnIng OBjeCTIveS Following this forum..D.m. Ticket holds seat for only 15 minutes after the official start time. 2. Please note: meeting room locations are subject to change. Ph. 2.D. burning mouth. InvITeD SPeAKeRS Nasim Fazel.aad. Piette. DeSCRIPTIOn This session begins with an outline of the differences in diagnoses between venous thromboembolism and microvascular occlusion. 12:20 p. 1:40 p. Evaluate the various presentations of common erosive/ ulcerative oral conditions including acute oral ulcers and erosive lichen planus. no tuition fee. Evaluate and treat conditions of the tongue including burning mouth. Mirowski Questions and Answers / All faculty Scientific Sessions.. see page 24. Torgerson. Janellen Smith. The session concludes with a presentation of unknown purpura cases including simple hemorrhage. M. M.. M. Mirowski.

LeARnIng OBjeCTIveS Following this workshop. 3. LeARnIng OBjeCTIveS Following this forum. 2.D. Areas where data is lacking will be highlighted and panelists will discuss how to make management decisions when clear evidence does not exist. Scientific Sessions 70 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 .00 Category 1 CME Credits DIReCTOR Jeffrey Phillip Callen. Apply current treatment recommendations to patient care as appropriate. InvITeD SPeAKeRS Jerry D. access and fees. to 2:00 p. DeSCRIPTIOn This session is an interactive session in which we will utilize an audience response system. F020 Tumor Board Room: Sutton Center W006 Practical Approaches to Patient Problems Room: Rendezvous Trianon DIReCTOR Chrysalyne Delling Schmults. Available evidence and current treatment recommendations will be reviewed. an expert panel will discuss their approach to the problem. Audience questions and participation will be encouraged. dermatologic surgery.m. Cases will focus on common tumors such as melanoma and SCC but will also include more unusual tumors and interesting clinical scenarios. Brewer.m. Patient cases will be presented followed by a series of questions upon which audience input will be sought.D.scientific sessions For a description of session categories. M. Ticket required for admission. DeSCRIPTIOn Cases of cutaneous malignancy will be presented by the moderator and discussed by a multi-disciplinary panel comprised of experts in dermatology.00 Category 1 CME Credits Saturday.D. Please note: meeting room locations are subject to change. August 6. see page 24. Diagnose systemic manifestations of skin disease. Construct a plan for evaluation of patients with cutaneous disease. M. Develop appropriate management strategies when scientific evidence is lacking. Erik J. Develop a therapeutic ladder based upon the best evidence available. WORKSHOP 12:00 p.D. 2.D. and radiation/surgical oncology. Stratman. See page 32 for more information. Julie V. dermatopathology. 2. Tuition fee and ticket required for admission.D. FORuM 12:00 p. M. the attendee should be able to: 1. Following polling. Jorizzo. Summarize available evidence that impacts management of cutaneous cancers. 2. 3. to 2:00 p. M. the attendee should be able to: 1. no tuition fee. oncology. Ticket holds seat for only 15 minutes after the official start time.m.m. M. Joseph L. Schaffer. M.

The format will follow that of the popular game show “Jeopardy. Ph. the attendee should be able to: 1.” such that each audience member can test their current knowledge in selected areas. It is aimed toward the dermatology resident and the private practitioner. 2.. DeSCRIPTIOn This will be an interactive review of important new and fundamental concepts in pediatric dermatology.50 Category 1 CME Credits DIReCTOR Paolo Romanelli. M. DeSCRIPTIOn Nanotechnology is a burgeoning field with tremendous potential for society and medicine. access and fees. Recognize the importance of nanotechnology in dermatology. to 1:45 p. Currently. 3. 3.aad. 1. it is entering an exponential growth phase in the number and variety of products soon to be or already available for consumers and patients.50 Category 1 CME Credits Scientific Sessions. The skin is the first point of contact and the first line of defense for nanomaterials. 1. Ticket required for admission.50 Category 1 CME Credits For the Latest Program Book InFormatIon PLease reFer to www. Recognize several important pediatric dermatology conditions. Better communicate to their dermatopathologist for the ultimate benefit of the patients. The session should both reinforce the audience members previous knowledge and help work through scenarios that may present in their future practice. Please note: meeting room locations are subject to change.D. 2. DeSCRIPTIOn We will cover multiple clinically difficult cases that needed a representative skin biopsy to obtain a correct diagnostic clinicopathological correlation.D. FOCuS SeSSIOn 12:15 p. August 6 u025 Impact of nanotechnology and Dermatology Room: Sutton South DIReCTOR Adnan Nasir. Ticket holds seat for only 15 minutes after the official start time. see page 24.org | 71 . M. LeARnIng OBjeCTIveS Following this focus session. in the effort to develop and optimize an effective future “tailor-made” treatment for every patient.m. 2. M. See page 32 for more information. Formulate appropriate treatment plans for certain pediatric skin diseases. Order appropriate IHC markers to optimize the therapeutic approach.m.scientific sessions For a description of session categories.D. Barrio. Recognize the importance of representative skin biopsy to diagnose skin disease more effectively. Identify potential hazards of nanotechnology. Together with most of the cases. Saturday. This presentation serves to educate attendees about the benefits and pitfalls of a new and exciting technology with enormous promise for the diagnosis and management of skin disease and for the maintenance of skin health. 1. Identify the key benefits of nanotechnology for consumers and patients in dermatology. the attendee should be able to: 1. LeARnIng OBjeCTIveS Following this focus session. u024 When Clinical and Histological Findings Converge: great Cases From a Dermatopathologist’s Perspective Room: Regent Parlor u026 Pediatric Dermatology jeopardy Room: Clinton Suite DIReCTOR Victoria R. LeARnIng OBjeCTIveS Following this focus session.D. some immunohistochemistry studies as potential therapeutic biomarkers will also be discussed. the attendee should be able to: 1. no tuition fee.

00 Category 1 CME Credits SCHeDuLe 2:00 p. Select appropriate treatment methods. 2. M.D. no tuition fee. Desiree Ratner. This session will review the various forms of morphea and discuss their similarities and unique attributes as it pertains to children and adolescents. the large problem of underreporting occupational exposures among students.D. John A. Questions 3:40 p.D. Shang I.m. 1. Saturday. Recognize the clinical variants of morphea in the pediatric patient. the attendee should be able to: 1. In Situ Photoimmunotherapy for Metastatic Melanoma / Dr. Bordeaux.D. M.5 Category 1 CME Credits 72 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 .m. residents. 3. 1. to 5:00 p.m.m. to 4:00 p. Bichakjian 2:45 p. R.m.D.m. M. Christopher K. LeARnIng OBjeCTIveS Following this focus session. M. FOCuS SeSSIOn 2:30 p. M. InvITeD SPeAKeRS Murad Alam. Alam 3:05 p. during. S010 DIReCTOR Cutting edge Surgery and Oncology Room: Grand Ballroom East/West Jeremy S.m. See page 32 for more information. Jerry D. Bordeaux 4:50 p. Identify the procedures and behaviors that place dermatologists at highest risk for occupational exposures. Formulate a multidisciplinary approach to patient evaluation and management. 3. and after in-office procedures. Describe strategies to implement in daily practice that will help eliminate the risk of occupational exposures. M. Ticket required for admission. Bichakjian. DeSCRIPTIOn The number of needlesticks and mucocutaneous splashes that occur in the United States is staggering. M.m.D. Update On Merkel Cell Carcinoma / Dr. Brewer 4:00 p. DeSCRIPTIOn The recognition and management of morphea in the pediatric population is primarily performed by dermatologists. Ticket holds seat for only 15 minutes after the official start time. Additionally.50 Category 1 CME Credits 2:30 p. Recognize the problem of occupational exposures within the field of medicine and those employees most suscept ble to percutaneous injuries and mucocutaneous splashes.D. A case portfolio will provide interactive discussion of typical and difficult issues often encountered by morphea patients and their physicians.D. Scientific Sessions LeARnIng OBjeCTIveS Following this focus session. benign and malignant lesions.m.scientific sessions For a description of session categories. Assess their ability to put the dermoscopic essentials into practice. Davis. Brewer. Reconstructing a Full-Thickness Defect of the Eyelid / Dr.m. SYMPOSIuM 2:00 p. S013 DIReCTOR Procedural Safety in Dermatology Room: Nassau Suite A/B Joseph Sobanko. Please note: meeting room locations are subject to change. Wang.D. Ticket required for admission. 3. DeSCRIPTIOn The objective of this symposium is to update attendees on cutting edge topics in dermatology related to the diagnosis and treatment of skin cancer and surgical techniques. Brian Jiang. Christopher James Miller. Ratner 2:25 p. Open admission. M.m.50 Category 1 CME Credits LeARnIng OBjeCTIveS Following this symposium. u027 DIReCTOR Practical Dermoscopy Room: Regent Parlor Steven Q. Diagnose and treat skin cancer more effectively. Differentiate and utilize newer techniques and therapies in surgical dermatology.D. Ph. Questions and Answers u028 DIReCTOR Morphea: not just for Adults Anymore Room: Sutton South Dawn M. Attendees of this session will be able to identify and correct behaviors that place the practitioner and their staff at risk before. Carucci. The subject of bloodborne pathogen transmission will be discussed in detail. Introduction / Dr. the attendee should be able to: 1. Recognize all of the global patterns and local criteria essential to become a proficient dermoscopist.D. Ticket holds seat for only 15 minutes after the official start time. The opportunity to coordinate a multidisciplinary approach to patient care to optimize outcomes and satisfaction will be reviewed. Jian 4:20 p.P. no tuition or ticket.D. the attendee should be able to: 1. Melanoma of the Head and Neck: Practical Challenges Based on a Review of Greater Than 300 Cases at Penn / Dr. no tuition fee. Recognize the language of dermoscopy.m. 1. see page 24. Miller 3:25 p. Dermatologists and their staff are particularly at risk due to the high number of in-office procedures performed. What’s New In Translational Research of Skin Cancer / Dr. Bordeaux 2:05 p. 2.m...m. 2.m. the attendee should be able to: 1. to 4:00 p. 2.H. M. M. A self-assessment quiz will also be presented. Carucci 4:40 p. 3. Treatment of High Risk Squamous Cell Carcinoma With Cetuximab / Dr. August 6. DeSCRIPTIOn There will be a complete review of the classic and not so classic global patterns and local criteria used to diagnose melanocytic. non-melanocytic. access and fees.m. M. M. and physicians will be addressed. Non-Hodgkin’s Lymphoma and Skin Cancer / Dr. Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ With the Pulsed Dye Laser / Dr. This session is directed to surgically oriented dermatologists.m. LeARnIng OBjeCTIveS Following this symposium.

m. Abby S. August 6 For the Latest Program Book InFormatIon PLease reFer to www. response to previous treatments. 2. the attendee should be able to: 1. DeSCRIPTIOn The session will be helpful in expanding physician knowledge base and improving clinical confidence and effectiveness in treating psoriasis patients with a wide range of clinical presentations including psoriatic arthritis. Sundaram Scientific Sessions. Saturday. Hema A.D. Discuss the role of these new technologies in the physician’s armamentarium of treatment options.. M. DeSCRIPTIOn With the rapid proliferation of rejuvenation technologies.D.D. Burgess. See page 32 for more information. Lim 4:00 p.00 Category 1 CME Credits SCHeDuLe 3:00 p. quality of life issues. Lebwohl 3:10 p. Roberts.D. M. M.m. Heidi A.m. 4:15 p. Potions and Other Devices / Dr. Phototherapy for Psoriasis with case study / Dr.aad.D.m. access and fees. Lim. It will be structured in a question–and-answer format when case studies are discussed.m. Van Voorhees.m. Recognize and diagnose challenging clinical cases and select evidence-based treatment using the recently published AAD psoriasis evidence-based guidelines. and co-morbidities.m. it is important for the physician to be familiar with these emerging technologies and their possible roles in the armamentarium of treatment modalities offered to patients. LeARnIng OBjeCTIveS 1. Biologic Therapy with case study / Dr. see page 24. Topical Therapy for Psoriasis with case study / Dr.D.m. Studies have shown that high-quality guidelines can make important contribution to improving medical care. 3:55 p. Introduction and overview with survey / Dr. Panel Discussion with survey / All Faculty LeARnIng OBjeCTIveS Following this forum. 3. Describe new and emerging technologies in minimally invasive skin rejuvenation. Recognize the latest research supporting or negating these emerging technologies. 3:35 p. M. FORuM 3:00 p. 2.scientific sessions For a description of session categories. Ph. Bruce Elliot Strober.m. Fillers / Dr. Address gaps in clinical knowledge and care. Jackson Neurotoxins / Dr. M. Burgess Lotions. DIReCTOR Mark Lebwohl. Please note: meeting room locations are subject to change. Jackson. which includes best practices. Systemic Therapy with case study / Dr. M.m. Lebwohl 4:25 p. Wendy E. The session will consist of four presentations. with time available after each talk for interaction with the attendees. Develop skills to manage patients with psoriasis and psoriatic arthritis with an emphasis on decision making criteria that will enable the clinician to individualize therapy based upon disease type. Ticket holds seat for only 15 minutes after the official start time. to 5:00 p. Ticket required for admission.D. M. Waldorf Fat / Dr. Roberts Lasers / Dr.D.m.org | 73 . Van Voorhees 3:35 p. extent.D. M. Sundaram. and a follow-up survey will be conducted six months later to gauge and evaluate if guidelines/ implementation products and presentations were easy to translate into daily clinical practice. 2. Waldorf.00 Category 1 CME Credits SCHeDuLe 3:00 p. 4:40 p. M. A short survey will be conducted before and after the session.m. Strober 4:50 p. 2. 3. InvITeD SPeAKeRS Henry W.D. F021 new Technologies in Minimally Invasive Skin Rejuvenation Room: Sutton North F022 Psoriasis guidelines: Implementing them in Your Practice Room: Sutton Center DIReCTOR Brooke A. no tuition fee. InvITeD SPeAKeRS Cheryl M.m.

org/ meetings-and-events/ summer-meeting to register. 2. M.D..D.m.aad.D. Marley. See page 32 for more information. This forum will provide the opportunity to learn best practices in the complex management of psoriasis and psoriatic arthritis. access and fees. 74 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 .org/webinars for a schedule of upcoming webinars as well as a list of those past. which will assist in using the evidence-based AAD psoriasis guidelines in practice — FREE of charge! Visit www. M. M. Attendees receive a full set of recently published AAD Guidelines together with implementation products. 3.D. M. Please note: meeting room locations are subject to change. Identify how the audit process can affect your practice. Bruce Elliot Strober.scientific sessions For a description of session categories. Wayne M.00 Category 1 CME Credits Saturday.D. Scientific Sessions AAD Live Coding Webinars and On-Demand Webinars Get your coding updates throughout the year from the Academy’s expert coding team. M. WORKSHOP 3:00 p. August 6 3:00 p. M. LeARnIng OBjeCTIveS Following this workshop.D. – Director Abby S. InvITeD SPeAKeRS Paul Lizzul. DeSCRIPTIOn Inappropriate and inaccurate coding can adversely affect your practice’s financial well-being. Experts in the field will review the latest clinical guidelines with four question-and-answer presentations. M.. provide insight into what constitutes acceptable documentation of your services. Howard Woodling Rogers. DIReCTOR Allan S.m. see page 24.m. Henry W. M. the attendee should be able to: 1. Develop the necessary documentation required for CPT codes.aad.D. to 5:00 p. 2.D. Van Voorhees. Visit www. Reduce errors in CPT coding.D. through the use of audited records.D.m. Lim. Ph. Invited Speakers: Mark Lebwohl. – 5:00 p. Wirtzer. W007 Coding and Documentation Room: Rendezvous Trianon Psoriasis Guidelines: Implementing them in Your Practice Saturday. This session will provide information that will not only guide you in the selection of proper CPT codes but. Tune in for LIVE webinars quarterly and get your questions answered in real-time or check out our library of webcasts for any previously recorded sessions you may have missed or want to watch again. August 6. Tuition fee and ticket required for admission. Ph.

. . . 78 Scientific Sessions. . . . see page 24. . . . . to 8:45 a. . . . . . . . . . . . .m. . . .m. . . . . F023 Pathology and Procedures of the Aging Hand . . What’s Hot in Pediatric Dermatology .org | For the Latest Program Book InFormatIon PLease reFer to 75 . . . . . . . . . . . . . . . . . . . . . . Sunday.org www. 76 U031 The Interface of Skin and Psyche . . . . . . . . August 7 Focus Sessions — 7:15 a. . . . . . . U029 Leprosy . . 78 S011 S012 What’s Breaking Out: Acne and Rosacea . 76 U032 Spitz’s Genodermatoses . . . . . . . . . Restricted Session open to dermatologist and adjunct (researcher.AADdevelopment.m. . . . . . . . . . . . . . . corporate) members. . . . .m. A ticket is required for admittance M O C This activity has been approved by the ABD to satisfy component 2 of MOC-D Leadership Institute — addresses leadership competencies specific to dermatologists Practice Management Session open to eligible office staff/registered nurses Patient Safety Session Audience Response System Session Health Information Technology Sessions Sunday. . . . . . . . . August 7 Invest in the Academy’s mission of excellence! Your Sustaining Fund gift helps to… • Protect the Public • Expand Quality Dermatologic Care • Translate Evidence into Practice • Support Leaders in Dermatology Thank you for Furthering Excellence in Dermatology…Today and Tomorrow Learn more at the Academy Resource Center Booth 906 or visit www. . .aad. 77 Symposia — 9:00 a. . . . . . 77 Forum — 9:00 a. . . to 12:00 p. . 76 U033 Infectious Disease Update: What I Wouldn’t Have Known Without Evidence-Based Medicine . . . . . . . . See page 32 for more information. Please note: meeting room locations are subject to change. . .m. . . . . to 11:00 a. . . . . . . . . . . . .scientific sessions For a description of session categories. . . . . . 76 U030 Optimizing Management of Melanoma: Recognizing and Responding to Common Dilemmas in Patient Care . . access and fees. . . . .m.

D. no tuition fee.D. Recognize the main clinical features and be able to diagnose the more common genodermatoses.50 Category 1 CME Credits DIReCTOR Christopher James Miller.m.D. and aging can all be influenced by the skin-psyche connection. and optimal follow-up strategies. and physician extenders.m. clinicians. DeSCRIPTIOn The Leprosy Focus Session describes the clinical spectrum of Hansen’s disease and its diagnosis. 1. Treat and manage the most common genodermatoses. Clinical photos. Ph. access and fees. Recognize and respond to common dilemmas in which adherence to consensus guidelines is not possible. 2. LeARnIng OBjeCTIveS Following this focus session. Diagnose the different presentations of Hansen’s Disease. August 7. This session will use case studies to demonstrate common dilemmas encountered while managing patients with melanoma and review current literature to develop evidence-based responses.D.scientific sessions For a description of session categories. the attendee should be able to: 1. fun. Ticket required for admission. Controversial topics addressed in this session will include biopsy technique. “game-show” format to maximize learning and retention for board preparation and to gain a better understanding of these syndromes. See page 32 for more information. DeSCRIPTIOn This session will be a clinical overview of genodermatoses directed towards residents.50 Category 1 CME Credits DIReCTOR Richard G.D. M.50 Category 1 CME Credits 76 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . DeSCRIPTIOn There is an abundant and ever growing body of research documenting the inextricable link between the skin and psyche. 3. u029 Leprosy Room: Gibson Suite u031 The Interface of Skin and Psyche Room: Sutton South DIReCTOR Danielle M. Please note: meeting room locations are subject to change. the attendee should be able to: 1. acne. Define different types of stressors. LeARnIng OBjeCTIveS Following this focus session. the role of sentinel lymph node biopsy. to 8:45 a. Also presented will be the comorbidities and long term disabilities that are encountered in this patient population and the surrounding socio-economic challenges associated with Leprosy. Fried.D. Although consensus guidelines are useful for most steps of the management process. 2. 2.. see page 24. the necessity of bloodwork or imaging. 2. Scientific Sessions u030 Optimizing Management of Melanoma: Recognizing and Responding to Common Dilemmas in Patient Care Room: Regent Parlor u032 Spitz’s genodermatoses Room: Sutton Center DIReCTOR Joel L.50 Category 1 CME Credits Sunday. Ph. Develop effective management strategies to optimize outcomes of patients with melanoma. Ticket holds seat for only 15 minutes after the official start time. itch. Spitz. FOCuS SeSSIOn 7:15 a. the role of Mohs surgery. Discuss the common burden of chronic skin disease and its contributors to psychological distress in adults. psoriasis. M. Common skin disorders such as eczema. rosacea. M. 1. M. mutation updates and management will be stressed in this session based on Spitz’s Genodermatoses textbook. The reactions seen in Hansen’s disease and their treatment and management will be described. the attendee should be able to: 1. 1. dermatologists frequently encounter patients that challenge the simplicity of treatment algorithms. the attendee should be able to: 1. This session will review the most compelling data and provide suggestions on how patients can incorporate mind-body techniques. Standard treatment protocols developed by the WHO and the National Hansen’s Disease Program will be presented. 1. Miller. The presentation will be in an interactive. Evaluate the most current evidence to identify opportunities to enhance management of patients with melanoma. Treat the reactions seen in Hansen’s Disease. LeARnIng OBjeCTIveS Following this focus session. urticaria. 3. DeSCRIPTIOn Dermatologists frequently assume the primary role in managing patients with melanoma.. LeARnIng OBjeCTIveS Following this focus session. Manage the disabilities and comorbidities seen in Leprosy.

Fisher. the attendee should be able to: 1. 10:20 a. 2. M. Sunday.m. Jr.scientific sessions For a description of session categories. Questions and Answers / All faculty DIReCTOR Miguel R. access and fees.D.m. LeARnIng OBjeCTIveS Following this focus session. Ticket holds seat for only 15 minutes after the official start time. Use information to develop best practices to diagnose and treat mucocutaneous infectious diseases. Ticket required for admission..m.m. This session will review evidence from scientific studies to update the laboratory diagnosis and guide empirically supported treatment of bacterial.org | 77 . InvITeD SPeAKeRS Dee Anna Glaser. Participants should be able to describe the anatomy of the hand. See page 32 for more information. Glaser 10:50 a.aad. 3.m. M. 3. to 11:00 a. no tuition fee.m. Describe key anatomic features of the hands and utilize appropriate surgical techniques.00 Category 1 CME Credits SCHeDuLe 9:00 a. Please note: meeting room locations are subject to change. Gloster. Sanchez. FOCuS SeSSIOn 7:15 a.D. Diagnose common benign and malignant tumors of the hand and formulate treatment plans.m. no tuition fee. viral and parasitic infections. to 8:45 a. the attendee should be able to: 1. to impending epidemics. M. infectious diseases often capture the headlines of medical news. DeSCRIPTIOn Following this session. Evaluate evidence behind new therapeutic strategies. Ticket holds seat for only 15 minutes after the official start time. LeARnIng OBjeCTIveS Following this forum. Neff. Gloster Surgical Procedures of the Hand / Dr. Participants should be able to address common cosmetic concerns of the aging hand and various methods for treating and improving these changes. 2. But there is hardly another subspecialty in medicine or dermatology in which differentiating fact from anecdote is more crucial. Discuss methods for the treatment of common cosmetic concerns of the aging hand as well as evaluating and treating hyperhidrosis. Finally the treatment of hyperhidrosis of the hands will be covered. M. Neff Malignant Tumors of the Hand / Dr.D. as well as develop more effective strategies to manage these diseases. Hugh M.m. 9:50 a. u033 Infectious Disease update: What I Wouldn’t Have Known Without evidenceBased Medicine Room: Clinton Suite F023 Pathology and Procedures of the Aging Hand Room: Sutton North DIReCTOR Emily J. Benign Tumors of the Hand / Dr.D. Ticket required for admission. Fisher Cosmetic Procedures for the Aging Hand and Hyperhidrosis Treatment / Dr. diagnose and formulate appropriate treatment plans based on outcomes for the most common benign and malignant tumors found on the hands. Ann G. Examine data from studies of infectious diseases affecting the skin and mucous membranes. to vaccines. as well as utilize appropriate anesthetic and surgical techniques when performing surgery on the hand to avoid potential complications. the participant should be able to identify. 1.D. 2. DeSCRIPTIOn From antibiotic resistance. see page 24.50 Category 1 CME Credits Scientific Sessions.m. August 7 For the Latest Program Book InFormatIon PLease reFer to www. FORuM 9:00 a. 9:20 a. fungal. M.

Body mass index in young children and allergic disease: gender differences in a longitudinal study.m. and weight in pediatric skin disease will be reviewed in light of recent literature. DeSCRIPTIOn The session will cover several newer concepts and therapies in pediatric dermatology. SYMPOSIuM 9:00 a. Mancini AJ.m. M.D. Mulliken JB. 3. DeSCRIPTIOn The goal of this symposium will be to make practitioners better able to treat all acne and rosacea patients with an emphasis on providing good answers to commonly asked questions in day to day practice. Sunscreens.scientific sessions For a description of session categories. Kramer D. Del Rosso. Alan R. Frieden IJ. Acne and Rosacea Treatment Pearls: Lessons from Challenging Patients / Dr. InvITeD SPeAKeRS Helen Shin. Finally. 105:1986-93. Ethnic Skin Acne and Rosacea / Dr. Andrea L. M. Shalita. see page 24.m.D.D. Shin Sunday. SCHeDuLe 9:00 a. August 7. Kappelman MD. Treat acne in special populations including younger patients and ethnic skin patients. D. Zaenglein 11:30 a. as well as lecture on specific populations of early and ethnic acne patients. Update on Lasers and Lights for Acne and Rosacea / Dr. 41: 78-85. Iacobas I. M. Martin CF. S011 What’s Hot in Pediatric Dermatology Room: Grand Ballroom East/West S012 What’s Breaking Out: Acne and Rosacea Room: Trianon Ballroom DIReCTOR Nanette Blythe Silverberg. 2. a review of clinical pearls from contact dermatitis in these patients to acne surgery hints will complete the symposium. Murray CS. What’s New In The World Of Pediatric Dermatology / Dr.D. Scientific Sessions 78 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 .O. The lectures will include newer diagnostic paradigms and therapeutic options in hemangiomas of infancy. Woodcock A.D. Crockett SD. no tuition or ticket. Robert Silverberg. Heather Clare Woolery-Lloyd. Clin Exp Allergy. 3. A lecture will review the data on recent controversies in isotretinoin usage. Kaufman 11:05 a. The Role Of Obesity In Atopic Dermatitis / Dr. the attendee should be able to: 1. A thorough review on lasers/lights for acne and rosacea will be done. Silverman 11:20 a. J Pediatr.D. Silverman R. Silverberg 9:30 a. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Canoy D.m. Acne And Diet / Dr. The Role of Diet in Acne and Rosacea / Dr. Open admission. Paller AS.D. 3. 2. Joely Anne Kaufman. 2010. Robert Sidbury. Isotretinoin And Autoimmunity / Dr. 157: 795-801.m. Am J Gastroenterol. M. Shalita 9:50 a. The role of diet. M.m. M. Custovic A. Woolery-Lloyd 10:15 a. InvITeD SPeAKeRS Hilary E. Silverberg.D. M.m. to 12:00 a. Del Rosso 9:25 a. 2. M.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. Ph.m. Identify new diagnostic and therapeutic paradigms for hemangiomas of infancy. James Q..D.D. New Concepts In Clinical Pediatric Dermatology / Dr. Please note: meeting room locations are subject to change. Treating Early Acne: From Neonate to Adolescent / Dr. 3.m. LeARnIng OBjeCTIveS Following this symposium. Acne. Liang MG.m. Jonathan I. Perspectives on the Management of Acne and Rosacea: A Glance At The Past and A Peek At The Future / Dr. Sandler RS. access and fees. vitamins. Zaenglein. See page 32 for more information.D. Identify common patient questions regarding diet and over the counter products.m. Porter CQ.m. Cosmetics. Silverberg 10:10 a.m. Buchan I. Apply the latest evidence to treat acne and rosacea patients with conventional and emerging therapies. 2010. Baldwin. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. Simpson A. 3. M. Baldwin 10:40 a. 2011. Keri LeARnIng OBjeCTIveS Following this symposium. The session will begin with an update of the latest information on these conditions and will follow with specific insight into the role of diet in acne. the attendee should be able to: 1. Metry DW. There will also be a lecture on new disease findings and pediatric dermatological implications. and Other Interesting Topicals for Acne and Rosacea / Dr. DIReCTOR Jonette Elizabeth Keri. Analyze recent data on the role of diet and weight in pediatric skin disease.00 Category 1 CME Credits ReFeRenCeS 1.D. M. Wagner AM. Analyze recent data on the role of genetics in pediatric skin disease and new techniques in the therapy of genetic illnesses of childhood. Burrows PE. A good review of sunscreens and cosmetics as well as other non-prescription products will be reviewed including home based light technology. Sidbury 10:45 a. M.

oracea. 3.86(suppl 5[i]):7-15.001])1. ©2011 Galderma Laboratories. Mellonig J. Freeway Fort Worth. An open label. warnings. All contraindications. In clinical trials. Del Rosso JQ. Galderma Laboratories. L. Oracea® should not be used to treat microbial infections. USP) is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Novak MJ. n=826)3 • Favorable tolerability vs doxycycline 100 mg with 5x less gastrointestinal upset4 • No evidence of bacterial resistance in a long-term safety study 5 *Investigator’s Global Assessment. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. or during tooth development (up to the age of 8 years). community-based. 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40-mg (30-mg immediate-release and 10-mg delayed-release beads). Oracea and Galderma are registered trademarks of Galderma Laboratories. 2.2 • In a large community-based trial. and should be used only as indicated.The cycle of inflammatory rosacea warrants the only FDA-approved oral treatment. Webster GF. 5.79(3):440-452.56(5):791-802. J Am Acad Dermatol. L. P<. Oracea® patients should minimize or avoid exposure to natural or artificial sunlight. Data on file.005]. J Periodontol.P.P.P. 75% of patients were clear or near clear at week 12 (change in IGA* score. Cutis. by nursing mothers. 2007. et al. Schlessinger J.. the most common adverse events reported were gastrointestinal upsets. Galderma Laboratories. This drug is contraindicated in people who have shown hypersensitivity to any of the tetracyclines. and. L. Jackson M. * * References: 1. Del Rosso JQ. Formulated for an Effective Anti-inflammatory Response • Significant reduction in inflammatory lesion count seen as early as week 3 (vs placebo [P=. nasopharyngitis/pain. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease.7(6):573-576. The safety of Oracea® treatment beyond 9 months has not been established..P.com . 2008. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline. and precautions associated with tetracyclines must be considered before prescribing Oracea®. Please see brief summary of Prescribing Information on next page. TX 76177 ORA-525 Printed in USA 01/11 hcp. 4. 61% mean reduction at week 16 [N=251. like other tetracycline drugs. et al. USP capsules) administered once daily for treatment of rosacea. 14501 N. J Drugs Dermatol. Important Safety Information Oracea® (doxycycline. Werschler P. Webster GF. 2010. may cause fetal harm when administered to a pregnant woman. 2008. and nasal congestion/sinusitis. Although photosensitivity was not observed in clinical trials. Oracea® should not be used during pregnancy. L. Preshaw PM.

should not be used during tooth development unless other drugs are not likely to be effective or are contraindicated. Although doxycycline impairs the fertility of rats when administered at sufficient dosage. it should be used only as indicated. If patients need to be outdoors while using ORACEA.2 times that observed in female humans who use ORACEA (exposure comparison based upon area under the curve (AUC) values).. Most of the patients experiencing esophagitis and/or esophageal ulceration took their medication immediately before lying down. However. ORACEA should be discontinued and appropriate therapy instituted. An increased incidence of uterine polyps was observed in female rats that received 200 mg/kg/day. anaphylactoid purpura. and eosinophilia have been reported.232. 2. 2) The use of drugs of the tetracycline class during tooth development (last half of pregnancy. sclerae and heart valves. One ORACEA Capsule (40 mg) should be taken once daily in the morning on an empty stomach.9) 3 (1. 5. 7.6 times the amount of doxycycline contained in the recommended daily dose of ORACEA for a 60-kg human when compared on the basis of AUC estimates. Mutagenesis. HOW SUPPLIED ORACEA (beige opaque capsule printed with CGPI 40) containing doxycycline. Although this was not observed during the duration of the clinical studies with ORACEA. enterocolitis. alveolar bone). infancy.9) 12 (4. skin. vomiting. CONTRAINDICATIONS This drug is contraindicated in persons who have shown hypersensitivity to doxycycline or any of the other tetracyclines.9) 5 (1. ORACEA is a registered trademark of CollaGenex Pharmaceuticals. Results of animal studies indicate that tetracyclines cross the placenta. KY 40391 Fort Worth. This adverse reaction is more common during long-term use of the drug but has been observed following repeated short-term courses. including hematopoietic. Skin: maculopapular and erythematous rashes. including fungi.4) 1 (0.S. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving the capsule forms of the drugs in the tetracycline class. 5. it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.Rx Only Keep out of reach of children.572. Under such conditions. Patent Information: U. Impairment of Fertility: Doxycycline was assessed for potential to induce carcinogenesis in a study in which the compound was administered to Sprague-Dawley rats by gavage at dosages of 20. therapeutic measures should be initiated.5) 5 (1.1) Placebo 9 (3. MICROBIOLOGY The plasma concentrations of doxycycline achieved with ORACEA during administration (see DOSAGE AND ADMINISTRATION) are less than the concentration required to treat bacterial diseases. Gastrointestinal effects: Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range from mild to life-threatening. and other appropriate tests should be performed to evaluate the patients. To reduce the development of resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs. proton pump inhibitors. Doxycycline demonstrated no potential to cause genetic toxicity in an in vitro point mutation study with mammalian cells (CHO/HGPRT forward mutation assay) or in an in vivo micronucleus assay conducted in CD-1 mice. WARNINGS Teratogenic effects: 1) Doxycycline. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS INCLUDING THE DEVELOPMENT OF RESISTANT MICROORGANISMS. and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown).1) 3 (1.6) 4 (1. discontinue medication. (see WARNINGS section). 75. dysphagia. velocity.1) 7 (2. DOSAGE AND ADMINISTRATION THE DOSAGE OF ORACEA DIFFERS FROM THAT OF DOXYCYCLINE USED TO TREAT INFECTIONS. In moderate to severe cases. Enamel hypoplasia has also been reported. Autoimmune Syndromes: Tetracyclines have been associated with the development of autoimmune syndromes. The most frequent adverse reactions occurring in these studies are listed in the table below.5) 5 (1. This reaction was shown to be reversible when the drug was discontinued. the use of tetracyclines may increase the incidence of vaginal candidiasis. Note that 50 mg/kg/day is approximately 3. Although not observed in clinical trials with ORACEA. Tetracycline drugs. and inflammatory lesions (with vaginal candidiasis) in the anogenital region. as evidenced by increased time for mating to occur. Tetracycline therapy may induce hyperpigmentation in many organs. ADVERSE REACTIONS Adverse Reactions in Clinical Trials of ORACEA: In controlled clinical trials of adult patients with mild to moderate rosacea. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdose. The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. mucosa. (see WARNINGS section). 7. bone. can cause increased intracranial pressure. serum sickness. consideration should be given to management with fluids and electrolytes. Patents 5. arthralgia.P. Photosensitivity: Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. 537 patients received ORACEA or placebo over a 16-week period. it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. and concentration. data from an in vitro assay with CHO cells for potential to cause chromosomal aberrations suggest that doxycycline is a weak clastogen. Manufactured by: Marketed by: CardinalHealth Galderma Laboratories. are found in fetal tissues. intestinal tract. angioneurotic edema. Nursing Mothers: Tetracyclines are excreted in human milk. like other tetracycline-class antibiotics. Incidence (%) of Selected Adverse Reactions in Clinical Trials of ORACEA (n=269) vs. 3. Doxycycline induced reproductive toxicity at all dosages that were examined in this study. antacids containing aluminum. Pediatric Use: ORACEA should not be used in infants and children less than 8 years of age (see WARNINGS section). rash. Tissue Hyperpigmentation: Tetracycline class antibiotics are known to cause hyperpigmentation. ORACEA should not be used during pregnancy (see PRECAUTIONS: Pregnancy). Because of the potential for serious adverse reactions in infants from doxycycline. the concurrent use of an oral retinoid and a tetracycline should be avoided. Therefore.789.e. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. females are advised to use a second form of contraceptive during treatment with doxycycline. reduced sperm motility. If renal impairment exists. Bacterial resistance to tetracyclines may develop in patients using ORACEA. neutropenia. abnormal sperm morphology. and if therapy is prolonged. ANA. therefore. can cause fetal harm when administered to a pregnant woman. PRECAUTIONS General: Safety of ORACEA beyond 9 months has not been established. Skin pigmentation includes diffuse pigmentation as well as over sites of scars or injury. Placebo (n=268) Nasopharyngitis Pharyngolaryngeal Pain Sinusitis Nasal Congestion Fungal Infection Influenza Diarrhea Abdominal Pain Upper Abdominal Distention Abdominal Pain Stomach Discomfort ORACEA 13 (4. and can cause retardation of skeletal development on the developing fetus. Skin and oral pigmentation has been reported to occur independently of time or amount of drug administration. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs. i. There have been reports of pseudotumor cerebri (benign intracranial hypertension) associated with the concomitant use of isotretinoin and tetracyclines. If a diagnosis of pseudomembranous colitis has been established.4) 2 (0. Evidence of oncogenic activity was obtained in studies with related compounds. While this is not a problem in those with normal renal function. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin. Winchester. anaphylaxis. Nonteratogenic effects: (see WARNINGS section). Laboratory Tests: Periodic laboratory evaluations of organ systems. Keep out of reach of children. diarrhea. visceral tissue. Bottle of 30 (NDC 64682-009-01).1) 3 (1. the patient should be informed of the potential hazard to the fetus and treatment stopped immediately. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of “antibiotic-associated colitis”. higher serum levels of tetracycline-class antibiotics may lead to azotemia. treat symptomatically.4) 2 (0.(see WARNINGS section). whereas other pigmentation has been reported to occur upon prolonged administration. primarily minocycline. liver function tests.7) 1 (0.4) 3 (1. skin.7) Note: Percentages based on total number of study participants in each treatment group. Hepatotoxicity has been reported rarely. A decrease in fibula growth rate has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every 6 hours. Symptoms may be manifested by fever. patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Since both oral retinoids. USP in an amount equivalent to 40 mg of anhydrous doxycycline. including nails. and vagina. in patients with significantly impaired function. 4. thyroid. Hypersensitivity reactions: urticaria.7) 2 (0. lower than usual total doses are indicated. glossitis. The dosage of ORACEA differs from that of doxycycline used to treat infections. oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Administration of adequate amounts of fluid along with the capsules is recommended to wash down the capsule to reduce the risk of esophageal irritation and ulceration. Blood: Hemolytic anemia. No impact upon tumor incidence was observed in male rats at 200 mg/kg/ day. use of ORACEA may result in overgrowth of non-susceptible microorganisms. therefore use in children is not recommended. 6. (see ADVERSE REACTIONS section). nausea. or in either gender at the other dosages studied. calcium or magnesium and ironcontaining preparations.6) 1 (0. As with other antibiotic preparations. thrombocytopenia. serum level determinations of the drug may be advisable. These conditions disappeared when the drug was discontinued. ORACEA should not be used in mothers who breastfeed. Inc.7) 2 (0. In symptomatic patients. and institute supportive measures. To avoid contraceptive failure. OVERDOSAGE In case of overdosage. as even the lowest dosage tested (50 mg/kg/day) induced a statistically significant reduction in sperm velocity. L. ORACEA should be used with caution in patients with a history of or predisposition to candidiasis overgrowth. and increased pre-and post-implantation losses. patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using ORACEA. Brief Summary of Full Prescribing Information INDICATIONS AND USAGE ORACEA is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Pseudotumor cerebri: Bulging fontanels in infants and benign intracranial hypertension in adults have been reported in individuals receiving tetracyclines. ORACEA has not been studied in children of any age with regard to safety or efficacy. Photosensitivity is discussed above. Metabolic effects: The anti-anabolic action of the tetracyclines may cause an increase in BUN. and treatment with an antibacterial drug clinically effective against Clostridium difficile colitis.1) 7 (2. and the tetracyclines.267 and patents pending. Exfoliative dermatitis has been reported but is uncommon. pericarditis.775. (see DOSAGE AND ADMINISTRATION section).4) 1 (0. renal and hepatic studies should be performed. protein supplementation. Adverse Reactions for Tetracyclines: The following adverse reactions have been observed in patients receiving tetracyclines at higher. Results from animal studies indicate that doxycycline crosses the placenta and is found in fetal tissues. including isotretinoin and acitretin. Use of all tetracycline-class drugs should be discontinued immediately. and exacerbation of systemic lupus erythematosus. antimicrobial doses: Gastrointestinal: anorexia. eyes. a dosage that resulted in a systemic exposure to doxycycline approximately 12. preferably at least one hour prior to or two hours after meals. and acidosis. oral cavity (teeth.211. Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. Because tetracyclines have been shown to depress plasma prothrombin activity. Because of the potential for drugresistant bacteria to develop during the use of ORACEA. Oral administration of doxycycline to male and female Sprague-Dawley rats adversely affected fertility and reproductive performance. Absorption of tetracyclines is impaired by bismuth subsalicylate. ORACEA should be used only as indicated. light-resistant containers (USP). Doxycycline may interfere with the effectiveness of low dose oral contraceptives. TX 76177 7961-01 BPI 06/08 . If superinfection occurs. CBC. (see WARNINGS section). even usual oral or parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity. and 200 mg/kg/day for two years. Efficacy beyond 16 weeks and safety beyond 9 months have not been established.8) 3 (1. Drug Interactions: 1.919. Renal toxicity: Rise in BUN has been reported and is apparently dose-related. hyperphosphatemia.395. 3) All tetracyclines form a stable calcium complex in any bone-forming tissue. and malaise. CLINICAL PHARMACOLOGY Pharmacokinetics ORACEA capsules are not bioequivalent to other doxycycline products. In vivo microbiological studies utilizing a similar drug exposure for up to 18 months demonstrated no detectable long-term effects on bacterial flora of the oral cavity. Storage: All products are to be stored at controlled room temperatures of 15°C-30°C (59°F-86°F) and dispensed in tight. Evidence of embryotoxicity has been noted in animals treated early in pregnancy (see PRECAUTIONS: Pregnancy section). the effect of ORACEA on human fertility is unknown. Pregnancy: Teratogenic Effects: Pregnancy Category D. Labor and Delivery: The effect of tetracyclines on labor and delivery is unknown. Appropriate tests for autoimmune syndromes should be performed as indicated. Carcinogenesis.

Depression: 3 (<1%). upon initiation of ustekinumab in patients who are receiving concomitant CYP450 substrates. 36 (5%). Because clinical trials are conducted under widely varying conditions. osteomyelitis. 13 (2%). seizures and confusion. respectively. Serious malignancies included breast.g. Theoretical Risk for Vulnerability to Particular Infections Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria (including nontuberculous. Reversible Posterior Leukoencephalopathy Syndrome One case of reversible posterior leukoencephalopathy syndrome (RPLS) was observed during the clinical development program which included 3523 STELARA™-treated subjects. BCG vaccines should not be given during treatment with STELARA™ or for one year prior to initiating treatment or one year following discontinuation of treatment. 9 (1%). 14 (2%). and 373 exposed for at least 18 months. antibody testing was done at time points when ustekinumab may have been present in the serum. Consider anti-tuberculosis therapy prior to initiation of STELARA™ in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. and patients treated with 90 mg STELARA™ (n=666). 9 (1%). 9 (1%). Therefore. One case of RPLS occurred during clinical trials (see Warnings and Precautions). CONTRAINDICATIONS: None. dyspnea and hypotension). and urinary tract infections. TNFα. Adverse drug reactions that occurred at rates less than 1% included: cellulitis and certain injection site reactions (pain. antibody results were found to be positive. particularly those with a narrow therapeutic index. and RPLS (see Warnings and Precautions). Fatigue: 14 (2%). . Myalgia: 4 (1%). negative.g. swelling. However. The numbers (percentages) of adverse reactions reported for placebo-treated patients (n=665). for subcutaneous use See package insert for Full Prescribing Information INDICATIONS AND USAGE: STELARA™ is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. A role for IL-12 or IL-23 in the regulation of CYP450 enzymes has not been reported. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. Exercise caution when considering the use of STELARA™ in patients with a chronic infection or a history of recurrent infection. If RPLS is suspected. including 1970 exposed for at least 6 months. e. These serious infections included cellulitis. Infections In the placebo-controlled period of clinical studies of psoriasis subjects (average follow-up of 12. IL-6.24 per subject-year of follow-up). respectively. for cyclosporine) should be considered and the individual dose of the drug adjusted as needed (see Clinical Pharmacology).. eclampsia. No additional STELARA™ injections were administered and the subject fully recovered with appropriate treatment.02 per subject-year of follow-up) (see Warnings and Precautions). hemorrhage.g. Malignancies were reported among subjects who received STELARA™ in clinical studies (see Adverse Reactions). Fatal outcomes have been reported. Dizziness: 8 (1%). 18 (3%). Immunogenicity The presence of ustekinumab in the serum can interfere with the detection of anti-ustekinumab antibodies resulting in inconclusive results due to assay interference. adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. induration. RPLS is a neurological disorder. and 354 (48%) patients. seizures. the observed incidence of antibody positivity in an assay may be influenced by several factors. antibody results were found to be positive. which is not caused by demyelination or a known infectious agent. 1285 exposed for at least one year.9% of subjects (0. 28 (4%).39 per subject-year of follow-up) compared with 24% of placebo-treated subjects (1. Diarrhea: 12 (2%). and irritation). In STUDIES 1 and 2. 10 (2%). STELARA™ may decrease the protective effect of allergy immunotherapy and may increase the risk of an allergic reaction to a dose of allergen immunotherapy. and are highly dependent on the sensitivity and specificity of the assay. Pre-treatment Evaluation for Tuberculosis Evaluate patients for tuberculosis infection prior to initiating treatment with STELARA™. Concomitant Therapies The safety of STELARA™ in combination with other immunosuppressive agents or phototherapy has not been evaluated. timing of sample collection. The subject. Adverse reactions listed below are those that occurred at a rate of at least 1% and at a higher rate in the STELARA™ groups than the placebo group during the placebo-controlled period of STUDY 1 and STUDY 2.01 per subject-year of follow-up). Live Vaccines Live vaccines should not be given concurrently with STELARA™ (see Warnings and Precautions). patients should receive all immunizations appropriate for age as recommended by current immunization guidelines. concomitant medications and underlying disease. inhibition of IL-12/IL-23p40 increased the risk of malignancy (see Nonclinical Toxicology). acute hypertension. Headache: 23 (3%).4 weeks for STELARA™-treated subjects). have been reported post-marketing. Immune system disorders: Serious allergic reactions (including angioedema. 4 (1%)..3% of STELARA™-treated subjects (0. In STUDY 2 (N=1198). Patients receiving STELARA™ should be monitored closely for signs and symptoms of active tuberculosis during and after treatment. including sample handling. WARNINGS AND PRECAUTIONS: Infections STELARA™ may increase the risk of infections and reactivation of latent infections. Serious infections were reported in 0. fungal. for warfarin) or drug concentration (e. Because these events are reported voluntarily from a population of uncertain size. bruising. diverticulitis. Serious infections requiring hospitalization occurred in the psoriasis development program. Conditions with which it has been associated include preeclampsia. In STUDY 1 (N=743). 14 (2%). IFN) during chronic inflammation. If an anaphylactic or other serious allergic reaction occurs.Brief Summary of Prescribing Information for STELARA™ (ustekinumab) STELARA™ Injection. and inconclusive in 33 (3%). Injection site erythema: 3 (<1%).. For these reasons. it is not always possible to reliably estimate their frequency or establish a causal relationship to STELARA™ exposure.4% of placebo-treated subjects (0. 8 (1%). Serious infections occurred in 0. In the controlled and non-controlled portions of psoriasis clinical trials. In STUDY 2 the last ustekinumab injection was at Week 16 and the last test for anti-ustekinumab antibodies was at Week 24. 0. and inconclusive in 38 (5%). CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. 61% of STELARA™-treated subjects reported infections (1. pruritus. negative.6 weeks for placebo-treated subjects and 13. salmonella (including nontyphi strains). 27% of STELARA™-treated subjects reported infections (1. Upper respiratory tract infection: 30 (5%). stool culture. 7 (1%). 8 (1%). 8 (1%). patients treated with 45 mg STELARA™ (n=664). 12 (2%). DRUG INTERACTIONS: Drug interaction studies have not been conducted with STELARA™. 13 (2%). Serious bacterial. Non-live vaccinations received during a course of STELARA™ may not elicit an immune response sufficient to prevent disease. 351 (47%).. confusion and visual disturbances. comparison of the incidence of antibodies to ustekinumab with the incidence of antibodies to other products may be misleading. IL-10. Do not administer STELARA™ to patients with active tuberculosis. Patients being treated with STELARA™ should not receive live vaccines.g. gastroenteritis. kidney. The safety of STELARA™ has not been evaluated in patients who have a history of malignancy or who have a known malignancy. 90 (8%). STELARA™ (ustekinumab) Clinical Studies Experience The safety data reflect exposure to STELARA™ in 2266 psoriasis subjects. head and neck.01 per subject-year of follow-up) and in 0. The data reflect the percentage of subjects whose test results were positive for antibodies to ustekinumab in a bridging immunoassay. caution should be exercised in patients receiving or who have received allergy immunotherapy.80 per 100 subject-years of follow-up) (see Warnings and Precautions). viral infections. Hypersensitivity Reactions Serious allergic reactions. prostate. particularly for anaphylaxis. Immunizations Prior to initiating therapy with STELARA™.4% of STELARA™-treated subjects reported malignancies excluding non-melanoma skin cancers (0. hypersensitivity reactions (including rash and urticaria). monitoring for therapeutic effect (e. 33 (5%). Back pain: 8 (1%). tissue culture.36 per 100 subjectyears of follow-up). ADVERSE REACTIONS: The following serious adverse reactions are discussed elsewhere in the label: Infections (see Warnings and Precautions). colon. and thyroid cancers. Pharyngolaryngeal pain: 7 (1%). Initiate treatment of latent tuberculosis prior to administering STELARA™. IL-1.21 per subjectyear of follow-up). Pruritus: 9 (1%).8% of STELARA™-treated subjects (0. and viral infections were observed in subjects receiving STELARA™ (see Adverse Reactions). pneumonia. including angioedema and possible anaphylaxis. discontinue STELARA™ and institute appropriate therapy [see Adverse Reactions]. were: Nasopharyngitis: 51 (8%). and Bacillus Calmette-Guerin (BCG) vaccinations. STELARA™ should not be administered until the infection resolves or is adequately treated. presented with headache. STELARA™ should be discontinued and appropriate treatment administered. 49 (7%). Concomitant Therapies The safety of STELARA™ in combination with immunosuppressive agents or phototherapy has not been evaluated (see Warnings and Precautions). In rodent models. 32 (5%). RPLS can present with headache. Caution is advised when administering live vaccines to household contacts of patients receiving STELARA™ because of the potential risk for shedding from the household contact and transmission to patient. and 1075 (90%) patients. It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with STELARA™ will be susceptible to these types of infections. Malignancies STELARA™ is an immunosuppressant and may increase the risk of malignancy. 13 (2%). 56 (8%). Additionally. 6 (1%). 17 (3%). Theoretical Risk of Immunotherapy STELARA™ has not been evaluated in patients who have undergone allergy immunotherapy. Thus. environmental mycobacteria). Ultraviolet-induced skin cancers developed earlier and more frequently in mice genetically manipulated to be deficient in both IL-12 and IL-23 or IL-12 alone (see Nonclinical Toxicology). STELARA™ should not be given to patients with any clinically important active infection. Appropriate diagnostic testing should be considered. Malignancies (see Warnings and Precautions). cytotoxic agents and immunosuppressive therapy. respectively. as dictated by clinical circumstances. Post-marketing Experience Adverse reactions have been reported during postapproval use with STELARA™. ustekinumab could normalize the formation of CYP450 enzymes. who had received 12 doses of STELARA™ over approximately two years. Malignancies In the controlled and non-controlled portions of psoriasis clinical trials. Serious infections and fatal outcomes have been reported in such patients. Non-melanoma skin cancer was reported in 0. In STUDY 1 the last ustekinumab injection was between Weeks 28 and 48 and the last test for anti-ustekinumab antibodies was at Week 52.

Schaffhausen. Instruct patients of the importance of communicating any history of infections to the doctor. Infections Inform patients that STELARA™ may lower the ability of their immune system to fight infections. so it is expected that STELARA™ will be present in human milk. Allergic Reactions Advise patients to seek immediate medical attention if they experience any symptoms of serious allergic reactions. No ustekinumab-related abnormalities were observed in the neonates from birth through six months of age in clinical signs. STELARA™ should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. and contacting their doctor if they develop any symptoms of infection.5 mg/kg-treated monkeys. however. In an embryo-fetal development and pre. Ustekinumab is excreted in the milk of lactating monkeys administered ustekinumab. Nursing Mothers Caution should be exercised when STELARA™ is administered to a nursing woman. IN 47403 © Centocor Ortho Biotech Inc. six 22. Malignancies Patients should be counseled about the risk of malignancies while receiving STELARA™. or 45 mg/kg ustekinumab twice weekly from the beginning of organogenesis in cynomolgus monkeys to Day 33 after delivery. published data suggest that antibodies in breast milk do not enter the neonatal and infant circulation in substantial amounts. 1821 at Baxter Pharmaceutical Solutions. It is not known if ustekinumab is absorbed systemically after ingestion. IgG is excreted in human milk. three groups of 20 pregnant cynomolgus monkeys were administered subcutaneous doses of 0. Although no differences in safety or efficacy were observed between older and younger subjects. hematology. 2010 Vial Manufactured by: Centocor Ortho Biotech Inc. Bloomington. functional development after weaning. Horsham. clinical signs. 22. Pediatric Use Safety and effectiveness of STELARA™ in pediatric patients have not been evaluated.. Ustekinumab was tested in two embryo-fetal development toxicity studies.5 mg/kg-treated monkey and in one 45 mg/kgtreated monkey. it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment be instituted immediately.STELARA™ (ustekinumab) USE IN SPECIFIC POPULATIONS: Pregnancy Pregnancy Category B There are no studies of STELARA™ in pregnant women. Fetal losses occurred in six control monkeys. Horsham. or serum biochemistry. Prefilled Syringe Manufactured by: Centocor Ortho Biotech Inc. Neonatal deaths occurred in one 22. There were no treatment-related effects on functional development until weaning. PA 19044. hematology. morphological development.and postnatal development toxicity study.5 mg/kg intravenously have been administered in clinical studies without dose-limiting toxicity. No teratogenic effects were observed in the developmental and reproductive toxicology studies performed in cynomolgus monkeys at doses up to 45 mg/kg ustekinumab. body weight. In case of overdosage. No significant adverse developmental effects were noted in either study. Geriatric Use Of the 2266 psoriasis subjects exposed to STELARA™.5.. the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects. PA 19044. immunological development. a total of 131 were 65 years or older. or serum biochemistry in dams. which is 45 times (based on mg/kg) the highest intended clinical dose in psoriasis patients (approximately 1 mg/kg based on administration of a 90 mg dose to a 90 kg psoriasis patient). Switzerland 25ST10221 Save the Date This activity has been approved for AMA PRA Category 1 CreditsTM . The unknown risks to the infant from gastrointestinal or systemic exposure to ustekinumab should be weighed against the known benefits of breast-feeding. body weight. There were no treatment-related effects on mortality. Pregnant cynomolgus monkeys were administered ustekinumab at doses up to 45 mg/kg during the period of organogenesis either twice weekly via subcutaneous injections or weekly by intravenous injections. 1821 at Cilag AG. and five 45 mg/kg-treated monkeys. OVERDOSAGE: Single doses up to 4. License No. License No. and 14 subjects were 75 years or older. and gross and histopathological examinations of offsprings by the age of 6 months. PATIENT COUNSELING INFORMATION: Instruct patients to read the Medication Guide before starting STELARA™ therapy and to reread the Medication Guide each time the prescription is renewed. food consumption.

m.....aad................ – 5 p... August 6.2% and tretinoin 0..m........aad...7 a... contAct... AtoPic clinicAl dermAtology And otHer cutAneous disorders P700 The effect of parenting practices to behavior problems in children with atopic dermatitis P701 Involvement of human histamine N-methyltransferase gene polymorphisms in susceptibility to atopic dermatitis in Korean children P702 A safe....... and novel topical herbal preparation for the treatment of atopic dermatitis P500 Raynaud’s phenomenon of the nipple in breastfeeding mothers: An underdiagnosed cause of nipple pain P501 Health-related quality of life among Darier’s disease patients P502 Plasma histamine concentrations and diamine oxidase activities in chronic idiopathic urticaria P503 Shitake dermatitis and other flagellate dermatoses dermAtitis..m... pilot study to determine the efficacy and safety of a clindamycin 1..... – 6 p. A full schedule of presentations will be available on the Summer Academy meeting website at www.........025% combination gel for the treatment of acne rosacea P102 In vitro release of tretinoin from two clindamycin and tretinoin combination gel formulations P103 Bioavailability of clindamycin from a new clindamycin 1% – benzoyl peroxide 3% low dose gel P103 An open-label.m... Friday.... effective... split-face study evaluating efficacy and safety of photopneumatic therapy for the treatment of acne P504 Review: Timing of office visits can be a powerful tool to improve adherence in the treatment of dermatologic conditions P505 Unusual presentation of pleurocutaneous fistula P506 Trauma-induced neutrophilic dermatosis of the dorsal hands P507 Cutaneous metastasis to the head from prostate adenocarcinoma: Case report P508 POemS syndrome identified in a patient with multiple atypical hemangiomas P509 Sweet syndrome associated with chlamydia pneumoniae pneumonia P510 A case of plasma cell cheilitis arising from actinic cheilitis P511 mycosis fungoides palmaris et plantaris in childhood Poster exhibits Aging/geriAtrics P200 Clinical evaluation of cutaneous xerosis in elderly Arts........ August 4 ...... History... – 6 p. Allergic And irritAnt P800 Dermatitis in patients undergoing the Nuss procedure for correction of pectus excavatum For the Latest Program Book InFormatIon PLease reFer to www.......Poster exhibits Poster exHiBits Electronic Poster Exhibits/Poster Presentations: 3rd Level Lobby Thursday.............org. 7 a.. 7 a............. And HumAnities of dermAtology P300 On the 25th birthday of psychosomatic dermatology connective tissue diseAses P600 A case of atypical scleromyxedema P601 Tumid lupus erythematosus with progression to discoid lupus erythematosus BAsic science P400 The contribution of the lysine residue in the dermatological activities of GHK-Cu dermAtitis.... and posted on-site at the meeting... August 5..m.. electronic Poster exhibits viewing stations will be open during the following hours: Saturday.m. Poster authors will conduct brief presentations of their electronic posters at the Poster Presentation Center in the 3rd Level Lobby during the meeting...org | 83 ... placebo-controlled... Acne P100 A double-blind.

moderate.Poster exhibits dermAtoPHArmAcology/cosmeceuticAls P900 Single-center. double-blinded study comparing the long-term UV protective effects of three topical antioxidant products infection – BActeriAl And PArAsitic P901 efficacy and safety of a novel dual resurfacing product that combines the benefits of manual microdermabrasion and chemical peeling P1500 efficacy of topical imiquimod 5% with cryotherapy for treatment of anthroponotic cutaneous leishmaniasis. and severe psoriasis patients P1206 Are urgent referrals actually urgent? Findings from a newlyestablished dermatology urgent care clinic internAl medicine dermAtology P1700 Necrolytic acral erythema sine hepatitis C infection: A distinct entity or clue to etiology? P1701 Sweet syndrome with vasculitic pattern in a patient with POemS syndrome P1702 Reactive perforating collagenosis: A case study lymPHomA. tinea cruris and tinea corporis P1601 Naftifine 2% cream demonstrates a low propensity for irritation and no evidence of phototoxicity or photoallergenicity potential P1602 Naftifine 2% cream has demonstrated effectiveness in the treatment of tinea pedis and tinea cruris P1200 Identifying risk factors via a skin cancer screening program: The moffitt mole Patrol experience P1201 Increased dermatologist density associated with reduction in melanoma mortality P1202 Cosmetic and non-cosmetic skin-related procedures performed in the United States: A 12-year analysis P1203 Time series study of reasons for non-compliance with biologic treatments in psoriasis patients over three years P1204 Psoriasis patient preference study on injectable biologic medications and concerns about self-injection P1205 Adherence to prescription oral or topical treatments in mild. cutAneous/mycosis fungoides P1800 Abnormal B-cell clone in the setting of cutaneous T-cell lymphoma P1801 Paniculitic-like T cell lymphoma of unusual presentation genodermAtoses P1300 A case of lipoid proteinosis with oral ulcerative lesion melAnomA And Pigmented lesions HAir And nAil disorders P1900 Neonatal blue light phototherapy and melanocytic nevi: A twin study P1901 mitotic rate as a marker to assess tumor biology in single versus multiple primary melanoma P1902 A case of common blue nevus of the upper lip P1400 Oral supplementation of silicon and its impact on quality of hair P1401 Investigation of serum vitamin D levels in patients with scarring and nonscarring alopecia P1402 Assessing vitamin D levels in alopecia areata patients 84 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . compared with intralesional meglumine antimoniate P1501 Case reports of lip leshmaniasis in pediatric patients P1502 Secondary syphilis presenting with clinical features of adulthood atopic dermatitis P1503 mixed cutaneous infection after work accident – the importance of making cultures for different agents digitAl/electronic tecHnology P1000 A pilot study to evaluate high resolution skin imaging technology (HRSIT) in dermatology clinical practice educAtion And community service P1100 Assessing and improving patient knowledge about keloid scars infection – fungAl ePidemiology And HeAltH services AdministrAtion Poster exhibits P1600 Naftifine 2% cream has demonstrated safety in the treatment of tinea pedis.

clobetasol spray.025% tretinoin cream surgery – lAser PsoriAsis And otHer PAPulosquAmous disorders P2700 Treatment of various epidermal-dermal skin lesions with fractional er:yag laser: A Turkish experience P2701 The use of the 1450-nm diode laser in the nonablative treatment of acne scarring in Fitzpatrick skin types IV-VI: A prospective clinical study P2702 Correction of acne scars with fractional CO2 laser in darker skin assessment results and side effects P2703 Treatment of photoaging with CO2 fractional laser – evaluation of results and complication in ten dark-skinned patients P2704 Croll technique: Surgical reconstruction with localized laser in acne scars P2705 effectiveness of 595nm pulsed dye laser in the treatment of basal cell carcinoma and squamous cell carcinoma in situ P2400 Health-related quality of life in patients undergoing etanercept therapy for moderate to severe plaque psoriasis with involvement of the scalp P2401 An assessment of evidence from two phase III randomized placebo-controlled trials in the treatment of moderate-to-severe psoriasis: Benefit-risk analysis of ustekinumab P2402 Response to retreatment with ustekinumab after withdrawal from therapy in moderate-to.severe psoriasis patients: Results from the PHOeNIX 1 and ACCePT phase 3 clinical trials P2403 Consistency of responses across different ethnic populations with moderate-to-severe psoriasis: Results from the ustekinumab psoriasis clinical development program P2404 efficacy and safety of methotrexate in two fixed doses of 10mg or 25mg orally once weekly in patients with severe plaque type psoriasis: A prospective.aad. double blind.Poster exhibits non-melAnomA skin cAncer P2000 Low frequency of eGFR mutations but high frequency of eGFR copy number anomalies in cutaneous squamous cell carcinoma P2001 Practice trends in the treatment of actinic keratosis in the United States: 0. dose ranging study P2405 Psoriasis and palmoplantar pustulosis attributable to tumor necrosis factor alpha inhibitors: The mayo Clinic experience. emBryology And PHysiology P2500 The role of adenomatous polyposis coli (APC) in epidermal development and hair follicle morphogenesis P2501 Central sensitisation: An under-reported cause of chronic pain in vascular malformations PHotoBiology. randomized.org | 85 . 1998-2010 For the Latest Program Book InFormatIon PLease reFer to www. and calcitriol ointment in the treatment of generalized plaque psoriasis P2407 A qualitative analysis on treatment expectations and experiences among psoriasis patients in the United States P2408 Patient characteristics of ustekinumab utilization in a specialty pharmacy provider (SPP) setting PediAtric dermAtology P2100 Subcutaneous fat necrosis of the newborn following iatrogenic hypothermia skin AnAtomy.5% fluorouracil and combination cryotherapy plus fluorouracil are underutilized despite evidence of benefit P2002 A recurred case of malignant eccrine poroma on the ear P2406 efficacy and feasibility of combination excimer laser therapy. PHototHerAPy And PHotosensitivity diseAses P2200 Anatomically differentiated dosimetry for optimal phototherapy of generalized psoriasis P2201 An analysis of chronic actinic dermatitis over a period of 25 years surgery – cosmetic PigmentAry disorders And vitiligo P2600 Academic physicians’ attitudes towards implementation of multidisciplinary cosmetic centers and the challenges of subspecialties working together P2601 Development and use of a submental fat rating scale Poster exhibits P2300 Treatment of melasma with a hydroquinone skin care system plus 0.

Omnibus Study. coupons & more information! Targets severely dry skin— features ULTRAPLEX.02 . Reference: 1.When dry skin calls for a serious solution… Recommend AmLactin ® recommended by dermatologists for rough. Maple Grove. please refer to individual product labels. dry skin.upsher-smith. MN 55369 103985.. and alpha-hydroxy acid to exfoliate and hydrate dry skin and dry skin associated with Keratosis Pilaris (KP) ● AmLactin Moisturizing Body Lotion & Cream ® Everyday hydration— 12% lactic acid provides powerful therapy leaving skin noticeably soft and smooth ● AmLactin XL® Moisturizing Lotion Visit us online at www. dry skin1 AmLactin® Rejuvenating Moisturizers Nourishing formulas— combine emollients.com ©2010 Upsher-Smith Laboratories. clinically proven to improve smoothness and hydration Serious care for softer skin For complete directions and cautions. humectants.com for samples. TM 1-800-654-2299 www.® an extra-strength blend of three alpha-hydroxy compounds. May 2009. Most recommended moisturizing product for rough. Inc.amlactin. Dermatology Times.

. .... .. . . . . The products displayed in the technical exhibits area and their uses. . .. do not represent an endorsement nor imply that the products have been evaluated or approved by the American Academy of Dermatology... . . the technical exhibiting companies are listed alphabetically and the products/services they offer are identified as follows: • Associations. . . .aad.. .. . Unopposed exhibit hours . ..m... 3gen. .... . .m. . .. MN 55144 Phone: (800)228-3957 Product Category: Disposable Medical Supplies Abbott . llc/Dermlite . . . . ...... . . . . . Foundations... .. ... . to 2 p. .12 p. . . . . . .. . . . . . .... .. Montclair.. . 223 777 Old Saw Mill River Rd Tarrytown. . .. IL 60089 Phone: (224)377-2000 Fax: (646)805-1312 Email: contact@almalasers... .. .. For your convenience.. . . .m..... . . . . 509 5370 NW 35th Terrace.. Friday. ... . .. . .com Product Category: Computer Software and Hardware.. . 433 201 Claremont Ave. NY 11803 Phone: (888)228-7284 Fax: (516)326-3452 Email: rmcallister@acupath. . . . . 706 200 Abbott Park Rd Abbott Park..... . . . . . August 4 .. . ... . . ... .org Product Category: Associations.. .. ... .. . . . . . .. . 435 285 Terminal Drive Plainview. . . Lauderdale. . . .. . . ..... .com Product Category: Disposable Medical Supplies. . . ... .. The American Academy of Dermatology invites you to visit the technical exhibits as part of your educational experience at the Summer Academy Meeting 2011.. 10 a. . .. inc . . to 6 p. . . ... . . . to 6 p.. . . .. . . . . .....org Product Category: Associations.. . AlphAbeticAl Directory of exhibiting compAnies Companies confirmed as of January 7.. . ... 2011...m. . . . Bldg 275-3E-10 St. . .. . .. 405 31521 Rancho Viejo Rd.. . . ... August 5. . suggested by the manufacturers.. . to 2 p. .. . . . . ..... . .. . .. #104 San Juan Capistrano. . . Paul. . .. . .12 p. .. . . . . 833 485 Half Day Road. . . . . . Foundations. .. .. . Other Medical Equipment and Supplies American Academy of Dermatology . .. . . ...com Product Category: Laser and Laser Supplies Allergan ... . .. . Photographic Equipment and Imaging Services 3m Drug Delivery systems ... . . . . CA 92675 Phone: (949)481-6384 Fax: (949)240-7492 Email: info@3genllc.com Aerolase . . . .. . . ....... . .. . .. . August 6 .... . . 906 930 E Woodfield Rd Schaumburg. . . . .. .. .. . . Other Medical Equipment and Supplies Acupath laboratories . . . . Other Medical Equipment and Supplies.. IL 60173 Phone: (866)503-SKIN (7546) Fax: (847)240-1859 Email: mrc@aad. . IL 60064 Phone: (847)937-6100 Product Category: Pharmaceutical Acuderm... . . . Foundations and Medical Societies • Medical Lighting Equipment • Clothing • Office Equipment and Supplies • Computer Software and Hardware • Practice Management • Cosmetics and Skin Care • Other Medical Equipment and Supplies • Disposable Medical Supplies • Pharmaceutical • EMR/EHR Systems • Photographic Equipment and Imaging Services • Laboratory Services • Phototherapy Supplies and Equipment • Laser and Laser Supplies • Publishing and Educational Materials • Market Research • Surgical Instruments A listing by product/services can be found beginning on page 98. ... . .. .12 p. Office Equipment and Supplies.. ... ..m.. . .. .. .com Product Category: Laser and Laser Supplies. . .... CA 92612 Phone: (714)246-4500 Fax: (714)246-4971 Product Category: Pharmaceutical Alma lasers . . . . . and Medical Societies www. . and Medical Societies American Acne and rosacea society . . . . . Suite 100 Buffalo Grove. . . . . . . . .... .. . ... .. NJ Phone: (973)783-4575 Fax: (973)783-4576 Email: smoore@physicianresources.technical exhibits technicAl exhibit hours Thursday. .. . . . ..m. . 202 2525 Dupont Drive Irvine. ..... . . . . .. NY 10591 Phone: (914)345-8300 Fax: (914)345-8303 Email: information@aerolase. . .. . ... .. . . .... . FL 33309 Phone: (954)733-6935 Fax: (954)486-3602 Email: cust-service@acuderm. . . . Saturday. . . Ft.. .. .org | 87 technical exhibits A For the Latest Program Book InFormatIon PLease reFer to ... . . . . 302 3M Center. . . . . . . . . ..m. . .. . . . .m. . .

eucerinus. Ste 100 Costa Mesa. . TX 75039 Phone: (800)979-8292 Fax: (214)596-2229 Product Category: Laboratory Services centocor ortho biotech. . . . . . . . . . . . 425 2645 Townsgate Road. . . . MacArthur Blvd Irving. . . .oil . . Medical Lighting Equipment. . . . . . . NJ 07054 Phone: (973)206-8015 Fax: (973)206-9378 Product Category: Publishing and Educational Materials b technical exhibits c amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . . . Surgical Instruments canfield imaging systems . . . . . . . . . . . . . . . . . . Ste 200 Westlake Village. . . .com Product Category: Computer Software and Hardware. . . . . . MI 48220 Phone: (866)424-6735 Fax: (877)548-7100 Email: contactus@biopelle. . .com Product Category: Cosmetics and Skin Care bio . . 316 2015 Camino Vida Roble. . . . Medical Lighting Equipment 88 | carecredit . . . . . . . . . . . . . . . .technical exhibits Amgen . . . . . . . . . . . . . . . inc . . . . CA 92626 Phone: (866)247-3049 x2 Fax: (866)874-4093 Email: cosmeticsales@carecredit. . . . . . . . . . . . .com Product Category: Publishing and Educational Materials cutis and cosmetic Dermatology . . . . . . . . 306 187 Danbury Road Wilton. . . . . . . . . . . . . . . . . . . . . . . . . . . Surgical Instruments. . Pharmaceutical beiersdorf inc . . . . . . . 702 800 Ridgeview Drive Horsham. CA 92630 Phone: (949)598-2400 x257 Fax: (949)598-2424 Email: ktinsley@pwcosmetics. . . . . . . . . . . CT 06897 Phone: (203)563-5800 Fax: (203)563-5800 Email: www. . . .com Product Category: Disposable Medical Supplies. . . 415 P O Box 367 Pequannock. . . . . . . . Practice Management conmed . . 805 253 Passaic Ave Fairfield. . . . . . . . . . . . . . . . . . . . . . . . . . 821 525 French Rd Utica. . NJ 08830 Phone: (732)346-3089 Fax: (732)596-0016 Email: aammon@advanstar. 232 25800 Commercentre Drive Lake Forest. . . . . Other Medical Equipment and Supplies. CA 91361 Phone: (800)456-4522 Fax: (208)979-7789 Email: sales@compulinkadvantage. . . 826 105 Windermere Ave Ellington. . 623 3909 Hulen Street Fort Worth. . . NJ 07004 Phone: (973)276-0300 Fax: (973)575-9914 Email: info@canfieldsci. . . . . . . . . . Ste L Carlsbad. . . . inc . . . . . Office Equipment and Supplies. . . . . . . . . . . . . . . NJ 07440 Phone: (888)350-3790 Fax: (201)465-3041 Email: sales@cobaltmed. . . . . 326 2995 Red Hill Ave. . . . . . . .com Product Category: Practice Management caris life sciences . . . . . Pharmaceutical cosmetic surgery times/Dermatology times . . . . . Other Medical Equipment and Supplies. . . . . . . . . . . . . . . CA 92011 Phone: (866)494-4466 Email: customerservice@axiamedical. . . . . . . . . 310 7 Century Drive. . . . . . . Suite 302 Parsippany. . . . . .com Product Category: Pharmaceutical Axia medical solutions . . . . . . PA 19044 Phone: (610)651-6000 Fax: (215)325-4087 Product Category: Pharmaceutical cobalt medical supply . . . . . . . . Photographic Equipment and Imaging Services. . . . . . . . . . . . . . . . . 429 6655 N. . . . . . . . . 221 485F US Hwy 1 South. . . . 329 5115 Ulmerton Road Clearwater. .com Product Category: Computer Software and Hardware. . . CA 91320 Phone: (805)447-1000 Email: www. . . . TX 76107 Phone: (817)501-0372 Product Category: Cosmetics and Skin Care. . . 606 One Amgen Center Drive Thousand Oaks. . . . . . . . . . . . . . . . . . . . inc . . . CT 06029 Phone: (800)779-2796 Fax: (860)872-2371 Email: brymill@brymill. . . .com Product Category: Cosmetics and Skin Care biopelle. . . Pharmaceutical compulink business systems. . . . . . . . . . . . . . .com Product Category: Cosmetics and Skin Care. Surgical Instruments brymill cryogenic systems . . . . . . . . . . . . . . . . . . . . . . . . . . . Systems. . . . . . . . . . . FL 33760 Phone: (800)537-2790 Fax: (800)323-1640 Email: sales@boviemed. . 309 780 W 8 Mile Road Ferndale. NY 13502 Phone: (800)448-6506 Fax: (800)438-3051 Email: info@conmed. . . . . .com Product Category: Office Equipment and Supplies. . .com Product Category: Office Equipment and Supplies coria laboratories . . . . . . . . . . . . . . . . . . Suite 100 Iselin. . . . . . . . .amgen. . Other Medical Equipment and Supplies. . . . . . .com Product Category: Disposable Medical Supplies. . . . . . . EMR/ EHR. . . . . . .com Product Category: Cosmetics and Skin Care bovie medical corporation . .

TX 76177 Phone: (817)961-5000 Fax: (817)961-5507 Product Category: Pharmaceutical genentech . . . . . . . . . . . . . Pharmaceutical DeKA medical. . . . . .com Product Category: Cosmetics and Skin Care eZ Derm. . Laser and Laser Supplies. . . . . . . . 519 205 W Bement St. . . . . . . . Publishing and Educational Materials. . . . . . . . . .com Product Category: Computer Software and Hardware. Ste 101 Virginia Beach. . . . . . .com Product Category: Phototherapy Supplies and Equipment Dalos biopharma . . . . . . . . . . . . . . . 817 2055 Luna Road # 126 Carrollton. . Medical Lighting Equipment. . . . . . . . . 526 780 W Eight Mile Rd Ferndale. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . FL 34110 Phone: (800)44-EZDERM Fax: (239)598-0233 Email: info@ezderm. . . . . . . llc . . . . . . . . lp . . . . . . . . . . 414 421 S Lynnhaven Rd. . . . . . inc . . . . Bryan. . . . . . . . . . . . .com Product Category: Cosmetics and Skin Care. . . . . . . . . . . .org Product Category: Associations. Disposable Medical Supplies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430 1 DNA Way So. . 834 1901 McGee Street Kansas City. . . . . . . . . . . . . . . . . . 230 PO Box 4038 Weizman Science Park Ness Ziona. . . . . . . IA 51501 Phone: (800)831-6273 Fax: (800)320-9612 Email: questions@delasco. . FL 33418 Phone: (866)467-7546 Fax: (214)975-1301 Email: bmccarley@dermpathdiagnostics. . . . . . 808 608 13th Ave Council Bluffs. . . . . . . . . . . . . . . . . . . . . . . . .com Product Category: Cosmetics and Skin Care. . 806 3333 Royal Ave Oceanside. CA 94107 Phone: (877)844-5552 Fax: (415)358-8800 Email: info@dekamedinc. . NY 11572 Phone: (516) 594-3333 Fax: (516)569-0054 Email: ellman@ellman. . . . . inc . . . .org | 89 . . . . . IL 60201-4808 Phone: (847)328-2256 Fax: (847)328-0509 Email: dfgen@dematologyfoundation. . . . . . . . . . . . 203 2555 Industry Lane Norristown. . . . . . . . . . . . . . . Israel 74740 Phone: (972)8-9316233 Fax: (972)8-9474356 Email: info@foamix. . . . . . . . . . and Medical Societies Dermpath Diagnostics . . . . inc . . . Suite 400 Palm Beach Gardens. . . . . . . . . . EMR/EHR Systems fallene ltd . . . . . PA 19403 Phone: (800)332-5536 Product Category: Cosmetics and Skin Care ferndale healthcare. 818 1560 Sherman Avenue. . . . . . . . . . . . . . . . . . . Pharmaceutical. . . . . VA 23452 Phone: (888)321-6772 Fax: (757)631-2114 Email: sales@dalosbio. . MA 01887 Phone: (978)657-7500 Fax: (978)657-9193 Email: cs-dept@dusapharma. . . . . . . . . . . . . . . . . . Other Medical Equipment and Supplies. . . .co. . .il Product Category: Cosmetics and Skin Care. . . . . . . 208 25 Upton Drive Wilmington. . . . . . . Surgical Instruments DermAdoctor. . . . . . Suite 870 Evanston. .aad. . . .com Product Category: Laser and Laser Supplies Delasco . . . . Foundations. . . . . OH 43506 Phone: (800)322-8546 Fax: (419)636-1739 Email: sales@daavlin. . .com Product Category: Other Medical Equipment and Supplies. . . . . . TX 75006 Phone: (800)633-8872 Fax: (972)385-7930 Email: info@eltamd. . . . . . . . . . CA 94080 Phone: (650)225-2064 Product Category: Pharmaceutical e f technical exhibits g For the Latest Program Book InFormatIon PLease reFer to www. .com Product Category: Pharmaceutical foamix ltd . . . . . . . . . .com Product Category: Laboratory Services Dusa pharmaceuticals . . . . . . . . . . . . . . . . . 506 14501 North Freeway Fort Worth. . . . . . . . . . 510 7111 Fairway Drive. . . . . . MO 64108 Phone: (816)472-5700 Fax: (816)472-5752 Email: service@dermadoctor. . . . . . . . . . . . . . . . . Surgical Instruments eltamD skincare . . . . . 407 665 Third Street Suite 20 San Francisco. .com Product Category: Pharmaceutical ellman international . . . . . . 233 90 Cypress Way East Naples. . . . . . .Pharmaceutical galderma laboratories.com Product Category: Cosmetics and Skin Care Dermatology foundation . . . . . .technical exhibits D Daavlin . . . . . San Francisco. . . MI 48220 Phone: (800)621-6003 Fax: (877)548-7100 Email: contactus@ferndalelabs. .

. . . . . . . .org Product Category: Practice Management l la roche-posay . . . . . . Foundations. . 801 PO Box 1941 Morristown.com Product Category: Cosmetics and Skin Care iriDex . . 2750 Phone: (45)44945888 Product Category: Pharmaceutical amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . . . 325 1595 Paoli Pike #103 Westchester. . . . . . . . . . . . . . . . 426 1211 State Road 436. . . .com Product Category: Market Research i inga ellzey practice group. . . FL 32773 Phone: (800)344-5707 Fax: (407)649-9213 Email: maria@hillderm. . NJ 07962-1941 Phone: (866)463-3634 Fax: (973)966-3378 Product Category: Pharmaceutical 90 | K Kaiser permanente . . . . . . . . Surgical Instruments intendis. MA 01230 Phone: (800)762-1132 Email: info@janeiredale. . . inc . . . . . . . . . EMR/ EHR Systems. NY 10017 Phone: (888)577-5226 Email: customerservice@laroche-posay. . . . . . . . . . . . . . . . . Associations. .com Product Category: Clothing. . . . . . . Suite 140 Charleston. inc . . 308 1800 Harrison St. . . . . . . .A JsJ pharmaceuticals co . . . . . . . . . . 224 51 Church St Great Barrington. . . . . . . . Suite 300 Exton. . .altamirano@sanovaworks. . . . . . . . . . . . . . . . . CA 94612 Phone: (800)777-4912 Fax: (510)625-5487 Email: mdrecruitment. . . . 7th Floor Oakland.com Product Category: Practice Management innocutis . . . . .com Product Category: Pharmaceutical iredale mineral cosmetics . 307 400 Lanidex Plaza Parsippany. . . . . .com Product Category: Publishing and Educational Materials technical exhibits histopath lab pA . . . . . . . . .com Product Category: Cosmetics and Skin Care Johnson and Johnson consumer products company . . . . inc . . . . . PA 19380 Phone: (866)325-9907 Fax: (484)266-0726 Product Category: Publishing and Educational Materials Journal of Drugs in Dermatology/etAs . . . . . . . 505 199 Grandview Rd Skillman. . . . . . . . . . . SC 29401 Phone: (800)499-4468 Fax: (843)965-8333 Email: inquiry@jsjpharm. . . . . . . . . 802 6951 Via Del Oro San Jose. . . . . . 915 135 Duryea Road Melville. . . . . . . . NY 10016 Phone: (646)736-4333 Fax: (212)213-5435 Email: mary. . . . . . . . . . . Practice Management Surgical Instruments hill Dermaceuticals. . . Laboratory Services. . . . . . . . . . . . . . . . FL 34461 Phone: (352)527-1344 Product Category: Laboratory Services hrA research . . . . . . . . . . . . Computer Software and Hardware. . . . . . 236 Industriparken 55 Ballerup. . . . . . . . . . . Suite 297 Casselberry. . . . . . . 421 377 Park Ave South. . . . . . . . . . . . 212 171 Church St. . . . . . . . . . . . . . . . . . . . . NY 11747 Phone: (800)P-Schein Fax: (800)329-9109 Email: medsls@henryschein. . CA 94043 Phone: (800)388-4747 Fax: (650)962-0486 Product Category: Laser and Laser Supplies h henry schein . . . . .technical exhibits graceway pharmaceuticals . . . . . Mellonville Ave Sanford. . Disposable Medical Supplies. . . .com Product Category: Pharmaceutical. . . . . . . . . . . . . . . . . 513 1212 Terra Bella Avenue Mountain View. . . . . . . . . . . . . . . . . . . . 333 2671 W Norvell Bryant Hwy Lecanto. . Medical Lighting Equipment. . PA 19341 Phone: (267)948-0400 Email: info@gracewaypharma. . . . . . . . . . . . . . . . .com Product Category: Cosmetics and Skin Care leo pharma . . 6th Floor New York. . . . NJ 07054 Phone: (973)240-1204 Fax: (973)463-1888 Email: kdibiase@hraresearch. . . . . . . . . . . 432 222 Valley Creek Blvd. . . . . . . and Medical Societies. . . Pharmaceutical. . . .tpmg@kp. . inc . . . 827 2650 S. . . . . . . . . . . 605 575 Fifth Avenue New York. Cosmetics and Skin Care. . . . . . . . . . . . . . . . . .com Product Category: Pharmaceutical J Jan marini skin research. CA 95119 Phone: (800)347-2223 Fax: (408)362-0140 Email: info@janmarini. . . . . . . NJ 08558 Phone: (800)325-9821 Product Category: Cosmetics and Skin Care Journal of clinical and Aesthetic Dermatology . . . . Office Equipment and Supplies. . . . . . . . . . FL 32707 Phone: (407)571-5536 Fax: (407)678-5751 Email: mdelarosa@iegp. . .

Inc . JANMARINI.COM © 2011 Jan Marini Skin Research. rosacea and skin discoloration.NBSS211 .SKIN CARE MANAGEMENT SYSTEM TM B EA UTY CHO IC E PRODUCT NE WBEAUT Y WINNER AW ARD WITH LAYERED TECHNOLOGY 1 2 3 5 4 CLEANSE R E J U V E N AT E R E S U R FA C E H Y D R AT E PROTECT The 5-step system utilizes layered technology to measurably improve the appearance of common skin conditions such as fine lines and wrinkles. acne.

. . . . NC 27410 Phone: (888)merzusa Fax: (336)856-0107 Email: info@merzusa. . . . . . . . . . . . . NY 10025 Phone: (914)400-9964 Product Category: Publishing and Educational Materials lucid. 109th St. . . . . . . . CA 92673 Phone: (877)987-7979 Fax: (949)542-4101 Email: contact. . . . . . . . .com Product Category: Medical Lighting Equipment. inc . . .com Product Category: Computer Software and Hardware. . . . . . . . 409 50 S Buckhout St. . . . . 419 4915 St Elmo Ave. . . Suite 1 Irvington. . . . . . .com Product Category: Computer Software and Hardware. . . . . FL 32839 Phone: (407)538-5654 Fax: (407)557-3493 Email: sales@virabiotics. . Ste 407 Elmont. . . . . . . .com Product Category: Clothing. . Williams and Wilkins . . . . . . . .us@medelita. . . . . . . . . . . . . 321 1975 Linden Blvd. . . . . . . . . . . . . . . CA 91406 Phone: (800)442-5667 Product Category: Publishing and Educational Materials medicis . Photographic Equipment and Imaging Services mD moms . . . . . 324 7628 Densmore Ave Van Nuys. .com Product Category: Cosmetics and Skin Care medelita scrubs and lab coats . . . . . . EMR/EHR Systems. . . . . . . . . . Office Equipment and Supplies. . . . . .mccluskey@mti. . 520 7720 N Dobson Rd Scottsdale. inc . . . . . . . . . . . . . . . . . . . . . 420 5349 Lake Jessamine Dr Orlando. . . . . . . . . . . . . . . . . . CA 92648 Phone: (888)636-6672 Fax: (619)374-7121 Email: customerservice@mdmoms. . . . . . . . . . . . . . . . . . . . . . . . . D Amarillo. . . . . NJ 07036 Phone: (908)925-7519 Fax: (908)925-2841 Email: andreak@carestationmedical. . . . Surgical Instruments mJD patient communications . . . . . . .com Product Category: Pharmaceutical. . . . . . . . . . . . . . .com Product Category: Pharmaceutical. . . . . . . . . . . . . . . . . . . . Cosmetics and Skin Care mednet technologies. . . . . Other Medical Equipment and Supplies medesthetics magazine . . . Bldg. .net Product Category: Medical Lighting Equipment. . . . . . Photographic Equipment and Imaging Services merz pharmaceuticals . . . . . . . . . . . . . . . . . . . . . 413 1046 Calle Recodo. . . . . . . . . . . . .com Product Category: Pharmaceutical mti .technical exhibits lippincott. inc . . . . . . . . . . Publishing and Educational Materials melA sciences . MD 20814 Phone: (301)657-8010 Fax: (301)657-8023 Email: kristy@mjdpc. . . . . 422 PO Box 1378 Bellaire. . . . . . . . . . . . Practice Management microsurgery instruments. . . . . . . 424 9051 Goldenwest St. NY 14623 Phone: (585)239-9800 Fax: (585)239-9800 Email: colleen@lucid-tech. . . . . . NY 10533 Phone: (914)591-3783 Fax: (914)591-3701 Email: jglauda@melasciences. . . . . . . . . . . . . NJ 07004 Phone: (973)882-7512 Fax: (973)882-7502 Email: info@medimetriks. . . . . . . . . . . . . . UT 84104 Phone: (800)924-4655 Fax: (801)952-0548 Email: pat. .com Product Category: Photographic Equipment and Imaging Services molluscum rx . . . . . . 330 328 W St Georges Ave Linden. . . . . .com Product Category: Pharmaceutical medimetriks pharmaceuticals . . . . . 220 2320 Brighton Henrietta TL Rd Rochester. . . . . . . . . . . . . . . . . . . Practice Management. . . . Other Medical Equipment and Supplies m technical exhibits 92 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . . . . . . . . . . . Suite 306 Bethesda. . . NY 11003 Phone: (516)285-2200 Fax: (516)285-1685 Email: info@mednet-tech. . . . . . . . . . . . . . . . . . 322 363 Route 46 West Fairfield. . TX 79106 Phone: (800)235-1856 Fax: (806)463-7021 Email: sales@micro4. Other Medical Equipment and Supplies. . . . . . . . . 619 4215 Tudor Lane Greensboro. . . . inc . . . . . . . Practice Management molesafe usA . . . Cosmetics and Skin Care micro4. . . . . 206 3655 West Ninigret Dr Salt Lake City. Office Equipment and Supplies. . . . . 314 7118 I-40 West. .com Product Category: Computer Software and Hardware. . . Other Medical Equipment and Supplies. . .com Product Category: Laboratory Services. . . Suite D San Clemente. . . . AZ 85256 Phone: (602)808-8800 Fax: (602)808-0822 Email: customer_service@medicis. TX 77402-1378 Phone: (713)664-4707 Fax: (713)664-8873 Email: microusa@microsurgeryusa. . . . . . . . . 303 172 W. . . Apt 5E New York. . . . #106-136 Huntington Beach.com Product Category: Other Medical Equipment and Supplies.

** Average co-pay shown verified as of August 2010 based on reports from 380 health plans (eg. itching.. * Subject to eligibility. 2010.. On average. and local irritation. Trichophyton mentagrophytes. Bureau of Transportation Statistics. Epidermophyton floccosum and Trichophyton tonsurans (Gel only). Restrictions apply. HMO. The most commonly reported side effects of Naftin® are burning/stinging.http://www.1 Some will walk barefooted through airport security which may expose them to tinea pedis.transtats.bts. PPO. over 20 million people will board airplanes each month around the world. tinea cruris and tinea corporis caused by Trichophyton rubrum.) inclusive of all benefit designs/co-pay tiers.asp? Display_Flag=0&Percent_Flag=0. dryness. Accessed Aug 24. redness. Many eligible patients will receive the Naftin 90gm size at No Out-of-Pocket Cost!** UP TO $100 OFF * INSTANTLY FOR ANY NAFTIN (naftifine HCl 1%) • 90g Pump • 90g Cream • 90g Gel Rx product Instant Coupon available at www. . Important Safety Information Naftin® Cream and Gel are contraindicated in individuals who have shown hypersensitivity to any of their components and are for topical use only. Research and Innovative Technology Administration.gov/Oneway.NaftinCoupons. etc. Please see adjacent page for Full Prescribing Information 1 RITA.When they come to you .com or by calling 1 888 296 1852 Indication Naftin® (naftifine HCl 1%) Cream and Gel are indicated for the topical treatment of tinea pedis. IPA.

Trichophyton mentagrophytes. Store Naftin® Gel. Epidermophyton floccosum*. A sufficient quantity of Naftin® Gel. 1%. 1% contain the PRECAUTIONS: synthetic. Manufactured for Merz Pharmaceuticals. Because animal reproduction studies are not always predictive of human response. however. DOSAGE AND ADMINISTRATION: A sufficient quantity of Naftin® Cream. mutagenesis. including Candida albicans. 1% is supplied in collapsible tubes in the following sizes: 40g – NDC 0259-4770-40 60g – NDC 0259-4770-60 90g – NDC 0259-4770-90 Note: Store Naftin® Cream. Trichophyton mentagrophytes. 1% should be gently massaged into the affected and surrounding skin areas twice a day. the incidence of adverse reactions was as follows: burning /stinging (5. including Trichophyton rubrum. CHEMICAL NAME: (E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride. and a corresponding accumulation of squalene in the cells. rash (0. and tinea corporis caused by the organisms Trichophyton rubrum. Microsporum audouini.0%).1% are administered to a nursing woman. CONTRAINDICATIONS: Naftin® Cream and Gel. Naftin® Gel. this drug should be used during pregnancy only if clearly needed. Epidermophyton floccosum. Following single topical applications of 3H. 1%. Nursing mothers: It is not known whether this drug is excreted in human milk. ADVERSE REACTIONS: During clinical trials with Naftin® Cream. Greensboro. 1% are contraindicated in individuals who have shown hypersensitivity to any of their components. 1% are for topical use only and not for ophthalmic use. 1% contains polysorbate 80. cetyl esters wax. Structural Formula: CH 3 CH 2 NCH 2 H C= C H HCI General: Naftin® Cream and Gel. the incidence of adverse reactions was as follows: burning/stinging (6%). edetate disodium.2% of the applied dose was absorbed. 1% contains benzyl alcohol. polysorbate 60. Diagnosis of the disease should be confirmed either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium. Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician. 1% and Naftin® Gel. Information for patients: The patient should be told to: 1. Although the exact mechanism of action against fungi is not known. Naftifine hydrochloride has an empirical formula of C21H21N•HCl and a molecular weight of 323. local irritation (2%). Pregnancy: Teratogenic Effects: Pregnancy Category B: Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. CLINICAL PHARMACOLOGY: Naftifine Hydrochloride is a synthetic allylamine derivative. caution should be exercised when Naftin® Cream or Gel. sorbitan monostearate. 1% should be gently massaged into the affected and surrounding skin areas once a day. Pediatric use: Safety and effectiveness in pediatric patients have not been established. INDICATIONS AND USAGE: Cream. isopropyl myristate. erythema (2%). tinea cruris. and microsporum gypseum. NC 27410 © 2009 Merz Pharmaceuticals Rev 2/09 . and tinea corporis caused by the organisms Trichophyton rubrum. and fungistatic activity against Candida species. Naftin® Cream and Gel. Hydrochloric acid may be added to adjust pH. itching (1. itching (2%). 1%. no adequate and wellcontrolled studies in pregnant women. The hands should be washed after application.86. up to 4. WARNINGS: Naftin® Cream and Gel. 1% have not been performed.0%). If irritation or sensitivity develops with the use of Naftin® Cream or Gel. 1% is supplied in collapsible tubes in the following sizes: 30g – NDC 0259-4126-30 60g – NDC 0259-4126-60 90g – NDC 0259-4126-90 30g – NDC 0259-4126-03 (pump) 90g – NDC 0259-4126-09 (pump) Naftin® (naftifine hydrochloride) Gel. carbomer 934P. In vitro and animal studies have not demonstrated any mutagenic effect or effect on fertility.GEL CREAM Rx ONLY DESCRIPTION: Naftin® Cream. cetyl alcohol. antifungal agent naftifine hydrochloride. Naftin® Gel. HOW SUPPLIED: Naftin® Naftin® (naftifine hydrochloride) Cream. erythema (0. especially ergosterol. systemic absorption of naftifine was approximately 6% of the applied dose. Naftin® Cream and Gel.5%). 3-epoxidase. During clinical trials with Naftin® Gel. 2.5%). This inhibition of enzyme activity results in decreased amounts of sterols. Following a single topical application of 1% of naftifine cream to the skin of healthy subjects. Because many drugs are excreted in human milk. and Epidermophyton floccosum. purified water. Trichophyton tonsurans. 1% are for topical use only. impairment of fertility: Long-term studies to evaluate the carcinogenic potential of Naftin® Cream and Gel. and purified water. 1% is indicated for the topical treatment of tinea pedis. are for external use only. Trichophyton tonsurans*.5%). Keep Naftin® Cream and Gel. alcohol (52%v/v). 1%. in the morning and evening. Carcinogenesis. 1% below 30˚C (86˚F). the patient should be re-evaluated. dryness (3%). Naftifine hydrochloride has been shown to exhibit fungicidal activity in vitro against a broad spectrum of organisms. tinea cruris. Naftifine and/ or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days. broad-spectrum. Microsporum canis. diisopropanolamine.labeled naftifine gel 1% to the skin of healthy subjects. mouth and other mucous membranes. Inactive Ingredients: Naftin® Cream. 1% is indicated for the topical treatment of tinea pedis. The following in vitro data are available but their clinical significance is unknown. If no clinical improvement is seen after four weeks of treatment with Naftin® Cream or Gel. 1% away from the eyes. nose. naftifine hydrochloride appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2. 1%. treatment should be discontinued and appropriate therapy instituted. *Efficacy for this organism in this organ system was studied in fewer than 10 infections. 1% at room temperature. Pharmacokinetics: In vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes. and stearyl alcohol. sodium hydroxide. Contains: naftifine hydrochloride Active Ingredient: Naftifine hydrochloride………… 1%. Trichophyton mentagrophytes. There are. 1% have only been shown to be clinically effective against the disease entities listed in the INDICATIONS AND USAGE section. skin tenderness (0.

. . . . . . . . . . .com Product Category: Cosmetics and Skin Care neutrogena . . . and Medical Societies. . . . . . . . . . Pharmaceutical neogenomics laboratories . . . . . . . . . . 234 400 Highland Corporate Drive Cumberland. . . . NJ 08540 Phone: (800)628-9904 Fax: (800)636-7872 Email: custsvc@neostrata. . Publishing and Educational Materials ortho Dermatologics . . . . . . . . . Ste 350 Tampa. . . . . . . . . . . . . . . . . . . . #100 Royal Oak. . inc . . . . . . Foundations. . 613 23700 Mercantile Road Beachwood. . . . . . . . . . CA 92093 Phone: (877)311-8972 Fax: (619)294-6191 Email: raandpregnancy@ucsd. . . . NW Rochester. . .zucala@photocure. . . . CA 90045 Phone: (310)410-5813 Fax: (310)410-5945 Product Category: Pharmaceutical pharmaceutical specialties. 705 210 Park Avenue Florham Park. . . . 416 61 B Monroe Ave Pittsford. . . . . . . . . . . . . . . . 502 5760 W 96th St Los Angeles. .com Product Category: Cosmetics and Skin Care. . . PA 18936 Phone: (800)366-4758 Fax: (215)619-3208 Email: cust@photomedex. . . . . . . . . . . . . . . . . 820 5550 W. . .Pharmaceutical pharmaDerm . . . . . . . . . . . . . . . . . . . . . . 524 147 Keystone Drive Montgomeryville. . . 331 100 Overlook Center. . .com Product Category: Cosmetics and Skin Care technical exhibits p For the Latest Program Book InFormatIon PLease reFer to www. .aad. . Executive Dr. . . . . . . . . Laser and Laser Supplies. Eleven Mile Rd. EMR/EHR Systems.com Product Category: Cosmetics and Skin Care nextech . MI 48067 Phone: (866)636-2884 Fax: (313)664-0668 Email: contactus@neocutis. . . CA 90806 Phone: (562)628-1007 Fax: (562)628-1008 Email: lisae@obagi. . RI 02864 Phone: (310)503-4621 Email: mcurtin@onsettx. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Phototherapy Supplies and Equipment neocutis. . . . 523 3760 Kilroy Airport Way Long Beach. . . .com Product Category: Cosmetics and Skin Care. . . . 1013 4208 Six Forks Road 9th Floor Raleigh. . . . . . . .com Product Category: Pharmaceutical organization of teratology information specialists . .com Product Category: Cosmetics and Skin Care photomedex . . . . . . . . . . . . . FL 33609 Phone: (813)425-9200 Fax: (813)425-9292 Email: websales@nextech. 411 9500 Gilman Dr. 231 12701 Commonwealth Dr Ft Myers. . . . NY 14534 Phone: (585)586-5166 Fax: (585)586-1370 Email: seloverl@muhlbauerlab. 410 512 E. .com Product Category: Laser and Laser Supplies. .miller@nycomed. . . . . . . . . . . .com Product Category: Cosmetics and Skin Care. . . . . . . . . . . .org | 95 . . . OH 44122 Phone: (800)338-5045 x1 Fax: (216)765-0271 Email: info@PhototherapyExperts. . MC0828 La Jolla. . . . . . . . . . . . . . . . . . . . Pharmaceutical onset therapeutics . . . . . . . . . . NC 27609 Phone: (919)838-7800 Fax: (919)838-7812 Email: brandolph@strivectin. . . 602 5760 West 96th Street Los Angeles. . . . .technical exhibits muhlbauer Dermatopahology lab . . . CA 90045 Phone: (310)642-1150 Fax: (310)410-1631 Email: scropper@its. . . . . . . . .com Product Category: Cosmetics and Skin Care. . . .com Product Category: Laboratory Services obagi medical products . . . . . MN 55901 Phone: (800)325-8232 Fax: (507)288-7603 Email: order@psico. . . .jnj. . Phototherapy Supplies and Equipment o n national biological corporation . . . . . . . .com Product Category: Computer Software and Hardware. . . . . . . . . . (psi) . . . . . 2nd Flr Princeton. . . . . . . . Photographic Equipment and Imaging Services. . . . . . . . . . . . . . 807 307 College Road East Princeton. . . . . . NJ 08540 Phone: (609) 375-2263 Email: mike. . . . . . . . . . . . 823 1620 Industrial Dr. . . . . . . . . inc . .com Product Category: Pharmaceutical photocure .us. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Practice Management niadyne niA24/strivectin . . . . . FL 33913 Phone: (866)776-5907 Product Category: Laboratory Services neostrata company .edu Product Category: Associations. . NJ 07932 Phone: (866)337-6001 Email: tracey. .

. PA 19087 Phone: (484)581-1800 Product Category: Computer Software and Hardware. . . . . . . . . . . . 335 5909 Sea Lion Place. . . . . . .com Product Category: Cosmetics and Skin Care skinmedica. . . . . . . . . . . Ste H Carlsbad. . 608 c/o GSK 20 T.c. AL 35209 Phone: (205)290-8251 Fax: (205)290-4269 Email: sandstonemike@bellsouth. . . . . . 313 105 Citation Court Homewood. . . . . . . . . . 312 3098 Executive Parkway Suite 300 Lehi. . . . . . . . . . 332 65 Stults Rd Dayton. . inc . . . . . .tomlinson@admcorp. . . . . . . . . . . . . . LLC Wayne. . . . . . . . CA 92010 Phone: (866)867-0110 Fax: (760)448-3604 Product Category: Cosmetics and Skin Care smile reminder . . . . NC 27709 Phone: (919)990-6000 Product Category: Cosmetics and Skin Care. . . . . . 222 5635 Fishers Lane. .com Product Category: Practice Management skin cancer foundation. . . Market Research. .com Product Category: Computer Software and Hardware. . . . . . . . . . . . . . 734 149 Madison. . . . . . . . . . . . . 730 3402 West Miller Road Garland. 210 83 General Warren Blvd. . . . . . .org Product Category: Associations. Ste 100 Malvern. . . . Publishing and Educational Materials procter and gamble . . TX 75247 Phone: (800)385-6652 Fax: (214)630-1806 Email: info@revisionskincare. . . . . . . . Suite 901 New York. . . . MD 20852 Phone: (240)221-4405 Fax: (240)221-4400 Email: terrie@sdefderm. . . Pharmaceutical technical exhibits r ra medical systems. 515 1 PandG Plaza Cincinnati. . . 216 2270-L Camino Vida Roble Carlsbad. . . . . . . . llc . .com Product Category: Publishing and Educational Materials skin and cancer Associates/Advanced Dermatology mgmt . . . . UT 84043 Phone: (866)605-6867 Fax: (801)772-2034 Email: support@smilereminder. . . . . . . . Suite 300 Miami Gardens. .com Product Category: Laboratory Services saunders/mosby-elsevier . . . . 311 c/o Bryn Mawr Communications. . . . . . . . . . . . . . . . . . . . . . . .technical exhibits practical Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427 1355 River Bend Drive Dallas. 830 1600 JFK Blvd. . . . . . . . . . .com Product Category: Cosmetics and Skin Care. Practice Management. . . . . 323 200 Somerset Corporate Blvd Bridgewater. . CA 92011 Phone: (760)804-1648 Fax: (760)804-1657 Email: mburstein@ramed. . . . a gsK company . OH 45202 Phone: (513) 983-1100 Email: miller. . . . . . Pharmaceutical sandstone medical technologies . .com Product Category: Laser and Laser Supplies. . . . . . . . . . . Office Equipment and Supplies stiefel. . . . . . Foundations. Suite 6000 Rockville. . . . . . . . . 317 9019 Premier Row Dallas. . . . . . . . . .3@pg. . Research Triangle Park. . . . the . inc . . Practice Management. . . . . . . . . . . . . . . . . . . . . . . . and Medical Societies.com Product Category: Cosmetics and Skin Care revitalash 6295 McLead Las Vegas. . . FL 33169 Phone: (305)623-5595 Fax: (305)623-1937 Email: d. . . . 607. . . . . . . . . NJ 08807 Phone: (908)429-4500 Product Category: Pharmaceutical propath . . . Alexander Dr. . . . . . . . . . . . . . . . . . .net Product Category: Laser and Laser Supplies 96 | s amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 . . . . . . . . . . . . . . . . . . . . NY 10016 Phone: (212)725-5176 Fax: (212)725-5751 Email: info@skincancer. . . . . . . . . . .com Product Category: Cosmetics and Skin Care promius pharma. . TX 75041 Phone: (800)811-1660 Fax: (972)926-2950 Email: service@skinceuticals.W. NJ 08810 Phone: (609)655-0173 Fax: (609)655-9291 Email: sam@salvona. . . . . . . . .com Product Category: Publishing and Educational Materials skinceuticals . . . . . . . . . . NV 89120 salvona technologies . . . . . . PA 19103 Phone: (800)325-4177 Product Category: Publishing and Educational Materials skin and Aging . . . . . . . . . . . . . . . . . . . . PA 19355 Phone: (800)237-7285 Fax: (610)560-0501 Email: rehrlich@hmpcommunications. Phototherapy Supplies and Equipment revision skincare . . . . . . Publishing and Educational Materials skin Disease education foundation . . . . . . . 318 1111 Park Centre Blvd. . . . . . . . . . . TX 75247 Phone: (800)258-1253 Fax: (214)237-1844 Email: marketing@propath. . #1800 Philadelphia. .

. . . . . . . . . . . . . . . . . . . . . . 514 3 Goodyear. Vancouver. . . . . . . . . . . . . . . . Office Equipment and Supplies. Unit A Irvine. . . . . . . .com Product Category: Cosmetics and Skin Care tiber laboratories . . . . . . . . . . . . . 824 11 Commerce Dr Cranford. . . . . . .aad. . NY 11788 Phone: (800)843-6266 Fax: (800)577-6050 Email: sales@georgetiemann. . . . . . . . . . . . . . . .com Product Category: Laser and Laser Supplies taro pharmaceuticals . . . . . . Laser and Laser Supplies. . . . Surgical Instruments triax pharmaceuticals . . 320 103 G. . . . TN 38119 Phone: (888)437-2753 Fax: (888)437-1050 Email: customerservice@theraplex. . . . . . . . . . . . . . . . . inc . . . . . . 431 306-2309 West 41st Ave. . . . . . . . . . . Other Medical Equipment and Supplies. . . . . . . . . .com Product Category: Pharmaceutical upsher-smith laboratories. . . . . . . NY 10532 Phone: (914)345-9001 Fax: (914)345-0391 Product Category: Pharmaceutical theraplex company. Medical Lighting Equipment. . . MN 55369 Phone: (763)315-2000 Fax: (763)315-2244 Email: uslinfo@upsher-smith. . . . . . . .com Product Category: Disposable Medical Supplies Visicom . . . . . . .com Product Category: Practice Management y u yodle . . . . . . . . . . . . .com Product Category: Other Medical Equipment and Supplies Viscot medical . CT 06109 Phone: (860)529-7919 Fax: (860)529-6801 Product Category: Cosmetics and Skin Care. . . . . . llc . . .com Product Category: Cosmetics and Skin Care syneron and candela . . . . . . . . .com Product Category: Pharmaceutical tiemann-bernsco . CA 92618 Phone: (949)716-6670 Fax: (949)716-6555 Email: info@syneron. . . . . . . . . . . . . . . . . . . . . llc . . . . . . .com Product Category: Pharmaceutical uVbioteK. . . . . 428 319 East Stuart Ave. . . . . . NJ 07936 Phone: (973)887-9273 Fax: (973)887-3961 Email: romola@viscot. . . . . . . . . . . . . . . BC V6M2A3 Phone: (604)605-0507 Fax: (604)605-0508 Email: ctrinh@verisante. PA 19426 Phone: (610)454-1471 Fax: (610)454-1475 Email: info@sumlab. . . Practice Management t technical exhibits W Warner chilcott . . . . . . . . . . NJ 07866 Phone: (800)521-8813 Email: WCRX. Computer Software and Hardware. . . . . . . NY 10010 Phone: (877)276-5104 Fax: (646)753-6312 Email: info@yodle. . . . . . .org | 97 For the Latest Program Book InFormatIon PLease reFer to . . . . . CA 92374 Phone: (909)798-0601 Fax: (909)335-8644 Email: rkanavas@lepg. . . . . 406 25 Plant Ave Hauppauge. . . .com Product Category: Practice Management young pharmaceuticals. . . .com Product Category: Disposable Medical Supplies. . . Redlands. . . . . . . . . Ste 401 New York. . .net Product Category: Office Equipment and Supplies. 235 6410 Poplar Ave Suite 110 Memphis. . . . . . . . GA 30024 Phone: (678)208-0388 ext 241 Fax: (608)208-0988 Email: sdrody@tiberlabs. . . . . . . . . . . 328 4520 South 36th St Omaha. . . . . . . . . . . . . . . . . . . . . . . Clement Drive Collegeville. . 829 6701 Evenstad Dr Maple Grove. . . . 334 32 West Street East Hanover. . . . inc . . . . . NY 12839 Phone: (518)747-3310 x101 Fax: (518)747-2294 Email: gary@uvbiotek. . . . . . . . . . . . . . . . . . . NJ 07016 Email: info@triaxpharma. . . . . . . . . . . . . . . . . . .technical exhibits summers laboratories . . . . 227 3 Depot Street Hudson Falls. . . . . .the . . . . 609 1840 Berlin Turnpike Wethersfield. . . . NE 68107 Phone: (800)228-3400 Fax: (402)734-6815 Email: customerservice@visicom. 226 3 Skyline Drive Hawthorne. 418 5400 Laurel Springs Parkway Suwanee. . . . . 327 50 W 23rd Street. .com Product Category: Pharmaceutical West coast Dermatology billers.P. . . . . . . . . . . . . . . . . . . . . .com Product Category: Medical Lighting Equipment V Verisante technology. . . . . . . . . . . . . . . . . . . . . . . . . . . . inc . . . . . 305 100 Enterprise Drive Rockaway. . . . . Pharmaceutical www.

............................................................................................... LLC ..............................................................................523 98 | Caris Life Sciences.......................................................................231 ProPath .........................................................................................316 Beiersdorf Inc.............................................................................734 DisposAble meDicAl supplies clothing Henry Schein .203 Foamix Ltd.............................................................................609 AssociAtions........................................... Pharmaceutical Specialties....................613 PhotoMedex..............425 EZ Derm....414 Delasco ............................. Inc........Oil ..........619 MolluscumRx ................................. ..............425 EZ Derm..........................................331 PhotoMedex......................................................................................................410 NeoStrata Company .......502 Niadyne NIA24/Strivectin ........................................... (PSI)..............833 DEKA Medical ......................................................................................................................................................915 MELA Sciences ................................................... 420 Neocutis......................915 Mednet Technologies................................................................................................................ Inc............................................................. Inc....... ..............................805 Compulink Business Systems............ Inc..............................................................................................320 Theraplex Company.........................................................................................................................834 EltaMD Skincare ................................................................416 NeoGenomics Laboratories .........................................802 Johnson and Johnson Consumer Products Company ........... Inc.............510 Henry Schein ...............329 Cobalt Medical Supply .................................... Inc...................................................................................................................................................... Inc ...........................................................................................................................................................................................605 LEO Pharma ............................... Inc ......................609 3M Drug Delivery Systems ..233 Henry Schein ............................915 Histopath Lab PA .....................823 Photocure...........................................817 Fallene Ltd ........................ Inc............509 Bovie Medical ......................technical exhibits proDuct cAtegory Directory of exhibiting compAnies Companies confirmed as of January 7................232 Biopelle............820 Smile Reminder .....................................................................................................................................................................................................................................................................................................................................................................................................................334 emr/ehr systems Compulink Business Systems...808 DERMAdoctor.............................321 Micro4.......................................................... Inc .............................................................................302 Acuderm.................................................................................... .....................................................................915 Iredale Mineral Cosmetics ..429 Dermpath Diagnostics ..........................................................................................................................................................................................................................................The ....................309 Coria Laboratories...................................... AnD meDicAl societies American Academy of Dermatology.....................................317 Salvona Technologies ..................................230 Henry Schein .............................. Inc...................513 National Biological Corporation .............................................................515 Revision Skincare .................... Inc..........333 Muhlbauer Dermatopahology Lab ............................................................................................ LLC/DermLite .................306 Bio .....224 Jan Marini Skin Research... ...915 Medelita Scrubs and Lab Coats ............................................................................................... Inc..........................................424 Medimetriks Pharmaceuticals.730 Skin Medica ..............................................................413 computer softWAre AnD hArDWAre technical exhibits (by product category) 3Gen........808 Henry Schein ......... .......................................................................................................623 Dalos BioPharma ...807 Neutrogena .........223 Alma Lasers ........................................312 amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 ..............................235 Young Pharmaceuticals.....427 lAser AnD lAser supplies Aerolase ................................212 Organization of Teratology Information Specialists ................................... LLC ...................................................411 Skin Cancer Foundation................312 Young Pharmaceuticals.................................... ....................................................................................................... LLC .....................................A JSJ Pharmaceuticals Co..216 Sandstone Medical Technologies .......335 Summers Laboratories ....................................314 NexTech ..................................................................................................................................405 Canfield Imaging Systems ...........808 IRIDEX ..................818 Innocutis ............524 Procter and Gamble ......................................................... founDAtions.1013 Obagi Medical ......514 Tiemann-Bernsco ......................................................................................................... ......................................415 Delasco .233 Henry Schein .................................................................................................................... .............. Inc..........................313 Syneron and Candela ............................................................................................................. Inc..................... ......................................... The ........................................433 Dermatology Foundation ... .............307 Smile Reminder ..........................406 mArKet reseArch HRA Research......... Inc.915 Tiemann-Bernsco ............................... 236 MD Moms............................... 2011............407 Delasco .................332 SkinCeuticals ................................................................................................322 Merz Pharmaceuticals ............................................505 La Roche-Posay .....................906 American Acne and Rosacea Society ............................... ...........................................................524 Ra Medical Systems..........406 Viscot Medical..............................................................................820 cosmetics AnD sKin cAre lAborAtory serVices Axia Medical Solutions .......................................................................... ......................................................................................... 409 Micro4............................314 NexTech .........................

...................................................................431 photogrAphic equipment AnD imAging serVices technical exhibits (by product category) 3Gen...................................................................................................................................808 Henry Schein .......................................................................................................................... ................................................220 Medelita Scrubs and Lab Coats ...........A JSJ Pharmaceuticals Co.... Inc...... Inc................................................405 Acuderm..................................... ..........................................................................613 phototherApy supplies AnD equipment Daavlin ................................................................................................................227 Henry Schein ........................org | 99 For the Latest Program Book InFormatIon PLease reFer to ......................................................607........................................... ...........414 Delasco ...........................................................327 West Coast Dermatology Billers...................................................................................... ............. Inc.................. Inc.......................................432 CareCredit ........ Inc.......................................... Inc....................................................................................................................................509 Bovie Medical ...........................................................430 Graceway Pharmaceuticals .........................312 VisiCom........................................ ....................................220 MELA Sciences .......................326 Compulink Business Systems Inc...............805 Cobalt Medical Supply ... LLC/DermLite ........................................702 Cobalt Medical Supply ....216 phArmAceuticAl prActice mAnAgement Abbott......................................................410 Obagi Medical ...........................................................................................................................................................................................................405 Canfield Imaging Systems ................................. ........................602 Pharmaceutical Specialties.................... Inc..............314 NexTech ........................................................... Inc............................143 Mednet Technologies...................143 MTI ........915 Lucid..................................................... LLC ....................................................208 Ferndale Healthcare................................................................................................................................................................613 Ra Medical Systems...................... LLC......... ....................................................................206 Tiemann-Bernsco ..................428 www.........................................................................................321 Micro4......915 Hill Dermaceuticals..................................................................................330 National Biological Corporation ........................................................... ................................. ...................................826 Cobalt Medical Supply ....................................................824 Upsher-Smith Laboratories................305 Young Pharmaceuticals...... ...............405 Brymill Cryogenic Systems...........................................................................................................................................915 Microsurgery Instruments................................................................................................328 Yodle .......................................................................808 National Biological Corporation .............................915 Inga Ellzey Practice Group.........................415 Delasco ..................................... ...................................................821 Henry Schein ................806 Henry Schein ..... Inc.................202 Amgen .........................................308 Medelita Scrubs and Lab Coats ............... ................. Inc.....234 Ortho Dermatologics .......................... ..................................................................415 Conmed ..................................................705 Promius Pharma.........413 Microsurgery Instruments................................827 Innocutis . LLC/DermLite ...............609 office equipment AnD supplies 3Gen...............................................706 Allergan ....................................526 Foamix Ltd..................... Inc..............415 Coria Laboratories................................................. LLC .......520 Medimetriks Pharmaceuticals.................................316 Centocor Ortho Biotech.....................................820 Skin and Cancer Associates/Advanced Dermatology Mgmt ....................................................................................................................425 Henry Schein ....406 Verisante Technology.............................................212 Intendis.................................519 Delasco ........................................................................332 Stiefel.............................................. Inc... LP..406 UVBIOTEK....................................... a GSK Company .....................................................aad...................................... Inc.......226 Tiber Laboratories ...................................................................................................... ................................................................................................. (PSI)..230 Galderma Laboratories............... ....................................619 Neocutis.. Inc...................................................................................823 PharmaDerm .. Inc..............................808 Ellman International .........................................................................................................328 other meDicAl equipment AnD supplies 3Gen.........523 Onset Therapeutics ..............................329 Brymill Cryogenic Systems..................406 VisiCom......801 Medicis ..............524 Tiemann-Bernsco .....312 Tiemann-Bernsco ................................................................................................................................................................................................ .................................206 PhotoMedex ......... ...... 608 Taro Pharmaceuticals ...................................................................................................................................................................... Inc.............................................. Inc...........................................826 Cobalt Medical Supply ......................................................206 Smile Reminder ................318 Smile Reminder ................................................623 Dalos BioPharma ................................. Inc..................409 MoleSafe USA.................................506 Genentech ..............................808 Dusa Pharmaceuticals ........................... ...................................................................................................422 MTI ...........technical exhibits meDicAl lighting equipment Canfield Imaging Systems ..323 Salvona Technologies ....................................................... Inc............418 Triax Pharmaceuticals..................805 Lucid...........................................415 Delasco ................. LLC .......................................................... LLC/DermLite ......................422 MTI .................................915 Medelita Scrubs and LabCoats ........................................................................................829 Warner Chilcott .............426 Kaiser Permanente ...............322 Merz Pharmaceuticals ............................. .........................................................................................................................606 Axia Medical Solutions .........................................................................................................................

...........................734 Skin Disease Education Foundation.........................421 Lippincott......... .................................................................................................................................................................................................................................310 Delasco .......826 Cobalt Medical Supply ...411 Practical Dermatology ............................................................. Inc.................................210 Skin Cancer Foundation............821 Delasco ....321 Organization of Teratology Information Specialists ................................A JSJ Pharmaceuticals Co...................................................324 Mednet Technologies...........323 Cosmetic Surgery Times/Dermatology Times ....................................................................................................................................................................................................................................808 Journal of Clinical and Aesthetic Dermatology .............915 Innocutis ..808 Ellman International ...........806 Henry Schein .........325 Journal of Drugs in Dermatology/ETAS ........................................830 Skin and Aging .......................................................... Inc......................................................................................................................................303 Medesthetics Magazine ......415 Conmed ......406 ADVANCE for Healthy Aging ............212 Microsurgery Instruments............ ........................................222 technical exhibits (by product category) 100 | amerIcan academy oF dermatoLogy • sUmmer academy meetIng 2011 .........221 Cutis and Cosmetic Dermatology ................................ Williams and Wilkins ............................................329 Brymill Cryogenic Systems..............................................................................................................................technical exhibits publishing AnD eDucAtionAl mAteriAls surgicAl instruments Bovie Medical . The ...........................................................422 Tiemann-Bernsco ........311 Saunders/Mosby-Elsevier .........................

Treatment beyond 2 weeks should be limited to localized lesions of moderate to severe plaque psoriasis that have not sufficiently improved after the initial 2 weeks of treatment with CLOBEX® Spray. Please see adjacent page for brief summary of Prescribing Information. is not recommended for use on anyone younger than 18 years of age. Clobetasol propionate spray should not be used in the treatment of rosacea or perioral dermatitis and should not be used on the face. In controlled clinical trials.05%. groin or axillae. hyperpigmentation. CLOBEX® Spray. pruritus. 0. CLOBEX® Spray. infections and infestations. upper respiratory tract infection. Pregnancy Category C. should not exceed 50 g (59 mL or 2 fl oz) per week. Treatment should be limited to 4 weeks.05%. is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older.05%. 0. Clobetasol propionate has been shown to suppress the HPA axis at the lowest doses tested. 0. the following adverse reactions have been reported: burning.For moderate to severe plaque psoriasis Important Safety Information CLOBEX® (clobetasol propionate) Spray. nasopharyngitis. . 0. and skin and subcutaneous tissue disorders.05%.

.

. . . . 5:00 p . .m . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12:00 p . SkinPAC Board of Advisors Meeting Madison Suite . . . . . . . . . . . . . . . . . . . . 2011. . . 12:00 p . to 5:00 p . . . . . . Academic Dermatology Leadership Program Session Morgan Suite . . . Development Committee Meeting Morgan Suite . . to 9:00 a . . . . . . . . . . .m . . . . . . . . . . . August 4 Corporate Relations Task Force Meeting Midtown Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Breakfast 6:30 a . .m . . . . . . Cevnal on Education Midtown Suite . . . . . . . . . . . .org | 103 . . . . . . . . . . . . . . . . . . . .m . . . . . . . . . . . . . . . . . . . . . . . . . August 5 – 6:30 a . . . .m . . . . . . . . . . . . . . August 5 – 9:00 a . . . . . . Saturday. . . . . . . . . . . . . . . August 6 – 9:00 a . . . . . . . to 9:00 a . . . . . . . . . . . . . . . . Health Care Finance Commitee Midtown Suite . Health Policy & Practice New York Suite . . . . . . 2:30 p . .m . . . . . .7:00 a . . . . . . . . . . . . . . . Friday. . . . . . . August 5 Corporate Partners Circle Meeting Petit Trianon . Saturday. .m . .m . . . . . . . . Leadership and Mentoring Reception New York Suite . . . 4:00 p . .m . . . . . . . . . . . . . . . . . . . . . .m . . . . . . . . . . . . . . . . . . . . . . . . . . . .m . . . . . . . . . . . . . . . . . . . . . . .m . . . . .m . . . . . . . . . . . . . .m . . . . . . . Meeting 7:00 a . . . . . to 3:00 p . . . . . . .m . . . . . . . . 5:00 p . . . . . . . . . . . . . . . . . . . . . .m . 1:30 p . . . . . . . . . . . . . . List current as of February 22. . . . 5:00 p . . . . . . WDS Center Concourse B . . . . . . .m . . . . . . . . . . . . . . Committee / ancillary meetings ancillary meetings All events are held at the Hilton New York unless indicated otherwise. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .m . . . 2:00 p . . . . . . . . . . . .m . . 4:00 p . . . .m . . . . . . . . . . . . . . . . . . . . . . . Friday. . . . . Major Gifts Work Group Lincoln Suite . . . . . . . 12:15 p .7:00 a . . . . . . . . WDS Board of Directors Meeting Concourse A . . . . . . . . . . . . .7:30 a . . . . .m . . August 6 Board of Directors Meeting Mercury Ballroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . Regulatory Policy Committee East Suite . . . . . . . . . . . . . . . . . . Corporate Partners Recognition Reception Petit Trianon . Scientific Assembly Committee Meeting Morgan Suite . Private Sector Advocacy Task Force Midtown Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Coding & Reimbursement Task Force Midtown Suite . . . . . . . . List current as of February 22. . . . . . . 1:00 p . . . . . Council of Government Affairs. . . . . . . . . . .m . . . . . . . . . Thursday. . .m . . . . . . . . . . Friday. . 3:00 p . . . . . . . .m . . . . . . . . . . . . For the Latest Program Book InFormatIon PLease reFer to www.aad. . . . . 4:00 p . . . . . . .m . . . . . . . . . . . . . . . . . . . . . .Committee meetings All events are held at the Hilton New York unless indicated otherwise. . . . . . . . . . . . . . . . . . . 2011. . . . . . . . . . Workforce Task Force Madison Suite . . . . . . . . . .m .

76 W003 OC Self-Assessment: Acne. 38 U008 uality and Customer Service for a Better Q Practice. 77 infestations/Bites F005 nfectious Disease and Infestation I Update. 43 S001 EADV/AAD Joint Symposium. 76 Th cutaneous Physiology U016 rom Bench to Bedside: F Important Clinical Advances. 43 F008 Cased Based Controversies: Medical. 58 Molecular Biology/genetics U016 rom Bench to Bedside: Important Clinical F Advances. 65 U025 mpact of Nanotechnology and I Dermatology. 71 S U032 pitz’s Genodermatoses. 78 U025 mpact of Nanotechnology and I Dermatology. 44 F012 Case Based Challenges for PA/NP’s. 71 U031 The Interface of Skin and Psyche. 59 inflammatory Disorders F006 hat’s Boiling Over: Atopic Dermatitis W and Other Eczematous Conditions. 58 Pathophysiology U016 rom Bench to Bedside: Important Clinical F Advances. 64 U031 e Interface of Skin and Psyche. 59 U020 Exploring Evidence Based Cosmeceuticals. 77 infections F005 nfectious Disease and Infestation I Update. 53 U016 rom Bench to Bedside: Important Clinical F Advances. 38 U008 uality and Customer Service for a Better Q Practice. 65 I U025 mpact of Nanotechnology and Dermatology. 69 S001 EADV/AAD Joint Symposium. 59 I U033 nfectious Disease Update What I Wouldn’t Have Known Without Evidence Based Medicine. 65 U025 mpact of Nanotechnology and I Dermatology. 76 genodermatoses U025 mpact of Nanotechnology and I Dermatology. 69 S001 EADV/AAD Joint Symposium. 68 U019 Cellulitis: A Common (Mis)Diagnosis?. M Eczema and Inflammatory Dermatosis. 49 immunology U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management. 59 Fungal S009 ermatology Grand Rounds: A Discussion D of Case-Based Dilemmas. 41 U002 Asian American Skin. M Eczema and Inflammatory Dermatosis. Psoriasis. The index is divided into nine different primary topics with subtopics listed alphabetically under these primary topics. 67 U020 Exploring Evidence Based Cosmeceuticals. 58 genetics U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management. 76 clinical Research U016 rom Bench to Bedside: Important Clinical F Advances. 51 endocrine Diseases U019 Cellulitis: A Common (Mis)Diagnosis?. 38 U004 edical Management of Actinic M Keratoses. 58 cLinicaL DeRMatoLogy acne & Related Disorders F004 ace to Face: Management of Facial F Dermatoses. 48 U018 Dermoscopy for the Non-Dermoscopist. 59 W006 ractical Approaches to Patient P Problems. 76 Hair Disorders F015 lopecia and Hair Loss. 70 cosmetics S008 What’s Hot in Women’s Dermatology. 49 Basic science oF DeRMatoLogy cell Biology U016 rom Bench to Bedside: Important Clinical F Advances. 77 Bullous Dermatoses F019 Oral Disease. 77 general Dermatology F008 Cased Based Controversies: Medical. 71 U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care. 49 F U016 rom Bench to Bedside: Important Clinical Advances. 64 I U025 mpact of Nanotechnology and Dermatology. 44 U019 Cellulitis: A Common (Mis)Diagnosis?. 44 W006 ractical Approaches to Patient P Problems. 71 collagen Vascular Disorders F008 Cased Based Controversies: Medical. 60 F019 Oral Disease. 40 S005 edication Monitoring and M Complications. Psoriasis. 43 F008 Cased Based Controversies: Medical. 58 U025 mpact of Nanotechnology and I Dermatology. 71 U031 e Interface of Skin and Psyche. 58 Photobiology U017 Photodynamic Therapy. 68 F006 hat’s Boiling Over: Atopic Dermatitis W and Other Eczematous Conditions. 44 eczemas F004 ace to Face: Management of Facial F Dermatoses. including Lasers U017 Photodynamic Therapy. 58 Physiology U016 rom Bench to Bedside: Important Clinical F Advances. 59 U019 Cellulitis: A Common (Mis)Diagnosis?. 44 U003 Hidradenitis Suppurativa: An Update. 71 U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care. 48 S012 hat’s Breaking Out: Acne and W Rosacea. 58 Pharmacology U016 rom Bench to Bedside: Important F Clinical Advances. 51 104 | aging/geriatrics U004 edical Management of Actinic M Keratoses. 43 P U022 atch Test Allergens 101: A Detective’s Toolkit. 38 U019 Cellulitis: A Common (Mis)Diagnosis?. 59 U022 atch Test Allergens 101: A Detective’s P Toolkit. 40 F006 hat’s Boiling Over: Atopic Dermatitis W and Other Eczematous Conditions. 58 structure and Function of skin U010 Skin of Color. 38 AmerIcAn AcAdemy of dermAtology • SUmmer AcAdemy meetIng 2011 . 48 U013 hat’s New in Non-Melanoma Skin W Cancer. 71 U033 nfectious Disease Update What I I Wouldn’t Have Known Without Evidence Based Medicine. 71 U031 The Interface of Skin and Psyche. 41 U019 Cellulitis: A Common (Mis)Diagnosis?. 66 A Human Papilloma Virus U019 Cellulitis: A Common (Mis)Diagnosis?. 58 U025 mpact of Nanotechnology and I Dermatology. 43 U003 Hidradenitis Suppurativa: An Update. 58 Photophysics and Photobiology. 49 F U016 rom Bench to Bedside: Important Clinical Advances.Subject Index How to Use tHe sUBject inDex The subject index has been updated to help the attendees better plan their educational activities. 70 clinical Dermatology C003 Derm Exam Prep Course: Refresher. 76 Th Bacterial U025 mpact of Nanotechnology and I Dermatology. 71 U033 nfectious Disease Update What I I Wouldn’t Have Known Without Evidence- Based Medicine. 41 U025 mpact of Nanotechnology and I Dermatology. 58 U023 se of Light for Diagnosis and Treatment U in Dermatology. 76 W003 OC Self-Assessment: Acne. tHe PRiMaRy toPics aRe: • Basic Science of Dermatology • Dermatopathology • Diagnostic Methods • Clinical Dermatology • Surgery • Epidemiology • Therapeutics – Non-Surgical • Socioeconomic and Practice Issues Basic science Subject Index Basic Methodologies in skin Research U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management. 59 U033 nfectious Disease Update What I I Wouldn’t Have Known Without Evidence Based Medicine. 71 Diseases of connective tissue F008 Cased Based Controversies: Medical.

atrophies. 59 S003 egotiating Your Way to Great N Leadership. 57 U005 Pitfalls in Dermatopathology. 70 S001 EADV/AAD Joint Symposium. 71 DeRMatoPatHoLogy Subject Index ePiDeMioLogy epidemiology F013 Melanoma. 53 U021 Controversies in “Dysplastic” Nevi. 71 Disorders of Pigmentation U010 Skin of Color. 69 other U002 Asian American Skin. 57 W U024 hen Clinical and Histological Findings Converge: Great Cases From a Dermatopathologist’s Perspective.Subject Index U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management. 45 immunopathology S006 What’s Hot in Dermatopathology. 71 Psoriasis S008 What’s Hot in Women’s Dermatology. 47 E S007 ffective Communications: Delivering Key Messages. 39 U025 mpact of Nanotechnology and I Dermatology. 48 Papulosquamous Disorders F019 ral Disease. and other Disorders of Dermal connective tissue (includes Degenerative Disorders) U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologist’s Perspective. 49 Dermatopathology stains. 66 U005 itfalls in Dermatopathology. 50 S004 Leading High Performance Teams. immunohistochemistry.aad. 49 advanced F017 ase Based Controversies: C Dermatopathology. 77 sunscreens F002 Photoprotection. 77 Dermatopathologic Findings in the Perforating Disorders. 38 U008 uality and Customer Service for a Better Q Practice. 39 F012 Case Based Challenges for PA/NP’s. 60 F013 Melanoma. 72 P nail Disorders S008 What’s Hot in Women’s Dermatology. including Histochemistry. 44 C sexually transmitted S001 EADV/AAD Joint Symposium.org | 105 . 71 Pigmentary abnormalities/Vitiligo U014 astering Moles in Pediatric Patients. 71 Dermatopathologic Findings in Various connective tissue Diseases and other Rheumatologic Disease U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologist’s Perspective. 76 Viral U033 nfectious Disease Update What I I Wouldn’t Have Known Without Evidence Based Medicine. 51 internal Medicine F008 Cased Based Controversies: Medical. 71 oral/Mucous Membrane Disorders F019 Oral Disease. 51 U013 hat’s New in Non-Melanoma Skin W Cancer. 66 U005 Pitfalls in Dermatopathology. 66 Dermatopathology Differential Diagnosis: Dermatologic Diseases with nodular inflammation or infiltrates F017 ase Based Controversies: C Dermatopathology. 53 Patient communication F010 Legal Dilemmas in Dermatology. 44 F012 Case Based Challenges for PA/NP’s. 46 U014 Mastering Moles in Pediatric Patients. 67 Pruritus F022 soriasis Guidelines Implementing them in P Your Practice. 38 U008 uality and Customer Service for a Better Q Practice. 71 transplant Medicine F012 Case Based Challenges for PA/NP’s. 71 Photosensitivity Diseases F002 Photoprotection. 57 U005 Pitfalls in Dermatopathology. 76 S for the lAteSt ProgrAm Book InformAtIon PleASe refer to www. 38 U013 hat’s New in Non-Melanoma Skin W Cancer. 53 U025 mpact of Nanotechnology and I Dermatology. Eczema and Inflammatory Dermatosis. 71 U031 The Interface of Skin and Psyche. 60 U016 rom Bench to Bedside: Important Clinical F Advances. Psoriasis. 66 U005 Pitfalls in Dermatopathology. 46 U012 atients Satisfaction: Measurement and P Improvement. 49 U019 Cellulitis: A Common (Mis) Diagnosis?. 59 U027 ractical Dermoscopy. 38 H adult Disorders of cornification and keratinization U019 Cellulitis: A Common (Mis)Diagnosis?. 71 W003 OC Self-Assessment: Acne. 43 F008 Cased Based Controversies: Medical. 49 U025 mpact of Nanotechnology and I Dermatology. 71 Dermatopathologic Findings in Various Metabolic and systemic Diseases. 53 U016 rom Bench to Bedside: Important Clinical F Advances. 66 U010 Skin of Color. 59 O Pediatric Dermatology F006 hat’s Boiling Over: Atopic Dermatitis W and Other Eczematous Conditions. 45 U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologist’s Perspective. 71 non-Patient communication F010 Legal Dilemmas in Dermatology. 60 F018 Hypercoagulability. 48 U012 atients Satisfaction: Measurement and P Improvement. 71 inteRPeRsonaL anD coMMUnication skiLLs MeDicaL DeRMatoLogy adult adnexal Diseases U003 idradenitis Suppurativa: An Update. 53 Malignancy/tumors F002 Photoprotection. 69 Literature Update/what’s new U013 hat’s New in Non-Melanoma Skin W Cancer. 73 U025 mpact of Nanotechnology and I Dermatology. 58 Y U001 our True Colors: Know Yourself and Understand Others. 58 Urticaria U031 The Interface of Skin and Psyche. including alopecia F017 ase Based Controversies: C Dermatopathology. M Eczema and Inflammatory Dermatosis. 71 Dermatopathologic Findings in Various Benign and Malignant cutaneous neoplasms and neoplastic Diseases. 44 F012 Case Based Challenges for PA/NP’s. 60 U025 mpact of Nanotechnology and I Dermatology. 71 Dermatopathology F017 ase Based Controversies: C Dermatopathology. 59 U032 pitz’s Genodermatoses. 66 S006 What’s Hot in Dermatopathology. 67 U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management. 58 U001 our True Colors: Know Yourself and Y Understand Others. 53 U018 Dermoscopy for the Non-Dermoscopist. 39 U025 mpact of Nanotechnology and I Dermatology. 71 Dermatopathologic Findings in Various Papulosquamous Disorders U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologist’s Perspective. 50 F011 sing Technology to Improve U Dermatology Access. 53 U025 mpact of Nanotechnology and I Dermatology. 45 P clinical Pathologic correlations S006 What’s Hot in Dermatopathology. 53 U014 Mastering Moles in Pediatric Patients. 41 U004 Medical Management of Actinic Keratoses. 71 Dermatopathologic Findings of Hair and nails. 76 W004 Dermoscopy. 41 U033 nfectious Disease Update What I I Wouldn’t Have Known Without Evidence Based Medicine. including the Mucinoses U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologist’s Perspective. 45 Basic F017 ase Based Controversies: C Dermatopathology. Purpura and the Skin. 76 M W003 OC Self-Assessment: Acne. 42 S007 ffective Communications: E Delivering Key Messages. 67 occupational Dermatology U025 mpact of Nanotechnology and I Dermatology. 51 Psychocutaneous Disorders F008 ased Based Controversies: Medical. Psoriasis. 59 O U030 ptimizing Management of Melanoma: Recognizing and Responding to Common Dilemmas in Patient Care. including cutaneous Lymphomas F017 ase Based Controversies: C Dermatopathology. and immunofluorescence U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologist’s Perspective. 38 U006 Bringing Out the Best in Others. 45 U013 hat’s New in Non-Melanoma Skin W Cancer. 60 F020 Tumor Board. 64 U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologist’s Perspective. 59 I U025 mpact of Nanotechnology and Dermatology. 58 U018 Dermoscopy for the Non-Dermoscopist. 53 M Pregnancy S008 What’s Hot in Women’s Dermatology. 60 U007 Neonatal Dermatology.

78 Hereditary Disorders of cornification and keratinization U007 Neonatal Dermatology. Biopsy. 53 PeDiatRic DeRMatoLogy PRoceDURaL DeRMatoLogy Subject Index MisceLLaneoUs toPics controversies F010 Legal Dilemmas in Dermatology. Plan Formulation. 62 Pediatric Metabolic and systemic Diseases (includes endocrine Disorders and the skin) S011 What’s Hot in Pediatric Dermatology. 71 Metabolic and systemic Diseases F018 Hypercoagulability. 46 U032 pitz’s Genodermatoses. 71 infections. 50 S010 Cutting Edge Surgery and Oncology. 73 F023 athology and Procedures of the Aging P Hand. 71 Ultraviolet Light therapy and other Physical treatment Modalities U016 rom Bench to Bedside: Important Clinical F Advances. 72 Pediatric Disorders of Pigmentation U014 Mastering Moles in Pediatric Patients. 71 anesthesia and Monitoring U025 mpact of Nanotechnology and I Dermatology. 77 U025 mpact of Nanotechnology and I Dermatology. 59 U025 mpact of Nanotechnology and I Dermatology. 76 W001 MOC Self-Assessment: Skin Cancer. including Hemangiomas and Malformations S011 What’s Hot in Pediatric Dermatology. techniques and excisional surgery F023 athology and Procedures of the P Aging Hand. 38 U008 uality and Customer Service for a Better Q Practice. 76 adult Patient care: History taking and Physical Diagnosis U019 Cellulitis: A Common (Mis)Diagnosis?. 66 U018 Dermoscopy for the Non-Dermoscopist. 53 Pediatric infections. 78 Pediatric Patient care: assessment skills. 59 Participate in activities to assess and improve Quality Practice U008 uality and Customer Service for a Better Q Practice. 69 Miscellaneous U008 uality and Customer Service for a Better Q Practice. 48 I U025 mpact of Nanotechnology and Dermatology. 71 adult Patient care: Population Health and Preventive care U025 mpact of Nanotechnology and I Dermatology. 71 adult Patient care: Patient safety issues U025 mpact of Nanotechnology and I Dermatology. 62 PRactice-BaseD LeaRning anD iMPRoVeMent access. 78 U007 Neonatal Dermatology. 59 Disorders of Hair and nails S008 What’s Hot in Women’s Dermatology. 58 Vasculitis. 38 U025 mpact of Nanotechnology and I Dermatology. 66 U025 mpact of Nanotechnology and I Dermatology. 50 environment issues U009 Smoking and the Skin. 40 U004 Medical Management of Actinic Keratoses. 78 W005 OC Self-Assessment Pediatric M Dermatology. 72 U018 Dermoscopy for the Non-Dermoscopist. 71 U033 nfectious Disease Update: What I I Wouldn’t Have Known Without Evidence Based Medicine. 58 U018 Dermoscopy for the Non-Dermoscopist. 59 U025 mpact of Nanotechnology and I Dermatology. 60 F016 Consultative Dermatology. 57 N F021 ew Technologies in Minimally Invasive Skin Rejuvenation. 77 U025 mpact of Nanotechnology and I Dermatology. 71 Basic surgical skills. Pediatric cutaneous Malignancy. Purpura and the Skin. 78 Pediatric Patient care: non-surgical officebased Procedures S011 What’s Hot in Pediatric Dermatology. including cutaneous Lymphomas U016 rom Bench to Bedside: Important Clinical F Advances. and Patient/Family Recommendations U014 Mastering Moles in Pediatric Patients. 62 Vesicobullous Disorders of childhood S011 What’s Hot in Pediatric Dermatology. 46 ectodermal Dysplasia U032 pitz’s Genodermatoses. 53 W005 OC Self-Assessment Pediatric M Dermatology. and Bites W005 OC Self-Assessment Pediatric M Dermatology. 69 Pruritus U025 mpact of Nanotechnology and I Dermatology. 60 U026 Pediatric Dermatology Jeopardy. and tumor syndromes of childhood U014 Mastering Moles in Pediatric Patients. 50 Lasers F021 ew Technologies in Minimally Invasive N Skin Rejuvenation. 71 Pediatric Patient care: in-office and ancillary Diagnostics S011 What’s Hot in Pediatric Dermatology. 71 adult Patient care: in-office and ancillary Diagnostics U018 Dermoscopy for the Non-Dermoscopist. 59 U025 mpact of Nanotechnology and I Dermatology. 46 Pediatric collagen Vascular Disorders and other Rheumatologic Disease U028 Morphea: Not Just for Adults Anymore. 78 W005 OC Self-Assessment Pediatric M Dermatology. 71 Use technology to improve Practice F011 sing Technology to Improve U Dermatology Access. 53 U025 mpact of Nanotechnology and I Dermatology. infestations and Bites F016 Consultative Dermatology. 48 106 | AmerIcAn AcAdemy of dermAtology • SUmmer AcAdemy meetIng 2011 . 72 U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care. 71 U027 Practical Dermoscopy. infestations. Perforating Disorders. 72 graft Reconstruction F009 Review and Update of Regional Reconstruction. 67 eczematous Dermatoses U025 mpact of Nanotechnology and I Dermatology. 59 U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care. 48 Benign neoplasms.Subject Index adult Patient care: assessment skills. 78 U014 Mastering Moles in Pediatric Patients. Purpura and the Skin. 73 S010 Cutting Edge Surgery and Oncology. 71 atrophies. 51 Benign and Malignant cutaneous neoplasms. 50 instrumentation F009 eview and Update of Regional R Reconstruction. 45 teach and Facilitate Learning of others U001 our True Colors: Know Yourself and Y Understand Others. including atrophies S011 What’s Hot in Pediatric Dermatology. 59 U025 mpact of Nanotechnology and I Dermatology. 41 Flap Reconstruction F009 Review and Update of Regional Reconstruction. 53 Pediatric Patient care: History taking and Physical Diagnosis F012 Case Based Challenges for PA/NP’s. 76 S Hereditary Disorders of the Dermis. and Disorders of Dermal connective tissue W004 Dermoscopy. 78 U015 Laser Update. 78 U007 Neonatal Dermatology. 71 Vascular Disorders of infancy and childhood. 46 U032 pitz’s Genodermatoses. 77 Medical therapy F003 ase Based Challenges in Consultative C Dermatology. 58 U025 mpact of Nanotechnology and I Dermatology. 62 cutaneous Disorders of the newborn S011 What’s Hot in Pediatric Dermatology. 72 S011 What’s Hot in Pediatric Dermatology. 71 M W002 OC Self-Assessment: Office-Based Safety. 48 U016 rom Bench to Bedside: Important Clinical F Advances. 47 C002 ive Patient Demonstration: Neurotoxins L and Soft Tissue Augmentation. 78 normal skin Variants and Developmental anomalies S011 What’s Hot in Pediatric Dermatology. 71 cutaneous oncology S010 Cutting Edge Surgery and Oncology. 59 U018 Dermoscopy for the Non-Dermoscopist. 76 S eczematous eruptions S011 What’s Hot in Pediatric Dermatology. assess and incorporate evidence-Based Resources to improve Practice F011 sing Technology to Improve U Dermatology Access. and Patient Recommendations F012 Case Based Challenges for PA/NP’s. 71 Pediatric Patient care: Patient safety issues U025 Impact of Nanotechnology and Dermatology. 76 S Medical therapy issues in the Pediatric Patient S011 What’s Hot in Pediatric Dermatology. Plan Formulation. 78 U007 Neonatal Dermatology. Vasculopathy and Purpura F018 Hypercoagulability. 71 Botulinum toxin and chemodenervation C001 ive Patient Demonstration: Botulinum L Toxin and Fillers.

48 Volunteerism and social consciousness U025 mpact of Nanotechnology and I Dermatology. 76 Phototherapy U023 se of Light for Diagnosis and Treatment U in Dermatology. 72 C anesthesia F014 Finessing Surgical Technique.R. 53 Utilize Practice services to improve your Practice. 50 F014 Finessing Surgical Technique. 58 U025 mpact of Nanotechnology and I Dermatology. 38 U006 Bringing out the Best in Others. Physician Demonstration.aad.R. 61 C002 ive Patient Demonstration: Neurotoxins L and Soft Tissue Augmentation. 48 antifungals U025 mpact of Nanotechnology and I Dermatology. 50 N S003 egotiating Your Way to Great Leadership. 61 S010 Cutting Edge Surgery and Oncology. 72 U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care. 71 Photodynamic therapy S011 What’s Hot in Pediatric Dermatology. 58 U025 mpact of Nanotechnology and I Dermatology. 57 F014 Finessing Surgical Technique. 48 U012 atients Satisfaction: Measurement and P Improvement. 48 U025 mpact of Nanotechnology and I Dermatology. 77 topical nonsteroidal therapy U025 mpact of Nanotechnology and I Dermatology. 38 U006 Bringing out the Best in Others. 44 S010 utting Edge Surgery and Oncology. 48 U016 rom Bench to Bedside: Important Clinical F Advances. 58 F014 Finessing Surgical Technique. 71 tHeRaPeUtics sURgeRy Subject Index Leadership S004 Leading High Performance Teams. 46 U008 uality and Customer Service for a Better Q Practice. 65 Retinoids S005 edication Monitoring and M Complications. 53 U023 se of Light for Diagnosis and Treatment U in Dermatology. Physician Demonstration. 71 PRoFessionaLisM anD Maintenance oF ceRtiFication socioeconoMic & PRactice issUes computers S002 E. 50 U008 uality and Customer Service for a Better Q Practice. 48 sensitivity to a Diverse Patient Population F011 sing Technology to Improve U Dermatology Access. 42 ethics F010 Legal D lemmas in Dermatology. 71 immunosuppression/cytotoxic therapy U016 rom Bench to Bedside: Important Clinical F Advances. 48 Risk Management/Malpractice F010 egal Dilemmas in Dermatology. 50 Q U008 uality and Customer Service for a Better Practice. 73 Lasers F021 ew Technologies in Minimally Invasive N Skin Rejuvenation.Subject Index Mohs Micrographic surgery F009 eview and Update of Regional R Reconstruction. 50 surgery F009 eview and Update of Regional R Reconstruction. 53 Quality assurance F010 Legal Dilemmas in Dermatology. 73 wound Healing and wound care F009 eview and Update of Regional R Reconstruction. 61 Basic/intermediate C002 ive Patient Demonstration: Neurotoxins L and Soft Tissue Augmentation. 71 Dermatopharmacology S005 edication Monitoring and M Complications. 65 U025 mpact of Nanotechnology and I Dermatology. 71 Professional Development S004 Leading High Performance Teams. 57 F007 Case Based Controversies: Procedural. 47 U001 our True Colors: Know Yourself and Y Understand Others. 77 tissue augmentation (Fillers and Fat transplant) C002 ive Patient Demonstration: Neurotoxins L and Soft Tissue Augmentation. 42 for the lAteSt ProgrAm Book InformAtIon PleASe refer to www.H. 57 F014 Finessing Surgical Technique. 48 P U012 atients Satisfaction: Measurement and Improvement. 76 surgical Repair Methods F007 Case-Based Controversies: Procedural.H. 71 skin cancer in the organ transplant Recipient U025 mpact of Nanotechnology and I Dermatology. 59 U008 uality and Customer Service for a Better Q Practice. 48 teamwork S004 Leading High Performance Teams. 71 gene therapy & Dna Vaccination U025 mpact of Nanotechnology and I Dermatology. 57 F021 ew Technologies in Minimally Invasive N Skin Rejuvenation. 39 I U025 mpact of Nanotechnology and Dermatology. 42 Q U008 uality and Customer Service for a Better Practice. 72 U025 mpact of Nanotechnology and I Dermatology. 46 U008 uality and Customer Service for a Better Q Practice. 73 S010 Cutting Edge Surgery and Oncology. 71 wound Healing F009 eview and Update of Regional R Reconstruction. 50 government S002 E. 71 Miscellaneous U008 uality and Customer Service for a Better Q Practice. 65 Micrographic surgery F007 Case Based Controversies: Procedural. 48 P F023 athology and Procedures of the Aging Hand. 72 complications – Prevention of C002 ive Patient Demonstration: Neurotoxins L and Soft Tissue Augmentation. 50 U025 mpact of Nanotechnology and I Dermatology. 61 S010 Cutting Edge Surgery and Oncology. 71 skin structure and surgical anatomy F009 eview and Update of Regional R Reconstruction. 44 F009 eview and Update of Regional R Reconstruction. including advocacy U008 uality and Customer Service for a Better Q Practice. 53 office Management/Marketing F010 Legal Dilemmas in Dermatology. 49 teaming with other Providers of care to Benefit your Patients U008 uality and Customer Service for a Better Q Practice. 50 L advanced C002 ive Patient Demonstration: Neurotoxins L and Soft Tissue Augmentation. 60 F021 ew Technologies in Minimally Invasive N Skin Rejuvenation. 58 I U033 nfectious Disease Update: What I Wouldn’t Have Known Without Evidence Based Medicine.org | 107 . 71 systeMs-BaseD PRactice Practice Management and the Business of Dermatology. 47 Y U001 our True Colors: Know Yourself and Understand Others. 72 U015 Laser Update. 44 F009 eview and Update of Regional R Reconstruction. 78 I U025 mpact of Nanotechnology and Dermatology. 48 U025 mpact of Nanotechnology and I Dermatology. 57 F021 ew Technologies in Minimally Invasive N Skin Rejuvenation. 38 U016 rom Bench to Bedside: Important Clinical F Advances. 77 corticosteroids U025 mpact of Nanotechnology and I Dermatology. 71 outcomes analysis U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care. 71 U023 se of Light for Diagnosis and Treatment U in Dermatology. 46 U008 uality and Customer Service for a Better Q Practice. 71 U033 nfectious Disease Update: What I I Wouldn’t Have Known Without Evidence Based Medicine. 76 nail surgery F001 Nails. 50 U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care. 49 U012 atients Satisfaction: Measurement and P Improvement. including office Regulation and accreditation F010 Legal Dilemmas in Dermatology. 58 U025 mpact of Nanotechnology and I Dermatology. 61 S010 Cutting Edge Surgery and Oncology. 47 U001 our True Colors: Know Yourself and Y Understand Others. 48 Drug Reactions S005 edication Monitoring and M Complications. 73 U004 Medical Management of Actinic Keratoses. 38 U006 Bringing out the Best in Others. 71 Miscellaneous U008 uality and Customer Service for a Better Q Practice. 48 U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management. 48 therapeutics – non-surgical F013 Melanoma.

.... Vol Prof. NY. M...... MI..D................. M..... Boston. WA U Sch of Med....... Cancer chem ... 47 Bhatia....... 55 coldiron. AL.... Clin Assoc Prof Derm...........D..... Science sect .................. 78 Baldwin.... ana M. M. 78 Barrio....D....... Sect Cut & Aesth Surg.. M.... Division emer ......Invited faculty Index aBBReViations affil...D.... Dept Derm.... Prof Ped Med Derm. 45 chang.D............... Birminham. CA....... Environmental exper .... Director Dis ....... Ralph.........D...... Experimental Fac ..... FL... john andrew...... Senior so........ Psychiatry Radiol .. M..................D. Assoc Prof.... Chicago... U of Michigan... Dir Pediatric Dermatology of New England...... M..... Foundation gen ......... Bryan erik..... Prof....... 43 elewski.... U KY.. Case Western Reserve University.D..... 66 Daniel........... 50.. Tulane U.. Cosmetic ctr . David eric....... Sewickley....D. Mohs Surg........ Medical/Medicine Microbiol . Valley Hosp Med Center.................. Dermpath.. M... Dermatopathology Dir .........D........... Mary wu...... Clin Prof Derm.... CA.. Newark..D..................... Asst Prof... Oncology.... Program Psych .. Branch canc ......... Scho Med.... cheryl M......H......... oscar. 38 Bichakjian.. 44 Del Rosso... Hilary e.. Rochester....... 66 B carlson..... Ph........ Pediatrics Pharmacol ..D............... Head Hlth . Dept Derm.D.... South/Southern st .. Health Hosp .D.. Associate Dean for TeleHealth.. NV........ General Hd . NY. M......... Assoc Clin Prof....D... Clin Asst Prof Derm.... Hospital immunol ........ 72 Bikowski.... Lexington KY... M.D..... 40. Chf Ped and Adol Derm...D.... Asst Clin Prof..... M...... 68 cohen.. Derm Res Director..... 72 Burdick..D............ Dept Derm............ Memorial Sloan-Kettering Canc Ctr..........Dept Derm... U AL...D. 39. Boni e..... Immunology infect . Asst Prof....... CT.......... Preventive Prof ........ Mass Gen Hosp.....................D.. Richard j....P.......... Professor.. Clin Asst Prof.. 41. Columbus..... New York......... Physician(s) Physiol ...... Professor. Yale U Sch Med.... MO. Mark a............ 42 eichenfield.... 72 andea................... KY... aleodor a......... North/Northern occup’l ...D... 45 anderson.... jonathan........ 50...... Dept of Derm.. Prof Med (Derm). Dawn M..... Chemical/Chemistry chf..... Cleveland.. 42............. M. Assoc Clin Prof....... simon... NY..... klaus j. Facility Fel .... Physiology Plast ..................... WI.. william Patrick.... Chf..... MA............D.D...... Plastic Podiat .... U Cincinnati. 67 AmerIcAn AcAdemy of dermAtology • SUmmer AcAdemy meetIng 2011 ..... Otolaryngology Parasit ...... 41 Baum.....D........... Dept Derm. 60 casparian... 71 Barton..... Department Derm........ CT. Penn St U........ Pharmacology Phys . Cincinnati......... Investigator Lect .... john a....P......... joseph s........... Los Angeles.......... 43 Burgess. M..... New Orleans.........D...... New Haven............ christian L.... M................. Dermatology Consulting Services...... U WI Med Sch..... christopher k. Fellow Fndtn .. Asst Prof......... MD.... M... 72 Davis........ M....... Biochemistry Biol....D.D.H........ M................... OH. 41 campen........ M.... NY......... Mark D....... M..... Cornell University............ State surg . Ann Arbor..... Lisa M.. FL..... M. 41 108 | e eastern......D... New Haven.... PA...... CT.. 68 antaya........ U MS.......o.Division of Dermatology......... MD..D....D....... Jackson......... Bikowski Skin Care Center.... Prof Derm.... NY........D.. M...... Asst Prof Derm... M........... Prof. West Hartford.......... NY.... CT.... M.. Cornell U... Surgery/Surgeon svc .. Weill Med Col of Cornell U... 62 cohen..... Chf Div Derm. M... M.......D............ OH State U....... M........ Anatomy asst ....... Dept Derm...... 50 cappel... 43 chiu.......D.D. Chairman clin. 61 colegio... Opthalmology otolaryngol . Asst Clin Prof.... M. Dept Derm... NYU School of Medicine.... M......... Vincent anthony........... Hershey.... Michael j......................... Chief chmn ...... Dept Derm/Ped. Venereology Vet.............. Information inst ...... M.................. New York..... Consultant cosm .. U CT. Veterinary a Invited faculty Index abrishami.. Disease(s) Div .. Las Vegas...... jacques Michael..... 72 Borradori. Brett M................................. jeffrey Phillip........... Dept Derm.D...... St Louis.. NY.. Radiology Res ....... neal D... Prof.. Luca.... Instructor int.D...D.... University of Miami..... 64 alam.....D...C... U AL.... 47 cornelius.D...................... 41 Bordeaux...... M.......... Murad. 70.... Bernard... Washington... Institute instr .......D........ New York... 41 Berson... james Q....... NW U.............. 64 D c callen..... National no ... Miami............S......... 39 Davey... Invest... Asst Prof Ped and Med (Derm).. Department of Dermatology........ 66 carucci. MN.................D..... Div Derm.. University Va ....D.. Ph....D.. Lecturer Med ..... M..... R...... jeremy s.. Vascular Venereol .. P.... Luke’s-Roosevelt & Beth Israel Med Ctrs. OH and Director..D. M.D..... Coral Gables. St. Georgetown U Hosp..... Birmingham........ Yale U.... High Point.......... NY...... CA. DC.. School sci. Assistant assoc ........... Lynn anne......... 73 Busam. M................... Microbiology nat’l .. M.. Affiliate anat .. David Geffen School of Medicine at UCLA.............. M... M......... M. M.......... Asst Clin Prof...... Univ Hosp Case Med Ctr.... 38 ciurea....... UMDNJ and Seton Hall U.. Dept Derm. 47 Draelos........ College cons .. Asoc Clin Prof... New Haven.. Section sen ............... AL...D..... joseph B.. Melvin w....... Resident Rsch . Dept Derm Yale U Sch Med. OH.. M....D. 43 Donofrio. Associate Biochem . San Diego......... Podiatry Prev .. Rebecca B... D...................... Mayo Clin.. 70 camilleri........... Professor Prog ... U Louisville.... Lawrence F........... U CA. U.. 44.. Albany............. Clin Asst Prof Derm. IL....... Pathology Ped ..... Victoria R..... Tropical U ...................... Rady Child Hosp..... M.......... 40 Bolognia..... Emeritus environ ... M. M.... M.. Infectious info .. Ms. Zoe Diana......... Clinic/Clinical col.. Biology Br ...... 42 Brewer..... Vets Administration Vasc .... New York................. c.. M..... Chf.D...... SUNY. 68......... Payam. Syphilology trop . M.... jean L... Derm........ M..... M. anne e..... Assoc Prof Clin Derm..... Clin Prof... M.... NJ. NC.... M....... 51 clarke.D............D... 42 Davis... 48... Diane s... j. PA...... U Miami..... Dept Derm........... jerry D.... Vice Chair Dept of Derm..... Madison.... M... Parasitology Path ..... 58 collishaw.. jennie t...... Div Dermpath.....D.... Service syphilol . Albany Med Col... 78 DeLeo. San Diego.. karen................ 72 carvajal...... Attending.. 60 cotliar.. Occupational opthalmal . Louisville.... Dermatology Dermpath .......... Internal invest .. Richard...... Chmn... Brooklyn.. Research sch ........ Center Dept . LA..... 41...

Dir Dermpath. PA. PA. Ann Arbor.. Assoc Prof. Mollie a. New York. Houston.D. Brian. M...D. 58 Margolis.. Ruth. St. U Miami.. MD/Ph. 58 Fazel. william D. Clin Assoc Prof. M. M. 66. Prof. 47 Lim. Prof. M.. NC. Sch Med.D. 57 grando.D... Yardley Derm. VA West.. jerome M.D.. DM. Assoc Prof. Rebecca L. Geisinger Med Ctr. M. Bethesda. ginat w. Chicago. Assoc Staff. 41. 46. M. M..D. NY. PA.. New York. Dept Derm. U of Illinois at Chicago.D. New York. Dir. 53.D. 46 Marmur. Dir Pgt Lsn. PA. Clin Prof. M. MA General Hospital. Assoc.D.. Lauren c. Dept Derm. Sacramento..D. MSKCC.D.. christopher james.. UCSF.D. M. IL. 46. NY.D. craig a. M.D. U CA. UC Irvine. 77 Fitzgerald.. jeannette o. jennifer.. 68 Marks. M.D. Dept Derm. 73 Lee.. 66 Farris...D. Lindy Peta.D. M. Vlada..D. M. MO. 61. 50.D. U PA.. U MI. M. Hillary.. 60 Hwang.D. Patricia.D. sam t. M..D.D.. 76 Miller.. Dept Derm. Mt. D.. M. 72 Maccormack. Los Angeles. Sch Med. 38 Levy. FL. UCLA.D.. 53 Marks. nathaniel j.. 58 n nasir. M.. Prof. Richard g... sergei a. M.. M.. 50.D. Hayes B. Dept Derm. Livingood Chr. M. New York. Cleveland Clin. M. tammie c. Assc Prof Dept Derm. TX Children’s Hosp. Farmington... Clin Prof Derm Ped. M. CA. M. PA. Ronald L.D. 45 johr. Ann Arbor..D. TX.D. M. Sch Med.D. Birmingham. iltefat H. Rochester.. New York. adnan. M. j.D. M. eva a. David j.. Asst Prof.D. Dir Derm Surg.D.. Dept Derm. Prof Derm & Ped. Philadelphia. clifford warren.aad. Victor james.. M... Northwestern. M.. OH.D. CA Dept Derm. MI. M. Northwestern. M. San Francisco..o. M. M. 61. amy B.. 42 keri. christopher c. Louis U. CA. AL.D.. CA. Victor allen. 67 Lebwohl. 55 Marks.D.. 56 gladstone.. TN Clin Rsch Ctr. LA. PA.. Dept Derm. 74 Lober. Miami. 47 Martin.D. M. Derm Svc. 66 Hurst...D.. kathleen julie.. PA.. M.D. 53 garg. Boston..D. Mayo Clin.. SUNY HSC. j..Invited faculty Index ellis. M. Derm Br. M. Philadelphia. University of Pennsylvania.D.. St. 69 Ferringer. Derm. Dir. Clin Dir.. 59 jellinek. M.D.D. Mary gail. 39. Ph. Clin Asst Prof. Mary c. M. Sr.D. Assoc Prof Derm. U MI Sch Med. Roy g... Brown Med Sch. Clin Asst Prof..D. Baylor Col Med. Philadelphia... Mt Sinai School of Med. CA.. Assoc Prof Clin Derm and Ped. M. U PA.D. CA. M. 57 graf. 67 Miller. University of Miami Miller School of Medicine. 57 Fox. Prof. Danville. 62 Lewis.D..D. Boston U Sch of Med. Dept Derm. 40. Chicago. AL.D. Clin Instructor. Stanford U.D. M. Assoc Clin Prof.D.D. MA. MI.. Michael H.. jane Margaret.. 57 Meehan. FL. Geisinger Med Ctr. U AL. 66 L g garden. NY. 44 kaufman. 48 elmets.. U Cincinnati Col Med. 54 johnson-jahangir. Robert H. PA..D. Metairie. Dept of Dermatology. NYU Med Ctr. 68 groysman. james g. 68 Mirowski. 68 Fried. NY. Ph. U AL Med Ctr. M. christen M.D.D. ellen s. joslyn s.. NCI. Dirk Michael. MN. Danielle M.D. 42 goldberg. David j. Dept Derm. 44 for the lAteSt ProgrAm Book InformAtIon PleASe refer to www. Hershey. Moise L. 61. Asst Prof. Brooklyn. Assoc Prof Derm.. 47.. 60 Hamzavi.. PA. Asst Prof. charles n.. Prof and Chmn. M. U of AL. 50 Lucas. 51 kroshinsky. M.. M. M. Derm/Otolaryngol... Detroit.D. Chapel Hill. Penn State Col Med. IL.. Robert a. MD. CT. Wake Forest U. U So FL. Rochester. 47 Invited faculty Index M Halpern. 51 Moy. Miami. 39 jiang. New York. Louis. Philadelphia. Div Derm. Mark. AL.. Assoc Prof. 43 Martini.. 67. M.D. NY. New York... Dir Derm Surg... Asst Clin Prof. 43 geronemus. 57 Mercurio. UNC.org | 109 .D. gary.D. M. Philadelphia. 69 Morel.. 51. MD..D. Clin Prof Derm. Ph. Assoc.D. 76 jorizzo.. Victor j. Dept Derm. M. Assoc Prof... M. M. Dept Derm.. IL. 70 junkins-Hopkins. Henry w.D.. Dept Derm. M.D. Danville.. Dermpath. M.D. jonette elizabeth. Chmn. M. Sch Med. Ph. Chmn and C..D. 61 glaser. Chmn. Ph. kimberly Dawn. Cincinnati.Sr Staff Phys. jacqueline M. M.D.. M. Henry Ford Hosp. NY.D. Clin Derm. M..... MI. Div Derm.. Director. 67 elston. M. Clin Prof. M.. Derm. Birmingham. U Rochester.. shang i. seth L. UCSF. Asst Prof Derm. M. U of Pennsylvania. Gold Skin Care Ctr.D. Chicago.D. Birmingham. M. Clin Volunteer Faculty. claudia... Clin Assoc Prof. Derm. Brooke a. Prof and Assoc Chmn. Boston. Cleveland. nasim. julie claire.. Henry Ford Hospital. Mark D. 54 Mugalian. Derm Surg. 68.. Ph. NC.D. M..D. Clin Prof Derm. Mount Sinai Sch of Med. M. 77 gloster.D. 38 Martinez.. Dept Derm. Asst Clin Prof.. 77 gold. Danville. 71 neel. Ph... elizabeth shannon. 51 Matarasso. UC Davis Sacramento. 48 grant-kels. 65 Harper. Chicago.D.. Ph. jose Dario. Ph.. M. Dept Derm... M. jeffrey j. 73 james.D. 42 goldenberg. M. Sch Med. Daniela. Dept Derm. 47.. 76 Miller. IL. FL.. 59 Hughey. M. 57 Fisher. Stanford. 55 H j jackson. M. M. M.D. Hugh M. PA. Dept Derm.. San Francisco. Providence. 48 Hectorne.. joseph L. Geisinger Med Ctr. 78 kirby. Invest. Dept Derm.D. Tampa. Assoc Prof. M. Prof and Fmr Chmn.D.S. CA. timothy M.D.D..D. UPENN. Univ of AL. joely anne.. allan c. 39..D. M... 66 k F kalaaji. amer nizar.. 40. 72. 68 gasbarre. Asst Prof. RI. M. shane a. Derm. Paul. amit. Div Derm Surg.D. Asst Prof.. Dee anna. Sinai.D. 78 kaufmann.D. NY. 72 Hernandez. emily j..D. MI.. NW U.. MA. Chf.D. Ph. Winston-Salem...D. Asst Prof Derm.. OH. U CT.D. 54 Lizzul.. Geisinger Medical Center. Dept Derm. Mt Sinai Sch Med. 72 johnson. M.D. Yardley. 59.. M. 60 Mowad.

Harvard Med Sch. Cleveland Clin. Houston. Ph.D. Seattle. Assoc Prof. Manisha j. M. Rolf-Markus.. MA. M. 53.. Ped Derm. M. oliver j.D. New York.D. Loma Linda U Med Ctr. Hd Occ Derm.. 41 Puttgen.. Prof Clin Med. Burlington. 73 szeimies. NY U. 68. NYU Sch Med. Metropolitan Dermatologic Surg. shari.. MA.D. Regensburg. P.. stephen P.Mohs & Cosmetic Derm Surgery Stanta Barbara. kanade. Dept Derm.D. 70 schwarzenberger. M.D. M. 77 sanders. erik j. Derm.D. NY. Clin Assoc Prof U C Irvine.D. North Carolina.D. Sch Med. 60 sengelmann. MA. ann g.D. U WA.D. 51 sadick. Clin Prof. M. M. Boston. 45 wolverton.D. Dir. 74 sanchez. M.P. john a. Mohs Micrographic Surgery. Dept Derm. and Prof. 73 Rogers.. 55. M. Dept Derm. james selwyn. 42 stratman... 73 sundaram. Assoc Clin Prof.. andrea L. Leonard c. Boston.. NC. allan s. Frank c. M. Asst Prof. New York.. Heather clare. CA. MS Hershey Med Ctr. Miller Sch Med. OH. Vice chairman. joel L. 73 wang. Germany. Div Derm. Assoc Prof.. M.. 59 stern. IN U Med Ctr. Dept Ped. 41 newman. Henry Ford Hosp. 60 tomecki.D.... Chicago. 44 willemze. joshua. 74 Rohrer.. Dept Derm. 47 Rokhsar.D. 62 Z Zaenglein. IL. 44 northington. M.. U TX SW Med Ctr. RI.. Dept Derm.D. 57 sanchez. 51 Zic.. 49 Rapini. M.D. Philadelphia. Brown U. FACP.. Brigham and Women’s Hosp.. M. M.. Dept Derm. CA.D. Clin Prof Derm. 66 shwayder. M... Hema a. katherine B. warren w.D.D. David M. TX.. M. tor a... VT. MI..D. Dept Derm and Ped. 70 schalock... New York.D. M. M. 40. 70 strober. NY. Boston U. M. Clin Prof. Assoc Prof... Harvard MS. Peter c.. 47 Patel. OH.. Columbia.. Skincare Phys of Chestnut Hill. Marshfield Clin. NY. Baylor Col Med.D. Univ Vermont.. 77 nemeth. 39. Vanderbilt U Sch Med. Leiden. M. 69 V Van Voorhees. abrar a.D. David a. Ph.D. 78 silverberg. Robert.D.D. FL.... Dept Derm. 43 torgerson. Prof Clin Derm. Providence. Miguel R. Louis. 43 Rosenbach.. M.D. M. Assoc Clin Prof. Uniformed Svc U. Derm and Ped.D. U Miami. alan R. theodore. 41 o olbricht. Columbus... M.. M.. New York. 72 Rich. M.H. 68 110 | AmerIcAn AcAdemy of dermAtology • SUmmer AcAdemy meetIng 2011 .. 43...D. Asst Prof. 41 wirtzer.. Miami... NY.. D. 39 weinkle. Mt Sinai... M. Cook Cty Hosp. U PA. Nashville. U Hosp Regensburg.. Div Derm. Assoc Prof Derm. 68. M. Assoc Prof. NYU. Asst Prof Derm...... M. susan H.. Asst Clin Prof.. Prof & Chmn. Lahey Clin. MO. kara s.. U NC. Prof Derm and Community Hlth. Boston. M.. Brigham & Women’s Hosp. M. Marian elizabeth.. Weill Med College Cornell. janellen. Div Derm. NY.. Hershey. Rochelle R. M.. Paolo. FL. Prof Derm.D. Dept Derm. St Luke’s Roosevelt Hosp Ctr. Houston. MD. 46 sidbury. Mater Hosp. Ph.D. Ph.. LUMC. Asst Prof. 66 spitz. M.D. kathryn.o. St Joseph’s Hospital. M. M. 73 w s waldorf. M. Fiona o’Reilly.. UNC.D. 41. wendy e. 43. Columbia U Med Ctr. julie V. AL.. Divya.D. neil s. Matthew. 45 thomas. Margaret e. Cleveland..D. New York. Uli..D.D. 47.. Dept Derm. Birmingham. jonathan scott. Cleveland Clin. TN. Dir.D. Bethesda. Dept Derm/dermpath. M.. 67 Roberts. New York Univ Med Ctr. Atlanta. Memorial Sloan Kettering Cancer Ctr. Ireland. M. PA. Assoc Prof.D.D..D.. Sch Med. M. 39 stone. 43 Ratner... NY. Detroit. M. Dept Derm..D.. M.. Dir. 57 weinstock. Reg Ctr Derm.. Indianapolis. Asst Prof.D.D. New York. U TX.D. teresa s.. Dept Derm. WA.. Dana w. CA. Dept Derm. Chapel Hill. Chr. Dept Derm.. 74 wisco.. 69 schmults.. M. 69 Powell.D. M.D.. FAACS. 57. M..D.D.. Dept Derm. Priv Pract. AssocProf.. nancy e. M.D.D.. Richard k. M. 40 Zwald. FACPh. 57 Romanelli.. NY.D. M.D. Rochester MN. Phoebe.. Sch Med. Ph. Chmn. cameron k. Dept of Derm OHSU and Private Practice Portland.D... M. New York. CA.D. Asst Clin Prof Med. FAAP. M. chrysalyne Delling. 39 Rigel.D. Div Derm. M.. Netherlands. M. Asst Prof. Dept Derm... RUSH Medical Center. M.D. M. GA.D. WI.D. OH.D. Penn State. 46 R t taylor. abby s. 48 Zirwas. Dept Derm.C. Darrell s..D. M. Ph.. M. Mayo Clin Col of Med.D.D.D... Bruce elliot. M. Derm.D... SIU Sch Med. 60 wetter. M. TX. 62 P Q Invited faculty Index Qureshi. Clin Asst Prof.D. thomas e. 61 Pandya.D. Co-Dir. Prof and Chmn. IN. Bethanee jean... New York. M. 78 smith. Sacramento.. 49. Loma Linda...D.D. Misha. Dept Derm. suzanne. Dept Derm. PA. M. 78 silverberg.. New York. Roberta D. Dallas. 78 Zeichner. Sherman Oaks. M. 67 nunley. St. Asst Clin Prof.D. 69 sperling. Martin a. nanette Blythe.. 67 schlosser. Cleveland. IL.. MA. CA.. Dublin.. M....D. Prof. jennifer a. 39 ozog. 60.D. Dir Ped Derm.. Brooklyn. M.k. M. Con Derm. NY.D. M. Div of Education. Private Practice. 57 Piette..D.. M. kenneth j. Chapel Hill. Chf Derm. 76 srivastava. 78 wright. SUNY Downstate Med Ctr. 78 shinkai. Heidi a. UC-Davis. Asst Prof. 61 osterwalder. Springfield. amit g. Boston. Dept Derm.. 45 stein. M. catherine clayton. Ronald P. TX.. NY. Howard woodling. 65 scher. Prof. Rishi R. M. U S FL.D. M. 48 woolery-Lloyd.D. M. jonathan i. Bradenton.Invited faculty Index neff. M. M. steven Q. Desiree. Columbia U. M.... 71 Rosen. 59 Parsons.D. OR.. Marshfield.. M.D. NY. 47 shalita. Rein. 60 Patel. M. NY. stephen e. 50 schaffer. Asst Prof. M.D. Prof Emer Derm.. Fitzgeraldo a.D.

.

. Mass.. 33 Academy Resource Center .............................................. Calif.................................com Amy Galey Phone: (913) 344-1359....................com Maureen Mauer Phone: (913) 780-6633......... 11.........................................................................................46 ................................................................... 81-82 Galderma Laboratories .. Fla....................... D................. 5............................ 10............... CO.................. 20..................61 ................................Advertisers Index Abbott Laboratories ....... N...................C.......59 Advertisers Index E-mail: mmauer@ascendintegratedmedia..68 Dermatology Self-Assessment Program (DSAP) Tools .....16A-F Centocor .............49 Sustaining Fund .65 Named Lectureships ..... american academy of Dermatology advertising Representatives Ascend Integrated Media...................................................... New York................................................. Fla....74 ........C...........................Y................42 Derm Exam Prep Course..............................3.......... Fax: (913) 780-0088 AAD............ AAD Buyer’s Guide ............7-9 Merz Pharmaceuticals .Y...................... New York................... Hynes Convention Center Hilton New York Hyatt Regency Chicago Hilton New York Boston.......... 36............................................ 86 Young Pharmceuricals ..56 Practice Management Essentials Webinars .......................... Psoriasis Guidelines: Implementing them in your Practice ............... San Francisco...Y................................... Jan Marini Skin Research . IL 66211 Cathleen Gorby Phone: (913) 780-6923......... Orlando..................64 AAD Sponsorship Recognition ......... Measurement Tools .................... Fax: (913) 344-1492 E-mail: galey@ascendintegratedmedia...........80A-D................74 See SPOT CD ................. N................ suMMer ACADeMY Meetings 2012 2013 2014 2015 2016 2017 August 15-19 July 30-August 3 August 6-10 August 19-23 TBD July 26-30 Hilton New York New York..................75 Transition into Practice: A Toolkit for Dermatologists Entering into the Workforce .............................................93-94 Upsher-Smith Laboratories ............................... Chicago.............................................................................. 111 .34. 79-80....... Washington........................... D..................................51 Leadership Institute .................................. LLC 7015 College Blvd...... Ill..... N..... Calif.........................com Future academy Meetings AnnuAl Meetings 2012 2013 2014 2015 2016 2017 2018 2019 70th Annual Meeting 71st Annual Meeting 72nd Annual Meeting 73rd Annual Meeting 74th Annual Meeting 75th Annual Meeting 76th Annual Meeting 77th Annual Meeting March 16-20 March 1-5 March 21-25 March 20-24 March 4-8 March 3-7 Feb.... 101-102................org ....... San Diego..........15-16...................... 35 Annual Meeting 2011 Audio Recordings ...... IBC-BC ....... Miami Beach.............. Suite 600 Overland Park............. Washington....................67 Dermatology in Action ........... 16-20 March 1-5 San Diego................91 Medicis .... Denver.....62 Dermoscopy ....................... Fax: (913) 780-4344 E-mail: cgorby@ascendintegratedmedia.................................... Calif............................................... 112 | AmerIcAn AcAdemy of dermAtology • SUmmer AcAdemy meetIng 2011 .....

a retinoid. Benzoyl peroxide has been shown to produce single-strand DNA breaks in human bronchial epithelial and mouse epidermal cells.0 mg adapalene/kg/day. teratogenic changes were observed in rats and rabbits when treated with oral doses of ≥ 25 mg adapalene/kg/day representing 123 and 246 times MRHD. Other most commonly reported adverse events (≥1%) in patients treated with EPIDUO Gel were dry skin. retinoids) when exposed to UV irradiation in the laboratory or sunlight. these levels are 27-40 times the MRHD. CONTRAINDICATIONS None. application site burning. 20 mg adapalene/kg/day (120 mg/m2/day. PATIENT COUNSELING INFORMATION – Advise patients to cleanse the area to be treated with a mild or soapless cleanser. L. d’Urfé. Carcinogenicity studies with adapalene have been conducted in mice at topical doses of 0. including sunlamps. 98 times the MRHD based on mg/m2/day comparison) did not affect the reproductive performance and fertility of F0 males and females. Wear sunscreen when sun exposure cannot be avoided. Recommend the use of sunscreen products and protective apparel. – Advise patients to minimize exposure to sunlight. pat dry.com . Erythema. animal studies have shown an increased tumorigenic risk with the use of pharmacologically similar drugs (e. Freeway Fort Worth. scaling. respectively. 14501 N. Galderma Laboratories.9. and burning. microphthalmia. Marketed by by: LABORATORIES. Adapalene did not exhibit mutagenic or genotoxic effects in vitro (Ames test.Rx only (adapalene and benzoyl peroxide) Gel 0. No fertility studies were conducted with benzoyl peroxide. patients should be advised to avoid or minimize exposure to either sunlight or artificial irradiation sources. or salicylic acid. WARNINGS AND PRECAUTIONS Ultraviolet Light and Environmental Exposure: Avoid exposure to sunlight and sunlamps. Pediatric Use Safety and effectiveness of EPIDUO Gel in pediatric patients under the age of 12 have not been established. and benzoyl peroxide. – Advise patients not to use more than the recommended amount and not to apply more than once daily as this will not produce faster results.P. In terms of body surface area. resorcinol. and umbilical hernia. and in mice topically treated with 5% benzoyl peroxide carbopol gel for two years. L. 1.P. ADVERSE REACTIONS Observed local adverse reactions in patients treated with EPIDUO Gel were erythema. Rats received maximum daily applications of 138 (males) and 205 (females) mg benzoyl peroxide/kg. Nursing Mothers It is not known whether adapalene or benzoyl peroxide is excreted in human milk following use of EPIDUO Gel.5. The role of benzoyl peroxide as a tumor promoter has been well established in several animal species. Made in Canada trademark. and has also induced a dose-dependent increase in sister chromatid exchanges in Chinese hamster ovary cells. and is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. No photocarcinogenicity studies were conducted with adapalene. dryness. L.P. However. stinging.epiduo. hat) when exposure cannot be avoided.1% / 2. Findings included cleft palate. such studies are not always predictive of human response. Geriatric Use Clinical studies of EPIDUO Gel did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. and 4. Carcinogenesis. (e. it has caused DNA-protein cross-links in the human cells. caution should be exercised when EPIDUO Gel is administered to a nursing woman. Pregnancy Pregnancy Category C.15 to 5.. However. mouse lymphoma TK assay) or in vivo (mouse micronucleus test).5% For Topical Use Only Not For Ophthalmic. In a photocarcinogenicity study conducted with 5% benzoyl peroxide carbopol gel. QC.8 (mice) and 7.15. TX 76177 EPI-613 Printed in USA 12/10 hcp. contact dermatitis. and 9. or growth. Impairment of Fertility No carcinogenicity. lips and mucous membranes. application site irritation. and 1.0 mg/m2/day). or Intravaginal Use. There are no well-controlled trials in pregnant women treated with EPIDUO Gel. BRIEF SUMMARY INDICATIONS AND USAGE EPIDUO Gel is a combination of adapalene.3.g. scaling. No significant increase in tumor formation was observed in rodents topically treated with 15-25% benzoyl peroxide carbopol gel (6-10 times the concentration of benzoyl peroxide in EPIDUO Gel) for two years. stinging or burning. Bacterial mutagenicity assays (Ames test) with benzoyl peroxide has provided mixed results.6-6. the highest dose levels are 9. avoiding the eyes. genotoxicity. GALDERMA LABORATORIES L P Worth. and in rats EPIDUO™ at oral doses of 0. – EPIDUO Gel may cause irritation such as erythema. In rat oral studies. In terms of body surface area. Animal reproduction studies have not been conducted with the combination gel or benzoyl peroxide.0. Mutagenesis. Although the significance of these findings to humans is not clear. Dermal teratology studies conducted in rats and rabbits at doses of 0. EPIDUO Gel should be used during pregnancy only if the potential benefit justifies the risk to the fetus.g. skin irritation. 0. therefore. and stinging/burning may occur with use of EPIDUO Gel. Similar results were obtained in mice topically treated with 25% benzoyl peroxide carbopol gel for 56 weeks followed by intermittent treatment with 15% benzoyl peroxide carbopol gel for rest of the 2 years study period.4. medicated or abrasive soaps and cleansers and products with high concentrations of alcohol or astringents in combination with EPIDUO Gel. Chinese hamster ovary cell assay. scaling. Oral. Apply EPIDUO Gel as a thin layer.0 mg/kg/day (1. However.9. development and reproductive function of F1 offspring. no increase in UV-induced tumor formation was observed in hairless mice topically treated for 40 weeks. Baie d Urfé QC H9X 3S4 Canada Canada. Because many drugs are excreted in human milk. GALDERMA is a registered trademark Revised: Revised December 2008 008 P51356-0 P51356 0 Galderma is a registered trademark. an increased incidence of benign and malignant pheochromcytomas in the adrenal medulla of male rats was observed.4 times (rats) the MRHD of 2 grams of EPIDUO Gel. mutagenic potential was observed in a few but not in a majority of investigations. In the rat study. the significance of this finding in humans is unknown. but may increase irritation. dryness. and 12 mg/m2/day).0 mg adapalene/kg/day [25-59 times (mg/m2) the MRHD] exhibited no fetotoxicity and only minimal increases in supernumerary ribs in both species and delayed ossification in rabbits. exophthalmos and kidney and skeletal abnormalities in rabbits. No teratogenic effects were observed in rats treated with oral doses of 0. Furthermore. – EPIDUO Gel may bleach hair and colored fabric. ©2010 Galderma Laboratories. Use with caution.5 mg/kg/day (0. Fort Worth Texas 76177 USA by: Manufactured by Galderma Production Canada Inc Inc. photocarcinogenicity. DRUG INTERACTIONS Exercise caution in using preparations containing sulfur.. up to 25 times (mg/m2/day) the maximum recommended human dose (MRHD) of 2 grams of EPIDUO Gel.2. 3. 3. encephalocele and skeletal abnormalities in rats. or fertility studies were conducted with EPIDUO Gel. Concomitant use of topical products with a strong drying effect can increase irritation. dryness.

. approximately 30% were clear or almost clear (IGA) by week 12 with a 70% median inflammatory lesion count reduction from baseline. a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic. controlled study in 1670 patients. Br J Dermatol. Pregnancy Category C. The most common adverse events associated with use of Epiduo® Gel are erythema. or with the elderly. Please see brief summary of Prescribing Information on next page. 2009. Adapalene–BPO Study Group. In clinical trials of over 1000 subjects. Glenn MJ. scaling. randomized.1%/2.5%— The only. Gollnick HPM. Adapalene–benzoyl peroxide. Excessive exposure to sunlight and sunlamps should be avoided during treatment.161(5):1180-1189.FIND THE RIGHT CHEMISTRY EPIDUO® (adapalene and benzoyl peroxide) GEL 0. stinging and burning. adverse events reported in greater than 1% of patients treated with the Gel included contact dermatitis and skin irritation. In addition. Concomitant use of irritating topical products (like products containing resorcinol. Reference: 1. Draelos Z. in clinical trials. Epiduo® Gel has not been tested in pregnant or nursing women. double-blind. once-daily adapalene/benzoyl peroxide combination for the first-line treatment of inflammatory and comedonal acne *Individual results may vary. et al. and use of sunscreen products and protective clothing is recommended. dryness. Important Safety Information Epiduo® Gel is a retinoid and antimicrobial combination product indicated for the topical treatment of acne vulgaris in patients 12 years and older. salicylic acid or sulfur) should be avoided.

Sign up to vote on this title
UsefulNot useful